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ABSTRACT
Post-translational modifications play a central role in controlling biological function and
cell behavior through changes in protein structure, activity, and localization. Prenylation is one
such modification wherein a 15- or 20-carbon isoprenoid group is attached to a cysteine residue
near the C-terminus of a substrate protein by one of three enzymes: protein farnesyltransferase
(FTase),

protein

geranylgeranyltransferase

type

I

(GGTase-I)

or

protein

geranylgeranyltransferase type II (GGTase-II, also known as Rab GGTase). These covalent
modifications can aid in protein association with cellular membranes, with this localization
necessary for function of many prenylated proteins. FTase and GGTase-I have been proposed to
recognize a four amino acid “Ca1a2X” C-terminal sequence based on biochemical, structural, and
computational studies of these enzymes. However, recent genetic screening studies in yeast
suggest the potential for FTase to prenylate sequences of the form -C(x)3X, with four amino
acids downstream of the cysteine residue to be prenylated. The work herein begins to define the
sequence scope for this -C(x)3X motif, establishes the biological relevance of this new class of
prenyltransferase substrates in cells, and supports future investigation of the impact of these noncanonical prenylated proteins on cell behavior and biological function.
With the discovery of new -C(x)3X recognition motifs in prenylation, new methods with
which to identify proteins capable of being prenylated are required. To this end, we have
explored the use of engineered FTase variants, specifically RL FTase, selected for the ability to
prenylate substrate sequences that are unreactive with WT FTase. Combining this engineered
FTase variant with functionalized FPP analogues yields a bioorthogonal selective technique for
isolating target proteins, even in the presence of other prenyltransferase substrate proteins in cell
lysates. The value of this method is demonstrated by selective pulldown of model fluorescent

proteins in bacterial lysates in the presence of competitor proteins. The selectivity of FTasecatalyzed prenylation and the minimal size of the C-terminal FTase recognition motif render this
approach applicable to a wide range of target proteins.
A second quantitative method introduced here is Protein-Lipidation Quantitation (PLQ);
a new method that can simultaneously measure the amounts of a non-lipidated substrate protein
and its lipidated product in a cellular context. In PLQ, use of a fluorescent protein fused to the
substrate under investigation allows for quantitative detection of both the non-lipidated substrate
and the lipidated product. Upon prenylation in cells, the substrate and the product in these cell
lysates are separated by surfactant-mediated capillary electrophoresis (CE) and quantitated by
integrating fluorescence intensity over respective CE peaks. This work demonstrates the
usefulness of PLQ both in principle and in application with its ability to confirm a link between a
mutation in the p53 tumor suppressor gene and cellular prenylation activity. The quantitative
capabilities of PLQ will allow researchers to address previously unanswered hypotheses
regarding protein lipidation and its roles in cellular regulation and biological function.
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Chapter 1: Introduction
1.1 Post-translational modifications
It has been predicted that while the human genome consists of between 20,000-25,000
genes, the human proteome contains a level of complexity far vaster than its genomic counterpart
(Figure 1.1).1-2 The ability of single genes to encode for many distinct proteins demonstrates the
importance of protein modifications in the cell. These modifications can occur during transcription
through use of multiple promoter and termination sites, through mRNA splicing, or recombination,
but can also occur after translation through post-translational modifications.3-4
Post-translational modifications are the selective covalent changes to proteins which have
crucial effects on protein structure, localization, stability, and protein-protein interactions. Protein
lipidation is one specific PTM in which proteins are altered through the addition of one or more
lipid groups to recognition motifs within the protein. Lipidation is often an important regulator of
protein trafficking to cellular membranes but also has some roles in protein-protein interactions
and stablility.5-7 Lipidation can occur in tandem with other modifications, such as proteolysis, or
the addition of the lipids to amino acids. The various lipid groups involved in this modification
include fatty acids, sterols, phospholipids, isoprenoids, and glycosylphosphatidylinositol (GPI)
anchors.5
Three types of lipid modification occur on the inner leaflet of the plasma membrane:
palmitoylation, myristoylation, and prenylation (Figure 1.2). These PTMs aid in localizing
modified proteins to the cytosolic side of the plasma membrane and play a significant role in
protein trafficking and regulation.9 Palmitoylation is the formation of a thioester linkage between
a cysteine residue and a palmitic acid containing a 16 carbon chain, although other amino acids,

1

Genome
20-25,000 genes

biotinylation

Proteins
~100,000

nitration
Trp

disulfide bonds

Glu
G

Cys

SUMOylation

glycosylation

Asn

myristoylation
acetylation

Lys

phosphorylation

palmitoylation
prenylation

Lys
Ser

Cys

GPI anchor
cholesterol

Cys

proteolysis

ubiquitination

methylation

Lys
Tyr

Pro

HOOC- Arg

amidation

Lys

ADP-ribosylation hydroxylation

formylation

sulfation

>1,000,000
molecularly distinct
proteins

Figure 1.1 The human proteome is much larger than the genome from which it originates.
Post-translational modifications create more than 1 million molecularly distinct proteins from just
20-25,000 genes. Representative modifications shown here are not represented with required
amino acid motifs or downstream processing.
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namely serine and threonine, are capable of undergoing the modification.7, 10-12 This lipidation is
unique in that it is reversible through thioester hydrolysis, allowing for palmitoylation to play
important roles in protein trafficking and stability.10, 13-15 Myristoylation occurs at an N-terminal
glycine residue through the addition of a 14 carbon myristic acid moiety.9, 16-18 This occurs through
the formation of an amide bond and plays a key role in protein signaling, with many kinases
undergo N-myristoylation.19 Prenylation is the irreversible attachment of an isoprenoid chain 15or 20-carbons in length. This modification is targeted to the C-terminal cysteine of a protein and
is found to be widespread among yeast and mammals.5-6, 20-23 Prenylation traffics proteins to the
plasma membrane where they are involved in cell signaling cascades and protein-protein
interactions.9
Two other types of lipid modification, glycophosphatidylinositol (GPI) anchors and
cholesterol attachment, occur in the endoplasmic reticulum (ER) and Golgi lumen before
trafficking of proteins to the outer leaflet of the plasma membrane (Figure 1.3).24-25 A GPI moiety
is attached to the C-terminus of a protein through its ethanolamine functional group and is involved
in cell signaling, prion disease, and protein incorporation into lipid rafts.24,

26-29

Cholesterol

attachment to proteins also occurs at the C-terminus of proteins through an ester bond.25, 30-31 This
modification is important in tissue repair, organ and stem cell development or maintenance, and
mainly occurs in the Hedgehog protein family.30-32
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Palmitoylation

Myristoylation

Farnesylation

Prenylation
Geranylgeranylation

Figure 1.2: Post-translational lipidation targeting proteins to the inner leaflet of the plasma
membrane. Palmitoylation occurs on a cysteine residue through a thioester linkage;
Myristoylation forms an amide bond to the N-terminal amino group of proteins; Prenylation has
two subgroups of modification: farnesylation (15 carbons) and geranylgeranylation (20 carbons).
It involves the formation of a thioester bond on a cysteine residue at the C-terminus.
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(B)
Ethanolamine

(A)

Figure 1.3 Post-translational lipidation targeting proteins to the outer leaflet of the plasma
membrane. (A) Glycophosphatidylinositol (GPI) anchors consist of an ethanolamine group, a
sugar chain (D-mannose and D-glucosamine), and a phosphatidylinositol group. Mannose
hydroxyl groups can also be various substitutions of long chain fatty acids. 26 (B) A proteincholesterol ester bond.25
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1.2 The prenylation pathway
Prenylation is a post-translational modification in which a hydrophobic isoprenoid, either
a farnesyl or geranylgeranyl group, is transferred to the C-terminal cysteine of a target protein.6,
20-22

Prenylation can be catalyzed by three different enzymes depending on the sequence to be

prenylated and the isoprenoid substrate to be attached: protein farnesyltransferase (FTase), protein
geranylgeranyltransferase type I (GGTase-I), and protein geranylgeranyltransferase type II
(GGTase-II).33 FTase catalyzes the addition of a 15-carbon isoprenoid group from farnesyl
pyrophosphate (FPP), while both GGTase-I and -II catalyze the addition of a 20-carbon isoprenoid
group from geranylgeranyl pyrophosphate (GGPP).6, 20 GGTase-II is unique in that it can modify
a variety of motifs from the Rab family of proteins including CC, CXC, CCXX, CCXXX, where
C is a cysteine which undergoes modification.34-39 GGTase-II also requires a Rab escort protein in
order to prenylate Rab proteins.40
For several decades, the prenylation pathway has been defined to follow a specific set of
modifications before the protein is trafficked to the cell membrane, with the first step comprising
cysteine alkylation by the FPP or GGPP prenyl donor. FTase or GGTase-I catalyze the addition of
the farnesyl or geranylgeranyl group via FPP or GGPP, respectively, to a cysteine near the protein
C-terminus.6, 21 This cysteine is historically part of the Ca1a2X sequence, recognized by these two
enzymes, in which ‘C’ is the cysteine to be prenylated, ‘a’ is any aliphatic amino acid, and ‘X’ is
an amino acid which determines which type of isoprenoid will be attached to the substrate
protein.20, 33, 41-42 FTase substrates typically have an X residue of serine, methionine, alanine, or
glutamine while GGTase-I usually recognizes leucine or phenylalanine at the X residue position.6,
43-46

Some substrates may also be recognized by both enzymes as targets for farnesylation and/or

geranylgeranylation.21, 47-48
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Following addition of a farnesyl or geranylgeranyl group to the cysteine, most prenylated
proteins then undergo two additional modifications before transport to the cell membrane. The last
three amino acids of the Ca1a2X sequence are removed by the “CaaX” proteases Rce1p or Ste24p,
with the resulting carboxylate undergoing methylation by the S-adenosylmethionine dependent
isoprenylcysteine methyltransferase (ICMT) to form a prenylcysteine methyl ester C-terminus on
the prenylated protein (Figure 1.4).49-58 All three modification steps are necessary for function of
most prenylated proteins.50, 54-55 Recently, it has been found that certain proteins in yeast undergo
prenylation but not proteolysis or methylation in what has been deemed the “shunt pathway”, with
evidence of these processing steps actually being deleterious to the protein’s function.8
Once processed, prenylated proteins are shuttled to the cell membrane by one of two
proposed mechanisms. For example, the majority of small GTPases in the Ras family contain a
second upstream C-terminal amino acid sequence which serves as a signal to aid in membrane
association. The isoform K-Ras4B contains a polybasic region which acts as a localization signal
with the amino acid sequence (KMSKDGKKKKKKSKTKCVIM).59-61 The positively charged
lysine residues (bolded in sequence) aid in localization of K-Ras to the cell membrane via
electrostatic interactions. A second upstream signal is observed in isoforms H-Ras and N-Ras
where cysteine residues near the C-terminus under palmitoylation in the Golgi apparatus,
increasing protein association with cell membranes.60-62 Palmitoylation results in a reversible
thioester bond which it believed to act as an “on/off switch” to control membrane association of
these proteins (Figure 1.5).63-64
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Figure 1.4 The prenylation pathway. Modification steps observed within the prenylation
pathway, including prenylation, proteolysis, and methylation. A shunt pathway for proteins
undergoing only prenylation without subsequent proteolysis is evidenced in some proteins in
yeast8 This figure has been reused with permission from reference 8 (Appendix V)
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within the cell. Prenylation occurs within the cytoplasm with subsequent proteolysis and
methylation occurring at the rough endoplasmic reticulum. Trafficking of the processed
proteins to the cell membrane can occur in one of two proposed ways. Yeast proteins which do
not undergo processing remain in the cytoplasm via the shunt pathway.
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1.3 Interactions and specificity between prenyltransferases and target proteins
FTase and GGTase-I are similar in structure, both being heterodimeric metalloenzymes
with their active site located at the interface of their α and β subunits (Figure 1.6).65 With a common
α subunit, distinctions in their specificity arise from their different, homologous β subunits.66-67
The proposed mechanism for both enzymes is alike in that the isoprenoid is proposed to bind first
followed by the substrate to be prenylated. In FTase, the negatively charged diphosphate group of
the isoprenoid is stabilized during catalysis through interaction with a bound Mg2+ ion (Figure
1.7).66 In GGTase-I this ion is not present, with lysine 311β taking on the role of stabilization.66
Both enzymes use a catalytic Zn2+ ion for activation of the cysteine to be prenylated through a
lowering of the thiol group of cysteine to a pKa near physiological pH.66 This newly formed
thiolate anion undergoes a nucleophilic attack on C1 of FPP or GGPP, forming a new thioether
bond on the cysteine residue.68-69
In addition to the interactions of the Zn2+ and Mg2+ ions described above, structural models
of FTase and GGTase-I propose specific contacts within the active site with the cysteine and the
carboxylate group of the Ca1a2X sequence that explain the apparent preference for the four-amino
acid Ca1a2X substrate sequence (Figure 1.8).70 The Ca1a2X motif was first described more than
30 years ago, when yeast mating factors, Ras GTPases, and nuclear lamins were found to be lipidmodified.71-76 Since its description, studies of FTase and GGTase-I preference for amino acids
within the Ca1a2X motif have focused on computational and biochemical techniques, such as single
amino acid mutations at each position of the Ca1a2X sequence and mutations of FTase and
GGTase-I to alter substrate selectivity.21, 47, 77

10

Figure 1.6 Structural homology of FTase and GGTase-I. (A) FTase with α subunit,
red; and β subunit, blue; catalytic Zn2+, pink. (B) GGTase-I. The α subunit is shared with
FTase; β subunit, purple. (C) Superposition of the β subunits of FTase and GGTase-I,
blue and purple, respectively. This figure has been reused with permission from reference
65 (Appendix VI).
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Figure 1.7 The role of metal ions in farnesylation. Magnesium, Mg2+, ions serve to activate
the pyrophosphate group on FPP as the leaving group while zinc, Zn2+, lowers the thiol pKa to
activate the sulfur. (Sulfur of cysteine to be prenylated shown in red.)
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Proteomic studies, bioinformatics analysis, and computational/docking approaches have
also been commonly utilized to predict which Ca1a2X motifs likely serve as substrates for FTase
and/or GGTase-I with sequences longer than four amino acids found to be consistently forbidden
for recognition by the enzymes.78-81 These studies have led to our current understanding of
prenyltransferase selectivity at each amino acid position within the Ca1a2X sequence but little to
no work has been published on the length requirements for this motif. Despite this variety of
approaches, there has been limited research on recognition sequences less than four amino acids
in length (-CXX) and no published investigation into a motif longer than four amino acids (CXXXX).82
In building to our current understanding of the interactions between prenyltransferases and
their substrate, crystallographic studies have provided evidence for specificity of FTase and
GGTase-I to only accept four amino acid motifs, providing a “molecular ruler” of the size and type
of amino acid which could be accepted at each position and generating a list of potential proteins
in the human genome that are targets of prenylation.35, 70, 83-86 An example of these studies from
Reid, T.S. et al. in 2004 provides a table of rules that govern the peptide specificity for FTase and
GGTase-I through a study of several differing amino acid sequences. They describe the peptide
binding site of the enzymes to be “rigid” with fixed anchor points at both the cysteine to be
prenylated and at the “X” position through hydrogen bonding. While these structural studies
provide a foundation for future biological studies of these enzymes, these studies were restricted
to four amino acid peptides.
Computational studies have also been designed to further understand the recognition,
selectivity, and restrictions of the Ca1a2X box on FTase and GGTase-I.79-80 An example is
illustrated by Maurer-Stroh in the development of the algorithm PrePS, a prenylation prediction
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tool.80 PrePS uses experimentally derived motifs as well amino acids just upstream of the cysteine
to be prenylated to predict the likelihood of a motif acting as a substrate for farnesylation or
geranylgeranylation. Due to the experimentally based nature of the algorithm’s development,
PrePS has the potential for many false negatives for a given set of motifs, restricting the number
of motifs being determined likely as substrates for prenylation.
A second computational approach by London and coworkers in 2011 involves a structurebased modeling approach used to determine all potential Ca1a2X motifs that can undergo
prenylation, including a new class of farnesylation targets.79 This tool known as FlexPepBind was
derived from knowledge of the enzyme’s structure, using molecular dynamics, to determine
binding energy of Cxxx substrates. FlexPepBind is a more powerful tool than PrePS as it has
predicted novel substrates through docking of all possible Cxxx motifs into the active site and
determining the minimal binding energy involved in the interaction.
Yet another approach in investigating Ca1a2X motif specificity involves biochemical and
cell-based studies, including single amino acid mutations at each position of the Ca1a2X sequence
and reengineering of FTase and GGTase-I selectivity at the level of the enzyme.21, 43, 58, 72, 77, 87-92
The first approaches to these biochemical studies employed radiolabeled 3H FPP and GGPP for
protein labeling, as well as upstream precursors of these prenyl donors.93-95 In these studies, cells
were grown in the presence of these radiolabeled compounds wherein the result was labeled
prenylated proteins that could be harvested from cells. These original techniques, while
fundamental to our understanding of prenylation, gave low yields of prenylated protein, were
expensive, and time consuming.
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Figure 1.8 Structural model of FTase recognition of a substrate sequence. The binding of
tetrapeptide (green) into the active site involves coordination of the cysteine thiol group to the
catalytic zinc ion (orange sphere) and hydrogen bonding between the C-terminus and FTase
residues (Q167) and (H149). (water, teal spheres) Image was generated from Protein Data Bank
code 1TN8 using PyMOL reused with permission from reference 181 (Appendix V).
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The use of reactivity series has also found use as a biochemical approach in identifying
prenylation substrates. For example, Hougland and co-workers have used Ca1a2X peptide libraries
of varying a1, a2, and X positions to determine amino acid preferences at each position for FTase
and GGTase-I.87, 91, 96 Their work revealed, for example, a preference against polar amino acids at
the a2 position, as this position is buried within the active site, and the notion that some sequences
may undergo what is called “single turnover” reactivity. Under single turnover conditions, enzyme
concentration is greater than that of substrate (STO, [E]>[S]). This state removes competition of
substrates for enzyme as there is sufficient enzyme to prenylate all the substrate molecules without
the need for product release (turnover) from the enzyme so that more substrate can bind. This is
opposed to the more biological “multiple turnover” reactivity (MTO, [E]<<[S]) in which product
must be released from the active site of the enzyme in order for more substrate to be converted to
product. If sufficient product formation is shown under STO conditions but not MTO conditions,
this evidences an issue in product release for a given substrate and enzyme. The determination of
sequence dependence on STO vs. MTO conditions provides new insight into potential regulation
of these prenylated proteins in the cell.
In recent years, the use of functionally labeled prenyl donors has gained popularity in
investigation of FTase and GGTase-I substrate specificity. For example, alkyne and azide-tagged
FPP and GGPP analogues (Figure 1.9) have been used to determine potential substrates for
prenylation in which the functional group incorporation into prenylated proteins allows for
detection and isolation of these proteins using a variety of techniques, such as fluorescent labeling
with TAMRA-azide, biotinylation with subsequent isolation using streptavidin beads, and MS
analysis following isolation.97-108
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Figure 1.9 Examples of FPP and GGPP analogues used in investigations of prenyltransferase
substrate specificity An (*) denotes a GGPP analogue is also available and was not included here
for space. This list of analogues is not exhaustive and are derived from the references provided.
109-115
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Some specific examples include work by Spielman and coworkers in 2005 wherein an
antibody-based detection of prenylated proteins from cells was achieved through use of an FPP
analogue anilinogeraniol, AGOH (labeled in Figure 1.9).116 This alcohol precursor is
diphosphorylated in cells to yield AGPP, which is then transferred to substrates in a reaction
comparable to that of FPP. In tandem with anti-anilinogeranyl antibody (polyAG-Ab) the use of
AGOH analogue was one of the early successes in non-natural prenyl group incorporation that did
not utilize radiolabeled isoprenoid donors to identify prenylated proteins in cells. This work using
AGOH and western-blot analysis gave insight into the prenylation state of multiple proteins, such
as Q61L oncogenic H-Ras, as well as investigated the effect of several FTI and GGTIs, such as
lovastatin.116-118 AGOH has since been examined in its role as an FTI itself in its ability to compete
with endogenous FPP for substrate.109
A second example of work with FPP and GGPP analogues comes from Alexandrov and
coworkers in 2009 in which a biotin-labeled geranylpyrophosphate (BGPP, Figure 1.9) was
utilized by both natural RabGGTase and mutant FTase or GGTase-I.115 Having all three enzymes
at their disposal, this work demonstrated the identification and quantification of prenylation
substrates and provided a more sensitive measure of the effect of prenyltransferase inhibitors on
in vivo activity. An example from this work includes investigation of inhibitor BMS-3 which was
confirmed to have no effect on GGTase-I in cells but was able to inhibit RabGGTase and FTase
with a Ki of 7 and 50 nM, respectively.116, 119 This inhibition was monitored in a simple and quick
fashion via blotting with streptavidin-HRP after exposing cells to BGPP and laid ground for some
of the first work on in vivo quantitation of prenyltransferase inhibition.
While the methods described above have provided invaluable insights into the structures,
substrate specificity, and cellular recognition involved in prenylation, the best quantitative method
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to understand of the role played by protein prenylation needs to simultaneously measure the
amounts of both non-lipidated substrate and lipidated product. The BGPP analogue developed by
Alexandrov provided a method for cellular quantitation of prenylated proteins, however, it could
not simultaneously measure both substrate and product. Without the ability to measure modified
and unmodified protein simultaneously, an accurate ratio between the two cannot be established.
Many of these analogue methods also use gel electrophoresis/immunoblotting for their analysis
with separation of proteins often being poor between substrate and product.
Computational methods have also provided valuable information as to the interactions
between prenyltransferases and substrates within the binding site necessary to understanding
substrate specificity and prediction of new substrates. These methods rely on known prenylation
substrates determined experimentally and are limited to Ca1a2X motifs. Any recognition sequence
outside the classic Ca1a2X could yield a false negative as being a potential substrate for
prenyltransferases.
The importance of expanding our approaches to determining potential prenyltransferase
substrates is highlighted in a study in which evidence for prenylation of non-canonical C(x)3X
motifs was observed while studying the role of prenylation and its post-processing in the yeast
heat-shock protein, Ydj1p, (see chapter 2).8 This protein is a type I Hsp40 co-chaperone which
ensures proper folding and stability of proteins during times of stress and must be prenylated in
order to perform this function.120-124 Unlike other proteins which undergo prenylation, Ydj1p does
not undergo subsequent proteolysis and methylation and is therefore found in the cytosol rather
than the cell membrane.8 This genetic screening provided the capability to investigate prenylation
motifs compatible with yeast FTase directly without the requirement for downstream processing.
During this investigation, a unique observation occurred in that C(x)3X sequences appended to
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Ydj1p, a product of randomized screening, showed evidence of prenylation through a
thermotolerant phenotype in yeast. This finding highlights the importance to develop new,
sensitive techniques which accurately predict and analyze sequences outside the traditional CaaX
box.
The C(x)3X sequences emphasize the importance of developing new methods for studying
prenylation. Use of fluorescence localization as a proxy for prenylation in cells would not be useful
for prenylated proteins with a cytosolic role, for example, as the entire cell would exhibit
fluorescence. Analogues could be useful in study of cytosolic prenylated proteins, however FPP
and GGPP analogues like BGPP are bulky and can interfere with binding to the enzyme or do not
bind with as high an affinity as natural substrates.115 The binding of BGPP was remedied through
mutation of the FTase and GGTase-I, a cumbersome process that does not yield quick results.
Turning to computational methods resolves the challenges of working in cells but it currently does
not use sequences longer than four amino acids in its algorithms and are likely to reject sequences
outside this range. The development of a method which not only identifies both substrate and
product simultaneously while providing a quantitative separation of the two species would change
the way current research is done to confirm and expand upon prenylation in cells.
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1.4 Biological significance of prenylation
Prenylation plays an important role in cell signaling, growth, differentiation and
proliferation, and cell migration.125-131 With prenylation being important in many cellular
functions, these prenylated proteins can be found to play a role in a wide variety of diseases, the
most prominent being cancer. The well-known GTPases H-Ras, K-Ras and N-Ras are involved in
signal transduction and cell growth and have known oncogenic forms through amino acid
mutations which keep the GTPase in an “always active” form, causing overgrowth of cells.118, 132134

Other proteins known to be prenylated, such as prelamin A, also play a role in diseases of cell

growth and aging through an improper processing of the prenylated form of the protein.135-137
These important roles in human disease have led to a robust interest in prenyltransferases as
therapeutic targets for disease. Prenylation is not only an important modification in humans but
also found in pathogenic organisms such as Plasmodium falciparum, Candida albicans, and
Legionella pneumophila, in which prenyltransferase inhibitors are currently being investigated as
potential therapeutics.138-140 A challenge in studying pathogenic prenylation is the identification of
the proteins undergoing the modification. It is known, for instance, that FTIs show promise as
potential antimalarial drugs, but identification of the proteins they specifically target has only
recently undergone investigation.141-142 Recently, use of an alkyne FPP analogues and the
algorithm PrePS identified several proteins which undergo prenylation in Plasmodium falciparum
such as FYVE-containing coiled-coil protein (FCP) which may be the target of FTI therapeutics.141
As discussed earlier, use of these techniques can be limiting in their ability to identify potential
target proteins and highlights the biological significance in developing new methods to study
prenylation.
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Despite its involvement in regular cellular functions, the involvement of prenylation in cell
growth affords its role in cancer as the most extensively studied disease related to this modification.
The connection between cancer and prenylation can be found in studying the family of Ras GTPase
proteins such as H-Ras, N-Ras, and K-Ras, as well as members of the Rap family of proteins.143148

These small, prenylated GTPases serve to proliferate a signal from primary messengers, such

as growth factors, to enzymes responsible for the formation of a secondary signal in the cell, such
as cyclic AMP. This secondary messenger then sets off a cascade of changes, often through a series
of kinases.149-150 In order for GTPases to send a signal downstream of its effector, it must switch
from an inactive GDP-bound form to an active GTP-bound form. In many types of cancer, Ras
proteins are found to be “stuck” in their active GTP-bound form due to mutations in their genetic
sequence.151 With the inability to terminate its signal to downstream kinases for cell growth and
proliferation, oncogenic GTPases are a primary target in cancer research.
With prenylation having a known role in cancer and tumor growth, several
farnesyltransferase inhibitors (FTI) and geranylgeranyltransferase inhibitors (GGTI) have been
explored as potential therapeutics.152-156 Despite the wide range of developed FTIs and GGTIs, all
have shown limited use at a clinical level for treating cancer but are still used widely at the research
level.152, 157-162 The low level of effectiveness for these inhibitors in cells and human patients stems
from the observation that there is no correlation between inhibition of tumor growth and the
mutations of Ras. While Ras is mutated and involved in cancer, the efficacy of these
prenyltransferase inhibitors lie in their ability to inhibit multiple proteins.163-164 For instance, KRas and N-Ras have been found to undergo geranylgeranylation when farnesyltransferase is
subjected to an FTI.165 This realization highlights the importance of identifying other proteins that
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undergo prenylation in order to design new, better therapeutic inhibitors or improve upon
previously developed ones.
Hutchinson-Gilford Progeria Syndrome is another disease with connections to prenylation
of protein prelamin A.166-167 In order for prelamin A to function properly, a processing step
involving the removal of a 15-amino acid C-terminal peptide sequence by endoprotease
ZMPSTE24 occurs after the prenylation and processing of the Ca1a2X C-terminus.168 In progeria,
prelamin A cannot be cleaved by ZMPSTE24 and farnesylated prelamin A aggregates on the
nuclear envelope giving the affected person the appearance of rapid aging. Those with progeria
have significantly shortened life expectancies with many challenges.
Farnesylation was confirmed as the cause of prelamin A aggregation in 2005 wherein a
missense mutation on WT lamin A to produce a C-terminal SSIL was used to block prenylation of
the protein.169 No aggregation (nuclear blebbing) was seen with this mutation nor when the Cterminus was mutated to CSIL, which favors geranylgeranylation. As progeria is a farnesylationspecific disease, clinical trials for the use of FTIs as a therapeutic agent in humans began around
2012, after promising results in cells and mice.170-175 The use of FTIs such as lonafarnib,
pravastatin, and zoledronic acid increased life expectancy for children with progeria and improved
their quality of life through measurement of weight gain and arterial density.169,

175-179
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successful trial showed an improvement of 71% in weight gain for patients either treated with
lonafarnib alone or with combined FTI therapies, suggesting no real benefit from treatment with
multiple FTIs.179 The use of FTIs was also shown to decrease neurological episodes such as
seizures and headaches, of which these patients regularly suffer from.177 While FTIs are promising
treatment for progeria, they only treat symptoms and prolong life; they do not cure it. Research is

23

turning to gene therapy through stem cells and CRISPR/Cas9 gene editing as a way to possibly
cure those who suffer from the disease.180

1.5 Importance and objectives
Prenylation is a vital modification in the normal functioning of many proteins within cells
and also plays a role in a variety of diseases. With the estimation of over 1166 proteins in the
human proteome containing a CaaX motif at their C-termini, having a clear representation of the
actual number of proteins undergoing prenylation is an important step in understanding the roles
played by prenylated proteins in the cell and in disease.181 As stated previously, current
investigations into prenylation using structural, computational, and biochemical techniques have
been restricted in their length of the Ca1a2X motif to four amino acids only. With recent evidence
for prenylation of non-canonical C(x)3X motifs in yeast through the study of heat-shock protein,
Ydj1p, it is important to study the potential of these longer 5 amino acid motifs acting as
prenylation substrates in the human proteome.8
This work aims to define a new motif recognized by both yeast and mammalian FTase in
which we provide biochemical characterization at the peptide and protein level. Through study of
the sequences found in the yeast genetic screening, we can determine sequences within the human
genome capable of undergoing prenylation with a C(x)3X C-terminus and provide evidence of
biological relevance for this new recognition motif. The main objective of the work herein is to
characterize, identify, and expand upon the list of proteins that can be potentially prenylated both
in vitro and in mammalian cells using a C(x)3X C-terminal motif, breaking a decades-old dogma
for this post-translational modification’s requirements.
The advent of this new research emphasizes the importance of developing new and more
sensitive techniques to study prenylation, especially in the avenues of substrate identification,
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specificity and quantitation at the cellular level. An ideal method for studying these areas should
include the ability to clearly discern between substrate and product quantitatively, with minimal
to no purification of cell lysates before analysis. This not only provides a method that is quick and
easy to use, but also minimizes the loss of protein from the cells and therefore provides a more
accurate picture of the total protein being studied.
One approach to effective protein isolation uses prenylation as a means of tagging any
protein, not just ones which undergo prenylation, using the C-terminus CaaX motif as a tag. Herein
we describe a means of using prenylation by a mutant farnesyltransferase (W102R W106L) to
isolate protein using a non-natural CaaX sequence (-CVDS) and functionalized FPP analogue.
Chemical labeling with a functionalized FPP analogue allows for immobilization of the target
proteins via hydrazone ligation chemistry onto hydrazide beads prior to the release of the protein
from the beads for analysis. Several labs have utilized the specificity of endogenous
farnesyltransferase (FTase) in order to label proteins with FPP analogues with chemical reporter
function groups.182-189 However, these methods are limited to use in bacteria due to competition
between the functionalized prenylation reaction and the endogenous prenylation that occurs in
mammalian cells. Use of a mutant FTase and non-natural CaaX sequence eliminates the issue of
competition from natural proteins, allowing for biorthogonal labeling and isolation of targets from
mammalian cells.
While biorthogonal labeling in cells provides a new means of which to isolate proteins of
interest, it does not provide a means of quantitation for both unmodified substrate and modified
product. To meet this need, our work turned to development of Protein-Lipidation Quantitation
(PLQ), the first method to measure a quantitative level of substrate and product in a biologically
relevant context.190 Through use of a fluorescent protein-target protein fusion and capillary
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electrophoresis, PLQ is able to clearly separate lipidated product from its unmodified counterpart
without need of prior purification from cell lysates. PLQ is applicable to multiple lipid donors and
substrates and can be used to study prenylation’s role in a variety of cellular contexts, including
the presence of oncogenic proteins. Development of this new technique provides a new way of
studying a variety of lipidation modifications in a quantitative and biologically relevant manner
not possible until now.
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Chapter 2: Investigation of -C(x)3X sequence recognition by FTase and GGTase-I in vitro
and in cell
A portion of this chapter has been previously published in reference 58. Reprinted with permission
from Blanden, M. J.; Suazo, K. F.; Hildebrandt, E. R.; Hardgrove, D. S.; Patel, M.; Saunders, W.
P.; Distefano, M. D.; Schmidt, W. K.; Hougland, J. L., Efficient farnesylation of an extended Cterminal C(x)3X sequence motif expands the scope of the prenylated proteome. The Journal of
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2.1 Introduction
Protein lipidation (e.g. prenylation , palmitoylation, myristoylation) is a post-translational
modification that plays a direct role in protein trafficking to cellular membranes, as well as proteinprotein interactions.1-10 One type of lipidation, prenylation, involves the covalent attachment of a
hydrophobic isoprenoid group, either a 15-carbon farnesyl or 20-carbon geranylgeranyl group, to
a cysteine thiol side chain near or at the C-terminus of certain proteins. This cysteine is part of a
C-terminal CaaX recognition sequence recognized by protein farnesyltransferase (FTase) or
protein geranylgeranyltransferase type I (GGTase-I).11-14 Geranylgeranyltransferase type II
(GGTase-II) is a third enzyme of this class in which a cysteine present in a C-terminal CC or CxC
motif can be recognized for prenylation. GGTase-II is also known as Rab GGTase.15-18 Cysteine
prenylation alters the properties of proteins in several well-studied cases (e.g. Ras and Ras-related
GTPases), resulting in protein association with cell membranes where these proteins are involved
in cell signaling pathways.19-23
The prenylation pathway, as previously described, consists of number of modification steps
that can precede substrate protein localization to cellular membranes (Chapter 1, Figure 1.3). In
The pathway begins with the enzymatic alkylation of a cysteine by FTase or GGTase-I with a
farnesyl or geranylgeranyl group using farnesyl diphosphate (FPP) or geranylgeranyl diphosphate
(GGPP), respectively. Following modification by FTase or GGTase-I, prenylated proteins CaaX
often undergo additional modifications involving proteolysis and methylation of the CaaX
sequence.24-28 Proteolytic removal of the last three -aaX amino acids by membrane-associated
proteases Rce1p or Ste24p results in a C-terminal prenylcysteine residue bearing a negatively
charged carboxylate group. This carboxylate is then methylated by the SAM-dependent enzyme
isoprenylcysteine carboxyl methyltransferases (ICMT). These modification steps are necessary for
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most prenylated proteins to function, although there can be some exceptions to the extent of and
necessity for these modifications.29-30 Recently, a shunt pathway for prenylated proteins in yeast
has been reported by Hildebrandt and coworkers in which the CaaX motif undergoes prenylation
but no subsequent processing occurs. In this case, post-prenylation processing is not only not
required, it is actually deleterious to protein function.31
The CaaX motif classically thought of as being required for prenylation was first described
over three decades ago when studies of yeast mating factor, Ras proteins, and nuclear lamins were
being investigated for their ability to be palmitoylated.32-38 It was found that these different proteins
all contained a similar C-terminal C-X-X-X motif to which a lipid was bound that was smaller
than that of a palmitoyl group. Upon the discovery of an isoprenoid group as the lipid donor for
this modification, it was determined that a four amino acid C-terminus was required for prenylation
through a top-down approach, with all the proteins being studied for their ability to undergo
prenylation having this same motif and a general acceptance of this requirement was established.
While there were limited early investigations into shorter Cxx motifs,39 investigation of the CaaX
sequence has predominately focused on amino acid selectivity within the motif and not studied for
length requirements in recognition by FTase and/or GGTase-I. Biochemical studies which include
single amino acid mutations at each position of the CaaX, random library screening, and in vivo
studies all determined general rules for recognition and selectivity at each amino acid position for
prenylation.14, 39-46 Crystallographic studies have provided further evidence for specificity of FTase
and GGTase-I to only accept four amino acid motifs, providing a “molecular ruler” of the size and
type of amino acid which could be accepted at each position and generating a list of potential
proteins in the human genome that are targets of prenylation.47-48 These works have greatly
influenced the understanding in how the CaaX motif interacts with prenyltransferases at each end
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of the recognition sequence. An example of these studies from Reid, T.S. et al. in 2004 provided
a table of rules that govern the peptide specificity for FTase and GGTase-I through a study of
several differing amino acid sequences. This work describes the peptide binding site of the
enzymes to be “rigid” with fixed anchor points at both the cysteine to be prenylated and at the “X”
position through hydrogen bonding. Proteomics studies utilizing chemically modified prenyl
donors, bioinformatics analysis, and computational/docking approaches have further extended our
ability to identify and predict which CaaX motifs likely serve as substrates for FTase and/or
GGTase-I.47, 49-52 An example of which is illustrated by London and coworkers in 2011 in which a
structure-based modeling approach was used to determine all potential CaaX motifs that can
undergo prenylation, including a new class of farnesylation targets. This tool known as
FlexPepBind was derived from the structural features determined from previous crystallographic
studies in which a four amino acid CaaX box was used.
Recently, a novel thermotolerance screen for protein prenylation in yeast has expanded our
capability to identify prenyltransferase substrate sequences in yeast through use of genetic
screenings.31 This screen is based on the yeast protein Ydj1p, a type I Hsp40 co-chaperone that is
required for high-temperature growth. This protein is a type I Hsp40 co-chaperone which ensures
proper folding and stability of proteins during times of stress, such as elevated temperature, and
must be prenylated in order to perform this function.53-57 Unlike other proteins which undergo
prenylation, Ydj1p does not undergo subsequent proteolysis and methylation and is therefore
found in the cytosol rather than the cell membrane.31 This unique property of Ydj1p allows for
direct investigation of protein prenylation without the requirement for concurrent sequence
compatibility with Rce1p or Ste24p for subsequent proteolysis.
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The work herein supports the discovery of a five amino acid C(x)3X sequence motif
recognized by both yeast and mammalian FTase orthologs.58 Multiple C(x)3X peptide sequences,
originally identified by genetic screening in yeast, can be efficiently farnesylated in both peptide
and protein substrates. We demonstrate that several additional C(x)3X sequences derived from
human proteins are efficiently prenylated by rat FTase, and that a reporter protein terminating in a
C(x)3X sequence exhibits sufficient reactivity to be farnesylated under biologically relevant
conditions within a human cell.
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2.2 Genetic screening in yeast suggests prenylation of C(x)3X sequences by yeast FTase
Our investigation into the prenylation of C(x)3X sequences began in part by the observation
that the CGGDD sequence of human annexin A2 has been identified as potentially prenylated in
several studies using in vivo farnesylation probes.51, 59-62 This observation suggests prenylation
and associated processing may be compatible with sequences of non-canonical length. To examine
this possibility, we initially used yeast a-factor as a genetic reporter to identify whether C(x)3X
sequences could serve to be recognized by farnesyltransferase. Farnesylated a-factor is a secreted,
diffusible signaling molecule produced by MATa haploid yeast that temporarily triggers cell cycle
G1 arrest in nearby MAT haploid yeast so that mating can occur; this arrest is enhanced in certain
mutant backgrounds (e.g. MAT sst2-1).63 Using this a-factor induced growth arrest phenotype, a
plasmid-based library of a-factor mutants with C-terminal C(x)3X sequences was produced to
observe evidence of prenylation through the growth arrest assay. A plate containing a population
of MATa colonies expressing mutants was printed onto a thin lawn of MAT sst2-1 yeast, the
printed plate incubated for a period of time, and individual colonies surrounded by a zone of
MAT growth inhibition, known as a halo, were scored as positive hits; associated plasmids were
recovered and sequenced. We estimate 22.5% of the possible C(x)3X combinations were evaluated
(i.e. ~40,000 colonies; see Section 2.10 for description of coverage estimate).64 With this limited
coverage of the potential sequence space, the a-factor screen yielded two C(x)3X hits (Table 1).
The two C(x)3X sequences were retested with other a-factor mutant sequences using the halo assay
(Figure 2.1). The halos associated with the C(x)3X sequences were qualitatively smaller than that
those associated with wild type a-factor (CVIA C-terminal sequence). Unexpectedly, the CGGDD
sequence did not produce a halo; this was true even when encoding the mutant in an overexpression vector.
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Figure 2.1 Phenotypes and isoprenylation status of C(x)3X motifs identified by yeast-based
screening. a) Plasmid-encoded a-factor C(x)3X variants were evaluated for their ability to
produce a-factor in SM2331 (MATa mfa1 mfa2) using a spot halo assay. Strains were spotted
onto YPD, cultured for 48 hours at 30 °C, and replica transferred onto a thin lawn of RC757
(MATα sst2-1). Plates were imaged after 16 hours incubation at 30 °C. The values represent
the results of quantitative mating analyses and are reported as percent relative to control
(CVIA). b) Plasmid encoded Ydj1p C(x)3X variants were evaluated for their ability to rescue
growth of yWS304 (ydj1∆) at indicated temperatures. Each set of spots represents a 10-fold
dilution series prepared from a saturated culture grown in selective media that was spotted onto
YPD. Images are representative of data from 2 separate experiments in which at least 2
replicates of each strain were evaluated. c) Immunoblot of lysates from strains containing the
indicated Ydj1p C(x)3X variant. Farnesylated Ydj1p has increased mobility compared to
unmodified Ydj1p. The strains used were yWS304 (WT) and yWS1632 (ram1); RAM1 encodes
the FTase α subunit. This figure has been reused with permission from reference 58 (Appendix
V). This data was collected and analyzed by our collaborator Walter K. Schmidt (University of
Georgia).
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2.3 C(x)3X peptide substrates are substrates for mammalian protein farnesyltransferase in
vitro
Evidence for the activity of Ydj1p with non-canonical C(x)3X sequences in yeast led to the
design of an in vitro system to test the activity of these motifs in a reaction with synthetic peptides
and using purified mammalian FTase and GGTase-I in cell-free prenylation assays. This system
addressed the ambiguity presented by potential proteolysis by a carboxypeptidase in cells,
producing a typical CaaX motif. Mammalian FTase was also used to test whether prenylation of
these C(x)3X sequences was exclusive to yeast. For these assays, fifteen C(x)3X sequences
identified by yeast screening were synthesized as 6-mer peptides with each C(x)3X sequence
preceded by a glycine residue. Each peptide was appended by an N-terminal dansyl fluorophore
producing a peptide design of dns-GC(x)3X (Table 2.1). As demonstrated in previous studies using
canonical CaaX sequence peptides, attachment of the environmentally sensitive dansyl
fluorophore allows real-time monitoring of prenylation through dansyl group fluorescence
enhancement upon addition of the hydrophobic farnesyl group on cysteine to monitor activity over
time.65-68 Using this assay, incubation with purified rat FTase and FPP resulted in significant
fluorescence enhancement (>5-fold, relative to negative “-FPP” control) with 5 of the 15 sequences
(Figure 2.2 and Table 2.1). Among these sequences, two peptides (dns-GCMIIM and dnsGCAVGP) exhibited a leveling off of fluorescence over time consistent with complete
farnesylation within 4 hours. (Figure 2.2b). In contrast with GGTase-I and GGPP, none of the dnsGC(x)3X peptides exhibited an increase in fluorescence as compared to controls, suggesting no
geranylgeranylation activity. The annexin CGGDD sequence was also evaluated and observed to
be unreactive under all conditions tested.
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Table 2.1 Mammalian FTase reactivity with C(x)3X sequences derived from yeast mating
and thermotolerance screening.

Peptide sequence

Reporter / source

Fluorescence
enhancement of
dns-GC(x3)Xa

HPLC detection of
farnesylated
dns-GC(x3)X

CGGDD

(59)

-

-

CMIIM

a-factor

+

+

CVLMM

a-factor

not determined

not determined

CAVGP
CAYVL
CCAGH
CFFYI
CFNSL
CIPVQ
CLPIV
CQGFL
CSIQG
CSRLQ

Ydj1
Ydj1
Ydj1
Ydj1
Ydj1
Ydj1
Ydj1
Ydj1
Ydj1
Ydj1

+
+
not determined
+
+
-

+
+
not determined
+
+
+
+
+
+
+

CSSLQ
CVSFG
CWAGG
CWGEV
CWGGA

Ydj1
Ydj1
Ydj1
Ydj1
Ydj1

-

+
+
+
+
+

a

Activity in the fluorescence-based screening determined by >5-fold enhancement of prenylation
reaction compared to a negative control reaction, as described in Experimental Procedures.
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Figure 2.2 Dansyl-GC(x)3X peptides can be efficiently farnesylated by mammalian FTase. a)
Fluorescence-based screening for FTase-catalyzed farnesylation of dns-GC(x)3X peptides. b)
Farnesylation of dns-GCMIIM (top) and dns-GCAVGP (bottom) by FTase as monitored by
fluorescence enhancement. Red trace, farnesylation reaction; blue trace, control reaction lacking
FPP. c) Reverse phase HPLC analysis of FTase-catalyzed farnesylation of dns-GCMIIM (left) and
dns-GCAVGP (right); substrate and farnesylated product peaks are labeled. Red trace,
farnesylation reaction; blue trace, control reaction lacking FPP. d) ESI MS/MS analysis of
farnesylated dns-GCMIIM (left) and dns-GCAVGP (right). Reactions were performed and
analyzed as described in Section 2.10; tables of fluorescence screening data and ESI MS/MS ion
assignments are included in Appendix I. This figure has been reused with permission from
reference 58 (Appendix V) with ESI MS/MS analysis performed by Kial Suazo, Univeristy of
Minnesota.
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To confirm that the increase in dansyl fluorescence was due to prenylation, reverse-phase
HPLC was used to directly detect product formation by monitoring a shift in retention time
compared to the unmodified substrate. Under the same reaction conditions as the fluorescence
plate reader assay, dns-GCGGDD was the only peptide which displayed no evidence of activity
(Table 2.1 and Appendix I). As expected, dns-GCMIIM and dns-GCAVGP exhibited the complete
or near complete disappearance of the substrate peak with a new product peak forming at 27 and
25.5 min, respectively (Figure 2.2c). Also showing evidence of near-complete prenylation were
dns-GCWGEV, and dns-GCQGFL. All other sequences presented varying levels of activity as
evidenced by the prescence of both substrate and product peaks (Appendix I). Of note is the
difference in sensitivity of the two methods used to determine peptide activity. Sequences that did
not show an enhancement of the dansyl fluorophore and were comparable to their -FPP or -FTase
control counterparts, were still found to be active when analyzing peptides via direct product
detection using HPLC. These false negatives in the fluorescence assay highlighted the importance
of confirming dns-GC(x)3X peptide reactivity by RP-HPLC.
Farnesylation of dns-GCMIIM and dns-GCAVGP was further confirmed by ESI MS/MS,
with peaks at 1104.4 Da and 940.5 Da for dns-GCMIIM and dns-GCAVGP, respectively,
corresponding to their predicted masses when modified with a 205 Da farnesyl group. There was
no detection of the non-farnesylated substrates (dns-GCMIIM, 899.5 Da; dns-GCAVGP, 735.3
Da) (Figure 2.2d). The observed MS/MS fragments were consistent with the calculated a- and btype ions of the farnesylated peptides (Appendix I). In addition, the characteristic fragments from
the loss of thiofarnesyl moiety (b3* and b4*) were detected. This is a result of the side chain
cleavage between the cysteine β-carbon and sulfur atom, indicating the farnesyl group was indeed
appended to cysteine.69
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2.4 Steady-state kinetic analysis of dns-GC(x)3X peptide reactivity with FTase and the effects
of FTase inhibition by tipifarnib
While HPLC analysis was found to be more consistent in determining the reactivity of
C(x)3X sequences with FTase, use of the fluorescent plate reader assay allowed for determination
of steady-state kinetic analysis of the two peptides exhibiting the largest fluorescence enhancement
upon farnesylation (Figure 2.3, Table 2.2). We compared the activities of dns-GCMIIM and dnsGCAVGP with canonical sequences known to undergo prenylation such as dns-GCVLS derived
from H-Ras.70 To study the effect of the additional amino acid in the C(x)3X motif on kcat, Km, or
both parameters, the 5-mer peptides dns-GCMII and dns-GCAVG were also examined (Table 2.2).
The dns-GCMIIM and dns-GCAVGP peptides exhibit similar values for kcat, with the Km for dnsGCMIIM approximately 10-fold lower than that for dns-GCAVGP. Compared to dns-GCVLS
derived from the sequence of H-Ras (kcat =

0.3 s-1, Km = 1.5 μM),70 kcat values for both dns-

GC(x)3X peptides are reduced ~30-fold while Km increases ~4-fold for dns-GCAVGP and
decreases ~3-fold for dns-GCMIIM (Table 2.2). When compared to dns-GCMII and dns-GCAVG,
kcat/Km was increased 25-fold for dns-GCAVG relative to dns-GCVAGP and, surprisingly,
decreased 2-fold for dns-GCMII relative to its non-canonical counterpart, dns-GCMIIM (Table
2.2). With this change in activity arising from both kcat and Km, it can be inferred that the last amino
acid of these C(x)3X motifs affect both binding and catalytic turnover. Only dns-GCMII serves as
a GGTase-I substrate with a kcat/Km value comparable to dns-GCMIIM with FTase (1.4 +/- 0.1 x
104 M-1s-1, Table 2.2).
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Figure 2.3 Steady state characterization of the reactivity of dns-GC(x)3X and dns-GCaaX
peptides with FTase. a-d) Dependence of farnesylation activity on peptide substrate concentration
catalyzed by FTase: a) dns-GCMIIM; b) dns-GCAVGP; c) dns-GCAVG; d) dns-GCMII; e)
Dependence of geranylgeranylation activity on dns-GCMII peptide substrate concentration
catalyzed by GGTase-I. The curve represents the best fit to the Michaelis-Menten equation.
Reactions were performed and analyzed as described in Section 2.10. Error bars represent the
standard deviation from a minimum of three replicates. This figure has been reused with
permission from reference 58 (Appendix V).
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Table 2.2 Steady-state kinetic parameters: peptide reactivity with mammalian FTase and
GGTase-Ia
Reactivity with FTase
k cat

(s -1 )

Reactivity with GGTase-I

Km (µM)

k cat / Km

(M -1 s -1 )

k cat (s -1 )

Km (µM)

k cat / Km (M -1 s -1 )

Not reported

Not reported

Not reported

dns-GCVLSb

0.3

1.5

2 x 105

dns-GCAVGP

0.009 ± 0.001

5.6 ± 1.0

1.6 ± 0.3 x 103

No activity

No activity

No activity

104

No activity

No activity

No activity

dns-GCAVG

0.14 ± 0.01

3.5 ± 0.3

4.0 ± 0.2 x

dns-GCMIIM

0.009 ± 0.001

0.5 ± 0.1

1.9 ± 0.6 x 104

No activity

No activity

No activity

dns-GCMII

0.040 ± 0.002

4.6 ± 0.6

8.6 ± 0.6 x 103

0.0070 ± .0003

0.50 ± 0.07

1.4 ± 0.1 x 104

Steady-state parameters were determined at saturating FPP (10 μM) or GGPP (10 μM) and
There have been several studies in the development of inhibitors of FTase as a target of
varying peptide concentrations under conditions described in the Experimental Procedures.
Errors represent71-72
the standard deviation from a minimum of three replicates.
cancer
treatment.
One such inhibitor is Tipifarnib, currently under investigation as a
b
reference 69
a
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There have been several studies in the development of inhibitors of FTase as a target of
cancer treatment.71-72 One such inhibitor is Tipifarnib, currently under investigation as a
treatment for acute myeloid leukemia and breast cancer in which prenylation of H-Ras plays a key
role in tumor growth. Tipifarnib prevents the prenylation of the c-terminal motif through binding
at the peptide substrate binding site of FTase. When treated with varying amounts of tipifarnib,
prenylation was efficiently blocked for both dns-GCMIIM (IC50 = 23 +/- 7 nM) and dns-GCAVGP
(IC50 = 41 +/- 13 nM, Figure 2.4). This suggests prenylation of these non-canonical C(x)3X
sequences occurs through the same binding interaction as those sequences of the type CaaX with
the potential to be targeted by the same inhibitors currently being studied for known sequences
such as H-Ras.
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Figure 2.4 Inhibition of FTase-catalyzed farnesylation of dns-GC(x)3X peptides by
tipifarnib. a) dns-GCMIIM; b) dns-GCVAGP. Initial slopes were normalized to reactions
without tipifarnib and IC50 values were calculated as described in Section 2.10. Error bars
represent the standard deviation from a minimum of three trials. This figure has been reused
with permission from reference 58 (Appendix V).
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2.5 Prenylation of His6-eGFP-GCAVGP reporter protein with product detection through
mass spectroscopy and alkyne functionalized FPP labeling
The biological importance of the ability of FTase to prenylate C(x)3X sequences was
examined in a more relevant context of a purified folded protein, eGFP-GCAVGP. We bacterially
expressed this protein using an approach validated for detecting modification of eGFP fusion
proteins bearing canonical CaaX sequences.73-74 Farnesylation of eGFP-CAVGP was assessed via
LC/MS (Figure 2.5). In a reaction lacking the FPP co-substrate, only the eGFP-CAVGP protein is
detected with a mass consistent with the expected unmodified protein weight (28205.1 Da). Upon
incubation with both FTase and FPP, a new peak is detected in the chromatogram at longer
retention time with a mass of 28408.6 Da. This increase is 205 Da is the consistent with the addition
of a farnesyl group, providing evidence of successful farnesylation of a full length protein
terminating in a C(x)3X motif.
To further confirm FTase-catalyzed farnesylation of eGFP-CAVGP under in vitro
conditions, we evaluated the ability of purified FTase to modify eGFP-CAVGP using a FPP
analogue (C15AlkOPP) bearing an alkyne group to allow for post-prenylation protein labeling
(Figure 2.5).69 Following eGFP-CAVGP incubation with C15AlkOPP in the presence of FTase,
the modified protein was derivatized with TAMRA-azide using Cu-catalyzed alkyne-azide
cycloaddition.75-76 A single bold band was seen in TAMRA fluorescence scanning at a size
corresponding to 28.4 kDa, the size of farnesylated His6-eGFP-GCAVGP (Figure 2.5). The
negative control gave no band upon fluorescence detection, while Coomassie staining presents one
band in each positive and negative control samples indicating that the fluorescence in the
prenylation reaction is due to modification with an alkyne farnesyl group.
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Figure 2.5 A C(x)3X sequence is efficiently farnesylated in the context of a full length
protein. a) LC/MS analysis of farnesylation of an eGFP reporter protein terminating in a
C(x)3X sequence. LC chromatogram of in vitro farnesylation of eGFP-GCAVGP using purified
FTase in the absence (panel i) or presence (panel ii) of FPP, with absorbance detected at 555
nm. Negative absorbances are observed due to background fluorescence from eGFP. Peaks A
(panel iii) and B (panel iv) have deconvoluted masses of 28205.1 Da and 28408.6 Da,
respectively, that differ by 203.5 Da approximately corresponding to farnesyl modification
(theoretical mass of farnesyl group: 205 Da). b) In-gel fluorescence scan (top) and Coomassie
staining (bottom) of eGFP-GCAVGP subjected to in vitro prenylation using purified FTase in
the presence or absence of C15AlkOPP, shown below. This figure has been reused with
permission from reference 58 (Appendix V) with LC/MS and in-gel fluorescence scan
performed by Kiall Suazo, University of Minnesota.
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2.6 Expansion of the C(x)3X motif to proteins in the human proteome
To address the relevance of our findings to potential endogenous proteins within humans,
we expanded our investigation to include C(x)3X sequences derived from the human proteome to
explore the potential biological impact of this novel FTase substrate class. We began our study
into the biological relevance of these finding in the human genome by searching for proteins
containing a C(x)3X C-terminus motif. We approached identifying these sequence candidates
through sequence randomization. Using Prosite and our most active sequences from the Ydj1p
screening, we allowed for variability throughout the five amino acid motif one position at a time
before increasing variability to two, then three positions at random (Scheme 2.1). We were careful
to omit any sequence having more than one cysteine in the motif to eliminate classic four amino
acid motif (example: CCIIM) or for prenylation by GGTase-II, which recognizes the sewuence
motif CC or CxC in Rab proteins and other substrates.12
The Prosite scan yielded 965 potential proteins in the human genome which contain a
C(x)3X C-terminus. From our most active sequences in the Ydj1p screening (-CMIIM, -CAVGP,
and -CWGEV) six proteins were chosen from over 260 potential targets similar to these sequences
for characterization of their C(x)3X motifs (Table 2.3). This determination was based on the current
literature of the proteins, their location within the cell, and their amino acid variability (or
similarity) when compared to the Ydj1p sequences. These sequences were tested against the same
fluorescence-based assay and product detection via HPLC as used in the yeast screening described
above. Of these six sequences tested, half showed a detectable level of activity with FTase (Table
2.3). Those two resembling -CAVGP, dns-GCQTGP and dns-GCSQGP, were found to be most
active by exhibiting complete prenylation of the substrate peptide. One other sequence, dnsGCFSKM, also exhibited reactivity with FTase as detected via HPLC. As found previously in our
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screening of sequences derived from YDj1p screening, none of these sequences was found to be
active with GGTase-I (data not shown). While farnesylation of dns-GCQTGP and dns-GCSQGP
was confirmed by HPLC, the fluorescence enhancements for these peptides upon prenylation were
not sufficient to support steady state characterization.
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CMIIM>
CMxIM>
CMxxM>
CxxxM>
CMxxx>
Scheme 2.1 An example of introducing variability into C(x)3X sequences for Prosite
Search “x” indicates position in which variability is allowed in the Prosite Search; “>”
indicates the sequence must be C-terminal.
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Table 2.3 Mammalian FTase reactivity of C(x)3X sequences derived from the human
genome using randomization of yeast screening hits
Peptide

Human protein name and gene
identifier

Fluorescence
Enhancement assay

HPLC detection of
farnesylated peptide

INACTIVE

INACTIVE

dns-CLLHP Ras association domain-containing
protein 5
dns-CSQGP

Sushi, nidogen and EGF-like
domain-containing protein 1

ACTIVE

ACTIVE

dns-CQTGP

Putative glycosylation-dependent
cell adhesion molecule 1
Olfactory receptor protein

ACTIVE

ACTIVE

INACTIVE

INACTIVE

sorting nexin 4

INACTIVE

ACTIVE

Prostamide/prostaglandin F
synthase

INACTIVE

INACTIVE

dnsCSVKM
dns-CFSKM
dns-CDREV
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2.7 Use of fluorescence localization as a proxy for prenylation within HEK293 cells: C(x) 3X
sequences can be sufficiently prenylated in a biologically relevant context
To be considered biologically relevant, proteins terminating in C(x)3X sequences must
exhibit sufficient reactivity to be modified by endogenous FTase within an intact human cell. The
minimum reactivity is estimated to be in the range of kcat/Km = 0.5-2 x 104 M-1s-1 when peptide
reactivity is determined in an in vitro assay using purified FTase.77 The reactivity of the dnsGCMIIM peptide with purified FTase (kcat/Km = 1.9 +/- 0.6 x 104 M-1s-1, Table 2.2) suggests the
CMIIM sequence is sufficiently reactive to support protein farnesylation within mammalian cells.
The apparent reactivity observed for this sequence within yeast cells further suggests the ability of
this motif to be modified in a cellular setting.
Using a pEGFP-KRas mammalian expression vector (Casey Lab, Duke University), the
canonical motif -CVIM was modified to contain the four sequences above through PCR extension
and subsequent ligation (Section 2.10).78 Cloning of negative controls in which the cysteine to be
prenylated is replaced with a serine were also performed in the same way. Successful cloning was
verified by sequencing (Genscript, Inc.) The use of an eGFP-KRas fusion protein serves as a proxy
for directly measuring prenylation through visualization of eGFP fluorescence at the membrane
(prenylated) or diffuse throughout the cell (not prenylated, or prenylated but not processed).
Following transfection into HEK293 cells, eGFP-KRas-CMIIM displays membrane localized
fluorescence consistent with reporter protein farnesylation (Figure 2.6a). Treatment with tipifarnib
during transfection leads to diffuse eGFP-KRas-CMIIM fluorescence, as does mutation of the
C(x)3X cysteine to a serine (eGFP-KRas-SMIIM). A reporter protein lacking the last residue of
the CMIIM sequence (eGFP-KRas-CMII) also displays membrane localized fluorescence but is
unaffected by tipifarnib treatment. This behavior is consistent with the reactivity of the CMII
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sequence with GGTase-I (Table 2.2), which would lead to prenylation and membrane localization
in the presence of tipifarnib. This result also indicates CMIIM is modified selectively by FTase in
cells and is in fact the sequence being accepted by FTase, as proteolysis of CMIIM to CMII by
endogenous proteases would result in recuse of prenylation by geranylgeranyltransferase-I.
Overall, these studies support FTase-catalyzed lipidation of eGFP-KRas-CMIIM within the cell,
indicating that C(x)3X sequences can be sufficiently reactive to support biologically relevant
protein farnesylation. The ability of eGFP-KRas-GCMIIM to membrane localize in HEK293 cells
may be due to its being studied in a yeast a-factor-based screening. This a-factor is known to
undergo subsequent proteolysis and methylation in yeast which is also required for mammalian
prenylated proteins to exhibit membrane localization.79
The relative amount of fluorescence localization of eGFP-Kras-CMIIM in the absence and
presence of tipifarnib was also quantified. For each sequence and condition, a minimum of n=50
cells were counted and given the assignment of being membrane associated or diffuse. Upon
addition of tipifarnib, membrane localization dropped from 84% membrane associated to only 2%
membrane associated. A negative control of eGFP-KRas-SMIIM was also scored and found to
have zero cells exhibiting membrane association (Figure 2.6b).
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Figure 2.6 eGFP-KRas-CMIIM exhibits localization within a mammalian cell. a)
Representative images of HEK293 cells transfected with eGFP-KRas-XMIIM or eGFP-KRasCMII reporter proteins in the absence or presence of tipifarnib (FTI); scale bar = 20 µm. b) Scoring
of fluorescence patterns observed in HEK293 cells after transfection with eGFP-KRas reporter
proteins; an asterisk (*) indicates no cells exhibited membrane associated fluorescence. This figure
has been reused with permission from reference 58 (Appendix V).
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2.8 Metabolic labeling of eGFP-KRas-CMIIM in HEK293 cells
To provide definitive evidence that the eGFPKRas-CMIIM protein is farnesylated within
human cells, the protein can be enriched through metabolic labeling with alkyne-modified FPP in
HEK293 cells allowing subsequent conjugation with an affinity handle.80 To directly confirm
prenylation of the eGFP-KRas-CMIIM reporter protein by endogenous FTase within a mammalian
cell, transfected HEK293 cells were subjected to metabolic labeling using C15AlkOPP FPP
analogue. Following transfection with eGFP-KRas-derived fusion proteins, cells were incubated
with the C15AlkOPP FPP analogue for alkyne functionalization of the expressed protein. Cell
lysates were derivatized with TAMRA-N3 followed by in-gel imaging of TAMRA fluorescence as
described in section 2.5, with eGFP-KRas-CVIM serving as a positive control. A single major
band at the expected size of this fusion protein (50 kDa) was observed, with this band absent in
untransfected cells or transfected cells not treated with the C15AlkOPP FPP analogue (Figure
2.7a). A similar predominant TAMRA-fluorescent band was observed at the expected size of
eGFP-KRas-CMIIM in the presence of C15AlkOPP. This single bold band was not observed when
the CMIIM sequence in the reporter was mutated to SMIIM, with the SMIIM sample resembling
the negative control. The loss of reporter protein detection with the SMIIM sequence would be
expected due to the lack of a cysteine at the farnesylation site.
A quantitative analysis was performed on cell lysates obtained from eGFP-KRas-CMIIMvs eGFP-KRasSMIIM-transfected cells grown in the presence of C15AlkOPP. Lysates were
biotinylated with biotin-N3 followed by pull-down with avidin resin. Enriched proteins were
digested, labeled with a tandem mass tag (TMT) and analyzed via LC-MSMS. A volcano plot
generated after performing a two-sample t-test (FDR = 0.05, s0 = 0.5) across three replicates
strongly indicates that eGFP-KRasCMIIM is enriched over eGFP-KRas-SMIIM, further
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evidencing the in vivo farnesylation of this protein (Figure 2.7b). Parallel studies of eGFP-KRas
reporter proteins terminating in other FTase reactive C(x)3X sequences failed to demonstrate
metabolic labeling within transfected cells. This may reflect that the lower reactivity of these
sequences (e.g. CAVGP is 10-fold less reactive than CMIIM, Table 2.2) is insufficient to support
direct detection of transfected protein prenylation within cells by metabolic labeling or imaging
methods.77 Nevertheless, these imaging, metabolic labeling, and quantitative proteomic studies
support FTase-catalyzed lipidation of eGFP-KRas-CMIIM within the cell, indicating that a C(x)3X
sequence can be sufficiently reactive to support biologically relevant protein farnesylation.
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Figure 2.7 eGFP-KRas-CMIIM is efficiently modified by FTase within a mammalian cell. a)
In-gel fluorescence scan (top) and Coomassie staining (bottom) of lysates from HEK293 cells
transfected with eGFP-KRas reporter proteins and metabolically labeled with C15AlkOPP
followed by conjugation of a TAMRA-N3 fluorophore. Cells were either non-transfected
(HEK293) or transfected with eGFP-KRas-CVIM, eGFP-KRas-CMIIM, or eGFP-KRas-SMIIM
reporter proteins in the absence or presence of C15AlkOPP. b) Volcano plot for TMT-labeled
quantitative proteomic analysis of eGFP-KRasCMIIM- vs eGFP-KRas-SMIIM-transfected
HEK293 cells treated with C15AlkOPP and enriched via biotin-avidin pull-down. A two sample
t-test (FDR = 0.05, s0 = 0.5) from three replicates shows that GFP and KRas are statistically
enriched in eGFP-KRas-CMIIM transfected cells. This figure has been reused with permission
from reference 58 (Appendix V) with in-gel fluorescence and proteomic analysis performed by
Kial Suazo, Univeristy of Minnesota.
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2.9 Conclusions
Protein prenylation by FTase and GGTase-I is an important post-translational modification
involved in cell signaling and protein membrane localization. For several decades, a C-terminal
CaaX sequence has served as the required recognition motif for a protein to be considered a
substrate for prenylation. We have identified multiple C-terminal C(x)3X sequences representing
a new class of substrates for FTase. While biochemical, structural, and computation studies have
provided the essential foundation for the study of the modification, these C(x)3X substrates found
to undergo prenylation broaden the range of FTase substrate selectivity and expand the list of
potential prenylation targets within the human proteome.
The ability of FTase to prenylate C(x)3X sequences was not anticipated through previous
predictive studies. Multiple structural studies of FTase and GGTase-I complexes with peptide
substrates supported substrate length selectivity defined by two contact points: 1) the distance
between the coordination of the cysteine of the CaaX sequence to the catalytic zinc ion; and 2)
multiple hydrogen bonds (both direct and water-mediated) between the C-terminal carboxylate of
the CaaX sequence and residues in both subunits of FTase or GGTase I.48, 81-83 In turn, these contact
points were considered in the FlexPepBind computational approach for predicting peptide
sequence reactivity with FTase. FlexPepBind only predicts ~50% of the HPLC-verified FTase
C(x)3X sequences as potential FTase substrates. The ability of FTase to accept the longer C(x) 3X
motif indicates that its active site is more flexible than the previously proposed more rigid model.
The inability of GGTase-I to accept these C(x)3X substrates shows that it exhibits distinct
length and/or sequence requirements, unlike its close relative FTase. Two enzymes thought to be
so alike in their substrate requirements are now presenting an instance where they have distinct
differences in substrate specificity. Future studies will work to define the sequence selectivity
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within the C(x)3X sequence and explore the effect of changing the prenyl donor cosubstrate on
C(x)3X substrate reactivity, for comparison to prenyl-donor dependent changes in peptide substrate
selectivity seen with CaaX substrates.60, 84 These studies will provide functional insight into the
interactions formed with these longer peptide sequences within the FTase active site.
Understanding the active site adjustments required for FTase recognition and modification of
C(x)3X sequences will be aided by structural and computational modeling studies of peptides from
this new substrate class in complex with FTase.
The ability of both mammalian and yeast FTase to farnesylate proteins with the longer
C(x)3X motif has the potential to greatly expand the number of potential FTase substrates within
the human and yeast proteomes. The human proteome is predicted to contain 1008 proteins
terminating in C(x)3X sequences (as of June 2018, Appendix II). This prediction accounts for
canonical prenylation motifs, such as CCxxX or CxC. Allowing cysteine residues in only the first
position, 816 of these sequences contain only a single cysteine residue. This representation nearly
matches that of CaaX sequences in the human proteome (1205 sequences; 1059 with a single
cysteine). Biochemical and computational studies indicate that a large fraction of these CaaX
sequences can serve as FTase substrates.43, 47 Logically then, it is possible that a fraction of these
identified C(x)3X sequences could also be farnesylated. A similar proportion of proteins bearing
C(x)3X and CaaX motifs are observed in the S. cerevisiae proteome, with 117 C(x)3X proteins (88
with a single cysteine, Appendix III) and 120 CaaX proteins (101 with a single cysteine). Based
on these numbers, inclusion of C(x)3X proteins doubles the potential scope of prenylation within
the human and yeast proteomes. This idea of proteomic expansion could also have significance in
pathogenic organisms that employ either endogenous or host-mediated farnesylation, such as
Plasmodium falciparum, Candida albicans, and Legionella pneumophila.80, 85-89 Each of these
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pathogenic organsims contain a small number of proteins bearing a C(x)3X motifs that may
undergo prenylation by either pathogenic or host protein prenyltransferases (Appendix IV).
Our expansion of the potential substrates recognized by FTase highlights the importance
of continuing studies towards identifying additional new and biologically relevant protein
substrates and determining their prenylation state within the cell. In particular, identification and
isolation of endogenously prenylated C(x)3X proteins will be essential to understanding the impact
of prenylation of non-canonical FTase substrates within the cell. Given the established
involvement of prenylation in a range of disease states, our findings also carry the potential to
establish a link between farnesylation of unanticipated protein targets and cellular dysfunction that
could be exploited for treatment with the available range of potent farnesyltransferase inhibitors.
Our findings further support the “shunt pathway” model for protein prenylation wherein a
subset of farnesylated proteins can sidestep subsequent C-terminal processing steps.31 Such
proteins with canonical CaaX motifs include Ydj1p, Rab38, Phk/, and G5.25,

31, 90-91

The

majority of C(x)3X sequences described in this study were identified in yeast using a Ydj1p-based
screen that discriminates for shunted sequences. While none of the Ydj1p screen-derived C(x)3X
sequences exist in either the yeast or human proteomes, similar sequences do exist and are reactive
for farnesylation as demonstrated by the human sequences examined in this work. The state of
these substrates in a cellular context will also provide insight into the ability of the processing
enzymes, Rce1 and ICMT to accept these C(x)3X motifs as substrates. Another avenue of study
will be whether the ability for these new substrates to be prenylated, but perhaps not proteolytically
processed, gives way for new roles of prenylated proteins outside of membrane localization in
mammalian cells. After determination of how many naturally occurring C(x)3X proteins are
prenylated, the determination of what fraction of these C(x)3X proteins are shunted away from
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subsequent processing would provide insight into potentially new roles of prenylation in the cell.
Identifying protein prenyltransferase C(x)3X protein substrates may require application of
chemical biology, proteomics-based approaches or development of new analytical tools for
detecting endogenously prenylated proteins, especially since traditional assays for detecting in vivo
prenylation (e.g. fluorescence membrane localization) may not be relevant to shunted proteins
regardless of their C-terminal motif.
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2.10 Materials and Methods
2.10.1 Miscellaneous Methods: All in vitro FTase and GGTase-I assays were performed at 25
°C. All curve fitting was performed with KaleidaGraph (Synergy Software, Reading, PA).
Geranylgeranyl diphosphate (GGPP) and farnesyl diphosphate (FPP) were purchased from
Isoprenoids.com (Tampa, FL). Peptides were commercially synthesized (Sigma-Genosys, The
Woodlands, TX) and exhibited >90% purity, as determined by HPLC or after semi-prep
purification via HPLC. Peptides were solubilized in ethanol containing 10% (v/v) DMSO and
stored at -20 °C. Peptide concentrations were determined spectrophotometrically using Ellman’s
reagent. The isoprenoid analogue C15Alk-OPP was prepared as previously described.(73)

2.10.2 Yeast strains and plasmids (These experiments were performed in the Schmidt
laboratory, University of Georgia): The yeast strains used in this study were IH1793 (MAT
lys1), RC757 (MAT sst2-1 rme his6 met1 can1 cyh2), SM2331 (MATa trp1 leu2 ura3 his4 can1
mfa1 mfa2), yWS304 (MATa his3∆1 leu2∆0 met15∆0 ura3∆0 ydj1::KANR), and yWS1632 (MATa
his3∆1 leu2∆0 met15∆0 ura3∆0 ram1::KANR) and have been previously described.31, 63, 92-93 These
strains were routinely propagated at 30 °C (RC757, SM2331) or room temperature (yW304,
yWS1632) on either YPD or appropriate selective media when transformed with plasmid pRS315
(CEN LEU2), pSM1605 (2µ URA3 MFA1), pWS610 (CEN LEU2 MFA1), pWS612 (CEN LEU2
MFA1-CASQ), pWS942 (CEN URA3 YDJ1), pWS1132 (CEN URA3 YDJ1-SASQ), pWS1246
(CEN URA3 YDJ1-CTLM), and pWS1286 (CEN URA3 YDJ1-CVIA) have been previously
described.31, 94-95 pWS705 (2µ URA3 MFA1-CGGDD), pWS1170 (CEN URA3 YDJ1-CVLMM),
and pWS1488 (CEN URA3 YDJ1-CMIIM) were constructed by PCR-directed, recombinationmediated plasmid construction.96 In brief, PCR products designed to amplify the 3´ ends of MFA1
84

and YDJ1 with encoding for desired C(x)3X motifs were used to gap repair plasmids pSM1605
(2µ URA3 MFA1) and pWS1132 (CEN URA3 YDJ1-SASQ), respectively, as previously
described.31,
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These plasmids and others identified through our screening methods were

introduced into strains via a lithium acetate-based transformation procedure.97

2.10.3 Oligo design for generation of randomized C(x)3X sequences by PCR (These
experiments were performed in the Schmidt laboratory, University of Georgia): Synthetic
oligonucleotides were designed to PCR amplify the CaaX encoding region of YDJ1 and its
5´untranslated region as encoded in pWS1132. The forward PCR oligo was designed to encode
the C(x)3X sequences and was flanked on the 5´ end by 39 nucleotides homologous to the YDJ1
gene immediately before the CaaX motif (to facilitate recombination), and 19 nucleotides
homologous the UTR immediately after the stop codon (to facilitate PCR priming). The oligo used
for generation of CGGDD was designed specifically. The oligo used to generate a library of C(x)3X
sequences was synthesized to encode a cysteine codon followed by 4 random codons and a stop
codon. To limit the complexity of the codons synthesized yet allow for all possible amino acids,
only C, G and T were used at the wobble position of the (x)3 codons. To prevent formation of
premature stop codon yielding a canonical length motif (i.e. Cxxx) that would lead to false
positives, only A, C, and G were used at the first position of the X codon; this strategy
unfortunately disallowed incorporation of Cys, Phe, Trp, and Tyr codons.

2.10.4 a-factor mating pheromone screen, halo assay, and mating test (These experiments
were performed in the Schmidt laboratory, University of Georgia): SM2331 yeast (MATa trp1
leu2 ura3 his4 mfa1 mfa2) were co-transformed using a previously described PEG lithium-acetate
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method with MluI and SphI digested pWS1024 (CEN LEU2 mfa1 V34TAG; amber mutation at a1
position of CaaX motif) and PCR product engineered to encode 5-mer sequences. The
transformation mix was plated on SC-leucine solid media and incubated at 30 °C for 72-96 hours.
Estimates of colony numbers were determined, then colonies were replica plated onto a fresh SCleucine plate as well as a YPD plate containing a thin lawn of RC757 yeast (MAT sst2-1 rme his6
met1 can1 cyh2) prepared in the presence of 0.071% TX-100 (final concentration in cell
suspension prior to lawn preparation) and plates incubated at 30 °C for 16-20 hours. Colonies
displaying a halo were identified, and the corresponding colony on the SC-leucine replicate plate
was recovered. Expression of a-factor was confirmed by amplifying selected colonies in SCleucine liquid media and applying 20X concentrated spots of liquid culture onto RC757 lawns in
the presence and absence of TX-100. Plasmids were isolated and sequenced from the strongest
halo producing strains.
A modified version of the halo assay was used to assess relative strength of a-factor
production by the various a-factor CaaX mutants evaluated. Plasmid transformed MATa strains
were cultured in appropriate selective media (SC-leucine or SC-uracil), spotted onto YPD, and
incubated for 24-36 hours at 30 °C. The spots on the plate were replica transferred onto a thin lawn
RC757 yeast (no TX-100), and plates were incubated at 30 °C for 16-20 hours.
The quantitative mating test was performed essentially as previously described.31 In brief,
the MATa strains were independently cultured to saturation in selective media, and the IH1793
MAT lys1 strain was cultured in YPD. All strains were diluted to A600 ~1.0 using fresh culture
media. Empirically determined dilutions were spread on SD and SC-lysine solid media; the former
media is diploid selective while the latter is selective for MATa haploid cells and MATa cells that
have undergone mating to form a diploid cell. The total count of colony forming units (CFUs) on
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each media type was determined and used to calculate a mating frequency (i.e. diploid CFUs over
total CFUs); this value was used to determine the percentage mating of each condition relative to
the strain producing wildtype a-factor.

2.10.5 Thermotolerance screen (These experiments were performed in the Schmidt
laboratory, University of Georgia): yWS304 (MATa his3∆1 leu2∆0 met15∆0 ura3∆0
ydj1::KANR) yeast was co-transformed using a previously described PEG lithium-acetate method
with NheI digested pWS1132 (CEN URA3 YDJ1-SASQ) and PCR product engineered to encode
randomized 5-mer sequences. A small portion of the transformation mix was plated on SC-uracil
solid media and incubated at 25 °C for 96 hours to assess the total number of plasmids created by
the transformation procedure. The remaining transformation mix was plated on YPD solid media
and incubated at 40 °C for 96 hours. Colonies recovered by high temperature selection were retested for thermotolerance as patches on YPD, and individual plasmids recovered and sequenced.
The isolated plasmids were re-introduced into yWS304 to confirm plasmid-linked thermotolerance
prior to detailed thermotolerance analysis.

2.10.6 Thermotolerance assay (These experiments were performed in the Schmidt
laboratory, University of Georgia): Saturated cultures grown in SC-uracil liquid media at room
temperature were serially diluted into YPD and spotted onto YPD solid media (5 µl per spot) as
previously described.31 Plates were incubated at various temperatures (25 °C, 37 °C, or 40 °C) for
several days before plate imaging. Each experiment was performed at least twice on separate days,
and each strain was evaluated in duplicate within each experiment.
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2.10.7 Estimate of C(x)3X complexity in a-factor and thermotolerance screens (These
experiments were performed in the Schmidt laboratory, University of Georgia): The
estimated coverage of C(x)3X sequences evaluated was calculated using the GLUE-IT algorithm
based on the number of colonies screened and the number and redundancy of the codons used for
amino acid randomization.64 The number of colonies screened with the a-factor reporter was
estimated by direct colony counts on all plates evaluated. For the Ydj1p reporter, a known
percentage of the transformation mix was plated onto SC-uracil solid media, and the number of
colonies observed was used to determine the total number of colony-forming units (CFUs) in the
rest of the transformation mixture. The number of false positive colonies (i.e. background colonies
containing re-circularized or uncut plasmid) were not counted toward the total number of CFUs;
the false positive numbers were determined from transformation mixtures containing the linearized
plasmids alone and typically yielded a smaller number of CFUs relative to co-transformed sample
(typically <2%).

2.10.8 Immunoblot analysis for protein prenylation in yeast (These experiments were
performed in the Schmidt laboratory, University of Georgia): Whole cell lysates of mid-log
yeast were prepared as previously described using alkaline hydrolysis and TCA precipitation.31, 98
Samples and PageRuler size standards (Thermo Scientific, Waltham, MA) were separated by SDSPAGE (12.5%), transferred onto nitrocellulose, and blots incubated with rabbit anti-Ydj1p primary
antibody (courtesy of Dr. Avrom Caplan) and HRP-conjugated donkey anti-rabbit secondary
antibody (GE Healthcare, Chicago, IL). Immune complexes were detected by X-ray film after
treatment of blot with HyGLO development solution (Denville Scientific, South Plainfield, NJ).

88

2.10.9 Image analysis for yeast assays and immunoblots (These experiments were performed
in the Schmidt laboratory, University of Georgia): Plates and developed films were imaged
using a flat-bed scanner (300 dpi; grayscale), and resultant TIFF image files manipulated with
Photoshop (i.e. image rotation, image contrast adjustments, cropping) before final figure assembly
using PowerPoint. Plates were scanned face down without lids using a black background. Films
were scanned using a white background. For all plate scans, contrast settings were adjusted
manually using the same settings for all images. For film scans, contrast settings were adjusted
using Photoshop’s ‘Auto Contrast’ function.

2.10.10 Activity screening of dns-GC(x)3X peptides by fluorescence-based prenylation assay:
Prenylation of dansylated dns-GC(x)3X peptides was assessed by a time-dependent increase in
fluorescence (λex 340 nm, λem 520 nm) upon prenylation of the dansylated peptide.42, 48, 65-67 Assays
were performed at 25 °C in a 96-well plate (Corning, Corning, NY); Fluorescence was measured
as a function of time in a Synergy H1 multimode plate reader (Biotek, Winooski, VT). Negative
controls lacked the FPP or GGPP cosubstrate.
To determine if a given dns-GC(x)3X peptide is considered reactive with FTase or GGTaseI, the observed fluorescence at time zero for each peptide was subtracted from the fluorescence at
four time points (Ft – F0; t = 30, 60, 90, and 120 min) to determine the corrected fluorescence at
each time point for both the reactions containing the FPP or GGPP prenyl donor and the negative
control reactions lacking the prenyl donor cosubstrate. To be considered reactive, a peptide must
exhibit at least a 5-fold enhancement of fluorescence in the FTase or GGTase-I reaction compared
to the negative control [e.g. Corrected fluorescence (+FPP) / Corrected fluorescence (-FPP) > 5].
Fluorescence data and calculated fluorescence enhancements for reaction with FTase/FPP are
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reported in Appendix I. No dns-GC(x)3X peptides exhibited detectable fluorescence enhancement
in reaction with GGTase-I/GGPP.

2.10.11 Activity screening prenylation of dns-GC(x)3X peptides via HPLC: Reverse phase
HPLC analysis was performed on all dns-GC(x)3X peptides to confirm farnesylation (FPP and
FTase) or geranylgeranylation (GGPP and GGTase-I. Reactions were prepared as described above
for fluorescence-based activity screening and incubated at room temperature for 14 hours in lowadhesion tubes wrapped in foil. Reactions were halted by addition of an equal volume of 20%
acetic acid in isopropanol prior to analysis by HPLC (Zorbax Eclipse XDB-C18 column). Peptides
and products were detected by fluorescence (λex = 340 nm and λem = 496 nm). In all cases, HPLC
analysis indicates that the peak for the dns-GC(x)3X peptide shifts to a longer retention time upon
farnesylation, whereas parallel reactions performed without FPP showed no change in peptide
retention time. Representative HPLC traces are included in the Appendix I. Analogous reactions
with GGTase-I and GGPP provided no evidence for geranylgeranylation of any dns-GC(x)3X
peptides.

2.10.12 Steady-state characterization of dns-GC(x)3X and dns-GCaaX peptides: Steady-state
kinetics were determined as previously described for prenylation of dns-GC(x)3X and dns-GCaaX
peptides by FTase or GGTase-I by monitoring the time-dependent increase in fluorescence (λex
340 nm, λem 520 nm) upon prenylation of the dansylated peptide in a Synergy HI multimode plate
reader (Biotek).44, 68, 99
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2.10.13 Determination of tipifarnib inhibition of dns-GC(x)3X peptide farnesylation: Assays
were performed as described above, with varying concentrations of tipifarnib (0-100 nM) included
in the reaction. Initial slopes (fluorescence change per second) were determined for each reaction
and normalized to the reaction without tipifarnib. Normalized slope values were plotted against
tipifarnib concentration and analyzed using equation 1 to calculate IC50 values.

(1) Normalized Slope = 1 −

[tipifarni b]
[tipifarnib] + IC 50

2.10.14 ESI-MS analysis of farnesylated dns-GC(x)3X peptides (ESI-MS experiments were
performed in the Distefano laboratory, University of Minnesota): In vitro reactions with dnsGC(x)3X peptides (5 µM) were prepared in prenylation buffer in the presence of 100 nm FTase
and 10 µM FPP and incubated overnight at room temperature. Each reaction mixture was
separately loaded onto a pre-conditioned and pre-equilibrated Sep-Pak reverse-phase C18
cartridge (Waters Corp., Milford, MA) and washed with 0.1% TFA in H2O. A step-gradient elution
was carried out with 6-mL volumes of 10% (CH3CN/H2O; 0.1% TFA), 35% (CH3CN/H2O; 0.1%
TFA), and 100% CH3CN with 0.1% TFA. The 100% CH3CN fractions containing the modified
peptides (confirmed by fluorescence under UV lamp) were evaporated and residues were
redissolved in 30% CH3CN/H2O with 0.1% TFA. Samples were loaded to an LC column (Agilent
Zorbax SB-C18, 5 µm x 150 mm x 0.5 mm) coupled to an ESI-MS/MS ion trap mass analyzer
(Agilent 1100 Series LC/MSD). Runs were set to positive ion mode and CID MS/MS
fragmentations were triggered at 1.5 V. The theoretical masses of farnesylated peptides and their
fragments were calculated using Protein Prospector v 5.19.1 (http://prospector.ucsf.edu).
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2.10.15 Construction of pJExpress414 plasmid encoding the His6-eGFP-GCAVGP reporter
protein: A gene encoding the His6-eGFP-GCAVGP reporter protein was prepared by PCR using
the pJExpress414-eGFP-CVIA vector as a template with the GCAVGP C-terminal sequence and
HindIII restriction site encoded in the 3′ primer.100 PCR products were purified using the BioBasic
Inc.(Amherst, NY) EZ-10 Spin Column PCR Purification Kit following the manufacturer’s
instructions. Following digestion by NheI and HindIII, the His6-eGFP-GCAVGP insert was ligated
into the pJExpress414 expression plasmid using the Quick Ligase kit (New England Biolabs,
Ipswich, MA) per manufacturer instructions. Insert ligation was verified by analytical restriction
digest and DNA sequencing (Genewiz, South Plainfield, NJ).

2.10.16 Expression and purification of His6-eGFP-GCAVGP: Chemically competent BL21
(DE3) E. coli (Z-competent, Zymo Research, Irvine, CA) were transformed with
pJExpress414_His6-eGFP-GCAVGP per the manufacturer’s protocol. Following transformation
and antibiotic selection, a colony from the transformation plate was inoculated into LB media (5
mL) containing 100 µg / mL ampicillin. The culture was incubated with shaking (225 rpm) for 4
hours at 37 °C and subsequently used to inoculate 1 L of prewarmed autoinduction media
supplemented with 100 µg / mL ampicillin.101 Following overnight incubation at 28 °C with
shaking, bacteria were harvested, lysed, and His6-eGFP-GCAVGP was purified as previously
described.74 Protein concentration was measured using absorbance of eGFP at 488 nm (λ488 =
55,000 M−1cm−1).102

2.10.17 Farnesylation reactions with eGFP-GCAVGP (ESI-MS/MS and in-gel fluorescence
labeling experiments were performed in the Distefano laboratory, University of Minnesota):
Farnesylation of purified eGFP-GCAVGP was performed by incubation of purified eGFP92

GCAVGP (5 µM) with 100 nM FTase, 10 µM FPP or C15AlkOPP, and 5 mM MgCl2 in reaction
buffer (50 mM NaHEPPSO, 5 mM TCEP, pH 7.8) in a final volume of 2 mL (FPP, mass
spectrometry analysis) or 500 µL (C15AlkOPP, TAMRA labeling and in-gel fluorescence
analysis). Substrate protein was incubated in reaction buffer for 20 min prior to reaction initiation
by addition of FTase and prenyl donor to reduce disulfide bonds. Reactions were incubated
overnight at room temperature wrapped in foil, and then frozen for storage. In vitro reaction
mixtures were concentrated by lyophilization and injected to an LC column (Agilent [Santa Clara,
CA] Zorbax 300SB-C8, 3.5 µm x 100 mm x 0.3 mm) coupled to an ESI-MS/MS ion trap mass
analyzer (Agilent 1100 Series LC/MSD. The proteins were eluted with buffer A (0.1% HCO2H in
H2O) and buffer B (0.1% HCO2H in CH3CN) in the following gradient segments of buffer B: 2
mins, 10%; 3 mins, 10-25%; 35 mins, 25-60%; 10 mins, 60-90%. The m/z values from protein
fragments were deconvoluted to estimate parent protein masses. For in-gel fluorescence labeling,
eGFP-GCAVGP from in vitro farnesylation reactions (+/- 10 µM C15AlkOPP) was precipitated
out using a protein precipitation kit (ProteoExtract, Calbiochem, San Diego, CA). Protein pellets
were redissolved in PBS + 1% SDS and 14 µg of the proteins were aliquoted and subjected to click
reaction (25 µM TAMRA-N3, 1 mM TCEP, 0.1 mM TBTA, and 1 mM CuSO4) for 1 hour at room
temperature. An aliquot (3.5 µg) from the click reactions were mixed with Laemmli loading buffer,
boiled for 5 min, and loaded into a 15% SDS-PAGE gel. In-gel fluorescence was detected at
542/568 excitation/emission wavelengths on a fluorescence scanner (Typhoon FLA 9500, GE
Healthcare). Gels were stained with 1X Coomassie Blue and destained to visualize protein loading.

2.10.18 Identification of human C(x)3X sequences: To identify human C(x)3X sequence
candidates, we interrogated the Prosite database (http://prosite.expasy.org/scanprosite/) using
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highly active sequences from the yeast studies (CAVGP, CMIIM, CWGEV) and allowing
sequence variability at one, two, or three positions downstream of the cysteine residue. Sequences
containing more than one cysteine were eliminated to avoid canonical four amino acid CaaXcompliant motifs (example: CCIIM) or sequences potentially recognized by GGTase-II (examples:
CC or CxC).(18,20,21)The candidate sequences were chosen based on previous studies of the protein
bearing the C(x)3X sequences, their location within the cell (e.g. membrane associated), and the
degree of sequence similarity to the parent C(x)3X sequence from the yeast studies.

2.10.19 Construction of eGFP-KRas-C(x)3X reporter protein plasmids: Gene inserts encoding
eGFP-KRas-XMIIM and eGFP-KRas-XMII reporter proteins were prepared by PCR using the
pEGFP-KRas vector (Casey Lab, Duke University) as a template with the CMIIM, SMIIM, or
CMII C-terminal sequences and KpnI restriction site encoded in the 3′ primers.78 PCR products
were purified using the BioBasic Inc. EZ-10 Spin Column PCR Purification Kit following the
manufacturer’s instructions. Following digestion by NheI and KpnI, the eGFP-KRas-XMIIM or
eGFP-KRas-XMII insert was ligated into the pEGFP-KRas expression plasmid using the Quick
Ligase kit (NEB) per manufacturer instructions. Insert ligation was verified by analytical
restriction digest and DNA sequencing (Genewiz).

2.10.20 Cell culture, transfection, and imaging: HEK293 cells (ATCC) was maintained in 75
mL vented tissue culture flasks (Celltreat, Pepperell, MA), and were split upon reaching 80%
confluency. Cells were grown in complete DMEM (DMEM supplemented with 10% fetal bovine
serum (FBS) and 1% (v/v) penicillin-streptomycin [MediaTech, Manassas, VA]) in 5% CO2 at 37
°C. Transfections and imaging were performed as previously described,77 in a single glass well
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imaging dish (Corning) and allowed to adhere for 24 hours prior to addition of Turbofect
transfection reagent (Thermo Scientific) according to the manufacturer’s protocol. Tipifarnib was
added to a final concentration of 10 nM to the transfection mixture for those cells undergoing
inhibitor studies. Following 36 hours of transfection, live cells were imaged at 63x magnification
using a Zeiss (Jena, Germany) Axio Vert.A1 inverted fluorescence microscope with a 470/40 nm
excitation filter, a 495 nm beam splitter and a 525/50 nm emission filter.
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Chapter 3: Chemoenzymatic protein labeling and isolation from eukaryotic cell lysates using
enzymes with reengineered substrate selectivity

3.1 Introduction
Protein immobilization is a valuable tool for studying protein structure, function, and
interactions within biological systems.1-5 Immobilization through bioorthogonal chemistry is
particularly useful in its ability to isolate a protein of interest without interfering with native
chemical processes in a cell. There are two main steps in the use of bioorthogonal chemistry to
isolate proteins. First, the protein is modified by a chemical reporter probe in the cell followed by
a chemical reaction between the functionalized protein and a chemically complementary secondary
probe which allows for isolation. The most common example of bioorthogonal chemistry for
protein modification is the Cu(I)-catalyzed “click” reaction (also known as the Huisgen 1,3-dipolar
cycloaddition), but the utility of this approach is limited as the Cu(I) necessary for this reaction is
toxic to cells (Figure 3.1a).6 Oxime and hydrazone reactions have found popularity due to their
ability to selectively modify proteins in which aldehyde or ketone additions have been made to the
proteins of interest for immobilization (Figure 3.1b-c). This approach, however, is limited in the
number of N-termini which can be modified with a ketone or aldehyde functional group.7-12
Another route for immobilization of proteins involves the use of enzymatic labeling with
chemically modified groups. The use of enzymes for biorthogonal labeling solves several issues
such as promiscuous substrate selectivity and eliminates the need to add non-natural functional
groups to proteins for recognition by a secondary probe. An example of such an enzymatic reaction
used for bioothogonal labeling is prenylation.13-16 Prenylation is a post-translational modification
in which a hydrophobic isoprenoid, either a farnesyl or geranylgeranyl group, is transferred to the
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Figure 3.1 A representation of chemical modifications commonly used in biorthogonal
labeling of proteins. (a) Cu(I) catalyzed azide-alkyne cycloaddition reaction (b) oxime ligation
(c) hydrazone ligation; R and R’ represent protein and/or probe used for isolation.
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C-terminal cysteine of certain proteins.17-21 This cysteine is typically part of the CaaX sequence in
which ‘C’ is a cysteine, ‘a’ is any aliphatic amino acid, and ‘X’ is an amino acid which determines
which type of isoprenoid will be attached to the substrate protein. The prenylation pathway follows
a specific set of modifications before the protein is transported to the cell membrane, with the first
step comprising cysteine alkylation by the FPP or GGPP prenyl donor (Scheme 3.1). The first step
involves the enzymes FTase or GGTase which catalyze the addition of a farnesyl or geranylgeranyl
group, via FPP or GGPP, respectively. The CaaX sequence then undergoes a series of other
modifications, including proteolysis and methylation, which lead to its final incorporation to the
membrane.
Several labs have utilized the specificity of farnesyltransferase (FTase) to label proteins
with functionalized FPP.15, 22-28 These analogues include the addition of ketones and aldehydes to
the end of the isoprenoid chain for use in hydrazone reaction which immobilize the protein onto
hydrazide beads (Figure 3.2, Scheme 3.2). For example, Rashidian and coworkers in 2012
developed an approach using protein prenyltransferase-catalyzed modification to label and
immobilize green fluorescent protein (GFP) in E. coli lysates.15 The GFP to be isolated contained
a C-terminal -CVIA recognition sequence to be prenylated by FTase in the prescence of an
aldehyde functionalized FPP. Upon prenylation, GFP was captured using hydrazide beads and
could be released from the beads using aniline as a catalyst, successfully isolating GFP from the
lysate. This technique requires no prior purification of the bacterial lysate and is useful in its
ability to release the targeted protein from the hydrazide beads after capture, however, there are
limitations to its usefulness. Methods such as these are limited to use in bacteria due to competition
between the target prenylation reaction and the endogenous prenylation that occurs in mammalian
cells and other eukaryotes.
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Scheme 3.1 The prenylation pathway Prenylation consists of lipidation with an isoprenoid group
followed by proteolysis and methylation.18-19, 21 Figure provided by Dr. James L. Hougland.
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Figure 3.2 Functionalized FPP analogues for use in hydrazone ligation bead pulldown and
isolation.15 (1) Strained alkene (2) Aryl ketone (3) Aryl aldehyde (4) Alkyl aldehyde
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Scheme 3.2 Mechanism for hydrazide ligation. Prenylation is highly specific and can be used in
a pulldown as a means for isolation when used in conjunction with hydrazone chemistry at the Cterminus of proteins. Labeling with aldehyde functionalized FPP allows for isolation of fluorescent
reporter proteins on hydrazide beads through the mechanism shown.

115

An ideal biorthogonal labeling system for proteins in cells would be one in which
competition from endogenous reactions is limited or absent. One way in which this could be
achieved is through alteration of enzyme substrate selectivity. For instance, it has been found that
FTase can tolerate different mutations to its active site, with these mutations leading to differences
in reactivity with natural and non-natural CaaX sequences.29 In this work by Hougland and
coworkers in 2012, a study of the multiple interactions between the active site of FTase and
selected peptide substrates were examined to determine the requirements for FTase discrimination
against nonsubstrates in the cell. For example, through mutation of tryptophan 102 and 106 on the
β strand of FTase, selectivity of Ca1a2X sequences can be altered through affecting interactions
with the a2 position of the substrate (Figure 3.3a). One enzyme mutant of interest in the context of
bioorthogonal labeling is W102R W106L FTase (referred to as RL FTase) which was found to
more selectively prenylate the non-natural CaaX sequence –CVDS than the natural –CVLS
sequence derived from H-Ras (Figure 3.3b).
Using this engineered FTase variant with non-natural peptide selectivity in addition with
the previously designed FPP derivatives, it is possible to bioorthogonally select and purify proteins
of interest in the presence of other competing proteins in both bacterial and mammalian cells.
Prenylation by farnesyltransferase can be combined with the immobilization capabilities of
hydrazone ligation chemistry to isolate proteins through use of specific CaaX sequences.
This work herein aims to demonstrate the expansion of a previously designed approach to
bioorthogonal protein labeling, making it applicable across different systems, specifically in both
bacterial and mammalian cells. Using the combined techniques of a selective modification, like
prenylation, and an immobilization technique, such as a hydrazide bead pulldown, a new
bioorthogonal pulldown technology can be used to isolate proteins of interest that may be difficult
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to otherwise obtain. More specifically, isolation of proteins of interest can be achieved through use
of site-specific modifications involving engineered FTase variants and functionalized FPP
analogues with subsequent immobilization through hydrazone ligation chemistry. Modification of
the specific protein of interest with a non-natural CaaX sequence can act as a C-terminal tag to
allow for immobilization in the presence of natural, competing proteins in the cell, not recognized
by RL FTase.
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a)

b)

Figure 3.3 The FTase active site and its reactivity. (a) Structure of a peptide substrate bound to
FTase with emphasis on interactions with the a2 binding pocket. The a2 residue of the peptide
substrate (green) is surrounded by residues Trp-102β (orange), Trp-106β (red), and Tyr-361β (not
shown) within the active site of FTase. The a2residue also contacts the isoprenoid tail of the FPP
analogue inhibitor FPT-II (purple). The figure was derived from PDB ID 1D8D and adapted from
Reid et al.30 (b) Initial velocity for reaction with dns-GCVDS is shown as determined by a
fluorescence enhancement assay; squares, WT FTase; circles, W102R/W106L variant; triangles,
W102L/W106L variant; inverted triangles, W106L/W106K variant. The “RL” FTase variant
displays preference for noncanonical dns-GCVDS over the endogenous dns-GCVLS. These
figures have been reused with permission from reference 29 (Appendix VII).
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3.2 RL FTase farnesylation reactivity with dns–GCVDS and dns–GCVLS peptide substrates
As stated in section 3.1, unpurified RL FTase in crude bacterial lysate shows minimal
reactivity with a fluorescently labeled dns–GCVLS peptide substrate in comparison to reactivity
with dns-GCVDS peptide in reaction with the natural FPP prenyl donor cosubstrate.29 This
preference was found to hold true in reactions in which functionalized FPP analogues (Figure 3.2)
were used in place of non-functionalized FPP prenyl donor, with the aryl aldehyde FPP (2)
showing the greatest reactivity and discrimination between the two peptides (J. Hougland,
unpublished data). However, once purified, RL FTase exhibited comparable reactivity with both
the dns-GCVLS and dns– GCVDS peptide substrates (Figure 3.4). To determine the origin of this
change in relative reactivity between reactions using purified enzyme and enzyme in crude lysates,
components used to grow and lyse the bactreria in the original lysate studies were titrated into
reactions using purified RL FTase to determine the impact of each component on enzyme substrate
selectivity. Components included in these titrations were total bacterial lysate, ampicillin, luria
broth (LB) media, and Fast Break lysis reagent (Promega). It was determined that Fast Break (FB)
lysis reagent used to lyse cells in the original activity tests decreases reactivity of RL FTase with
the dansyl–GCVLS peptide, while maintaining its reactivity with dns-GCVDS, as determined by
HPLC analysis and product peak integration (Figure 3.5a). While the specific component of Fast
Break (FB) reagent responsible for altering RL FTase selectivity remains unknown, this findings
enables optimization of reaction conditions necessary for selective prenylation of –GCVDS tagged
proteins in vitro using purified components. When WT FTase was tested under the same
conditions, it was found that WT FTase reactivity with the dns-GCVLS peptide is not affected as
greatly by FB lysis reagent as is the RL FTase (Figure 3.5b).
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Figure 3.4 RL FTase reactivity with dns-GCVLS changes after purification of enzyme. (a)
Reactivity of RL FTase with dns-GCVDS using purified RL FTase (red) or FTase in bacterial cell
lysate (black); (b) Reactivity of RL FTase with dns-GCVLS using purified RL FTase (red) or
FTase in bacterial cell lysate (black); Reactions conditions include 50 nM RL FTase (or 10 µL cell
lysate), 3 µM peptide, 5 mM MgCl2, 50 mM NaHEPPSO (pH 7.5), and 5 mM TCEP.
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a)

b)

Product peak with:

Integration

2 uL Fast Break reagent
5 uL Fast Break reagent

5.93
3.85

10 uL Fast Break reagent

3.44

Figure 3.5 Fast Break Reagent affects the farnesylation selectivity of the RL FTase variant.
a) Effects of Fast Break lysis reagent on the activity of RL FTase with dns-GCVLS or dns-GCVDS
and endogenous FPP. Varying amounts of reagent, 2, 5, and 10 uL, were titrated into a reaction of
50 nM RL FTase, 3 µM peptide, and 20 µM FPP. Blue, 2 µL; Red, 5 µL; Green, 10 µL – Product
peak shown at 23.5 min and 19.5 min for dns-GCVLS and dns-GCVDS, respectively. b) WT FTase
activity with dns-GCVLS is not affected as greatly by addition of Fast Break reagent. In the
presence of FB reagent, dns-GCVLS is still nearly all converted to product (product peak shown
at 23.5 min) No product peak is detectable for WT FTase with dns-GCVDS (substrate peak shown
at 3.5 min).
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Characterization of the reactions catalyzed by purified RL FTase with dns-GCVLS and
dns-GCVDS using either endogenous FPP or aryl aldehyde FPP (2) is aided by steady-state kinetic
analysis of these reactions. Steady state characterization can be pursued using a previously
developed fluorescence-based assay for FTase-catalyzed peptide prenylation which utilizes the
environmentally sensitive dansyl fluorophore.13, 31-33 However, initial reactions using the FPP
analogue (2) indicated that this analogue could not be successfully support this assay due to the
low fluorescence enhancement obsereved upon peptide modification with this FPP analogue.
Consequently, steady state kinetic parameters (kcat/Km) for reactions with FPP were determined for
WT FTase with dns-GCVLS and for RL FTase with dns-GCVDS and dns-GCVLS (Table 1,
Figure 3.6). In the presence of Fast Break reagent, steady state kinetic constants for prenylation of
the dns-CVLS peptide by the RL FTase variant, as well as dns-CVDS peptide by WT FTase (both
with and without Fast Break), could not be determined due to low or no evidence of reactivity.
Catalysis of prenylation of the dns-GCVDS peptide by the RL FTase variant with the dns-CVDS
peptide is comparable (within -4-fold) to that for dns-CVLS farnesylation cataltyzed by WT FTase,
suggesting that the RL FTase is sufficiently active to allow CVDS prenylation in biological
samples.
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Table 3.1 Steady-state kinetics for farnesylation of dns-GCVLS and dns-GCVDS
catalyzed by WT and RL FTases.

Steady state reactions were performed under the following conditions:100 nM FTase , 10
µM FPP, 0.5-10 µM peptide substrate (dns-GCVLS or dns-GCVDS), 5 mM MgCl2, 50 mM
NaHEPPSO, 5 mM TCEP. “b.d.” denotes reactivity is below detectable limits.
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a
)

b
)

d
)

e
)

c
)

Figure 3.6 Steady state characterization of the reactivity of dns-GCVxS peptides with RL
or WT FTase. a-c) Dependence of farnesylation activity on peptide substrate concentration
catalyzed by RL FTase with and without Fast Break: a) dns-GCVDS; b) dns-GCVDS with Fast
Break; c) dns-GCVLS; . d-e) Dependence of farnesylation activity on peptide substrate
concentration catalyzed by WT FTase with and without Fast Break: d) dns-GCVLS; e) dnsGCVLS with Fast Break. The curve represents the best fit to the Michaelis-Menten equation.
Reactions were performed and analyzed as described in Section 3.9.8. Error bars represent the
standard deviation from a minimum of two replicates.
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3.3 WT FTase and RL FTase-catalyzed prenylation of dns-GCVDS and dns-GCVLS
peptides using an aryl aldehyde FPP analogue
To determine conditions for prenylation of full length proteins using FPP analogue (2) WT
FTase and RL FTase were used to explore prenylation of both the GCVDS and GCVLS peptides
using either FPP or FPP analogue (2). No activity was observed for WT FTase-catalyzed
prenylation of the dns–GCVDS peptide when monitored by HPLC, while the RL FTase catalyzed
complete modification of the dns–GCVDS peptide under the same conditions using the FPP
analogue (2) at varying concentrations between 10 - 70 µM (Figure 3.7a, 10 M FPP analogue (2)
reaction shown). Under the same reaction conditions in the presence of the FB reagent, RL FTase
catalyzed a low level of prenylation of the dns-GCVLS but did not completely modify this
substrate (Figure 3.7b). To determine the optimum reaction time to maximize modification of the
dns-GCVDS substrate while minimizing dns-GCVLS prenylation, a reaction time course was
performed to monitor RL FTase-catalyzed prenylation of both peptide substrates with the FPP
analogue (2). Prenylation of the dns-GCVLS substrate with FPP analogue (2) by the RL FTase is
not detectible before approximately 3 hours reaction time as monitored by HPLC, whereas
modification of the dns-GCVDS peptide is more rapid with evidence of prenylated product by 1
hour (Table 3.2). This time course allows us to optimize our reaction time, increasing the amount
of dns–GCVDS prenylated with FPP analogue (2) while minimizing prenylation of dns–GCVLS.
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A

B

Figure 3.7 RL FTase-catalyzed prenylation of dns-GCVDS and dns-GCVLS in the presence
of 10 M FPP analogue (2). (A) Prenylation reaction with dns-GCVDS; product peak is observed
at 14.3 min retention time. (B) Reaction with dns-GCVLS; product preak is observed at 17.6 min
retention time with unreacted peptide substrate detected at 6.6 min.
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Table 3.2 Comparative extent of reaction for RL FTase-catalyzed prenylation with dnsGCVDS and dns-GCVLS

Dns-GCVDS reacts >90% with RL FTase and FPP analogue (2) within 5 hours while
prenylation of dns-GCVLS is only detectible after 3 hours. “n.d.” denotes no detection of
product peak. Reaction conditions: 100 nM FTase , 10 µM analogue (2), 3 µM peptide substrate
(dns-GCVLS or dns-GCVDS), 5 mM MgCl2, 50 mM NaHEPPSO, and 5 mM TCEP.
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3.4 Examining RL FTase selectivity between dns–GCVDS and dns– GCVLS peptide
substrates in direct competition reactions
While the studies described above provided insight into the substrate specificity of RL
FTase in the presence of functionalized FPP and differing peptides, these reactions did not directly
examine the ability of RL FTase to selectively catalyze prenylation of the dns-GCVDS substrate
in the presence of competing peptides. As these peptides have distinct retention times on HPLC in
both their unmodified and prenylated forms, prenylation of both peptides can be monitored
simultaneously in reactions containing both peptides in direct competition for prenylation by RL
FTase. This competition experiment more closely resembles the reaction that will take place in
cell lysates when attempting to isolate a protein of interest.
In the presence of both peptides substrates at equal concentrations (3 M), RL FTase
preferentially catalyzed prenylation of the dns-GCVDS peptide in the presence of FPP analogue
(2). No prenylated product from reaction with the dns–GCVLS peptide was observed until after 8
hours reaction time (Table 3.3). Modification of the dns–GCVDS peptide was observed within 30
minutes (chromatograms for 30 min and 8 hour reaction time points provided in Figure 3.8). In
competition for RL FTase, dns-GCVDS is more active than dns–GCVLS and an optimal
incubation time for the prenylation reactions for isolation of target proteins was experimentally
determined.
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Table 3.3 Competition for farnesylation between dns-GCVDS and dns-GCVLS

In competition, dns-GCVDS shows evidence of prenylation by RL FTase and aryl aldehyde FPP
analogue as early as 30 min while dns-GCVLS prenylation is not observed until 8 hours. Reaction
conditions: 100 nM FTase , 10 µM FPP analogue (2), 3 µM peptide substrate of each, dns-GCVLS
and dns-GCVDS, 5 mM MgCl2, 50 mM NaHEPPSO, and 5 mM TCEP.
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Figure 3.8 HPLC analysis of dns-GCVDS and dns-GCVLS direct competition prenylation
reactions with RL FTase. Retention times are as follows: dns-GCVDS unreacted – 4.1 min (30
min), 3.6 min (8 hours); dns-GCVLS unreacted – 7.3 min (30 min), 6.7 (8 hours); dns-GCVDS
product – 14.6 min (30 min), 14.2 min (8 hours); dns-GCVLS product – 17.7 min (8 hours) Large
peak at ~2 min is due to buffer and is present in buffer-only control injection.
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3.5 Design and expression of fluorescent reporter proteins for validating FTase variant
protein labeling
To confirm the ability of engineered FTase variants to catatlyze modifications of folded
proteins, TagRFP (red fluorescent protein) and eGFP (green fluorescent protein) fluorescent
proteins were designed to serve as target and competitor proteins for RL FTase-catalyzed
prenylation (Figure 3.9). Fluorescent proteins allow for facile visual monitoring of protein
expression and for probe protein detection during and after protein pulldown. Use of both eGFP
and TagRFP as target and competitor proteins, respectively, allows for a direct measure of not only
the amount of target protein being immobilized (via fluorescence) but as an easy means of
measuring the amount of any competitior protein which may be labeled and captured as well.
To serve as probes for FTase activity, these proteins required addition of a Cterminal“CaaX” motif through PCR and subsequent cloning. As stated previously, the engineered
RL FTase variant recognizes a -GCVDS target sequence, and a –GCVLS sequence serves as a
competitor sequence representing natural FTase substrates. As a negative control, a probe protein
with a–GSVDS C-terminal sequence was also designed. In this protein, replacement of the “CaaX”
motif cysteine with a serine blocks prenylation by removing the thiol sidechain required for the
thioether bond present in prenylated proteins. The reporter protein sequences TagRFP-GCVDS,
TagRFP-GCVLS, and TagRFP-GSVDS proteins were cloned into the CDFDuet-1expression
vector, which contains a streptomycin resistance gene, while the eGFP-GCVDS protein was
cloned into pJExpress-414 vector which carries ampicillin resistance. (Vectors were a gift from
Mark DiStefano, University of Minnesota.) Use of these two expression vectors allows for probe
protein expression in separate samples alone or as a co-expression within the same cells using
simultaneous selection with both ampicillin and streptomycin. Each bacterial expression vector
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also contains a 6x-HisTag upstream of each cloning site for future purification of the probe proteins
proteins, if needed. The sequences of the final expression vectors were confirmed through DNA
sequencing (GenScript, Inc).
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Figure 3.9 Design of protein probes for bioorthogonal labeling using RL FTase and FPP
analogues. The target protein was designed as eGFP while competitor and negative control
sequences were designed into TagRFP.
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3.6 Isolation of –GCVDS tagged protein on hydrazide beads from bacterial lysates via
hydrazone ligations
Two approaches were used for isolation of C-terminally tagged -GCVDS proteins from
bacterial lysates using RL FTase and FPP analogue (2). The first utilizes the pulldown of the
aldehyde-functionalized proteins using hydrazide-functionalized agarose beads, as described in
section 3.1.15 A general overview of the immobilization is provided in Scheme 3.3.
During the immobilization and release reactions, measurements of both UV-Vis
absorbance (555 nm and 488 nm for TagRFP and eGFP, respectively) and fluorescence
(excitation/emission wavelength of 555/585 or 488/515 for TagRFP and eGFP, respectively) were
taken at each step during the procedure to track the fluorescent protein, determine potential protein
loss, and observe evidence of immobilization/release from the hydrazide beads. Absorbance
measurements of protein immobilized to the hydrazide beads were found to be non-reproducible
due to settling of the beads and high background arising from light scattering. Initial
immobilization attempts were performed using varying initial reaction volumes of 500 µL, 1 mL,
or 10 mL prenylation reactions containing 2.5 µM of fluorescent protein in bacterial lysates based
on UV-Vis absorbance of the lysate. These reactions are then concentrated to 500 µL, if necessary,
before being run through a NAP-5 gravity flow desalting column (GE Healthcare) to remove
excess FPP analogue (2) via gel filtration to avoid competition of protein immobilization to the
hydrazide resin by free aldehyde analogue. It was found that 10 mL reaction volumes produced
enough protein to efficiently track immobilization as described below.
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Scheme 3.3 A general overview for the immobilization of aldehyde-functionalized
prenylated proteins. PB = phosphate buffer, KCl = 50 mM potassium chloride
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Hydrazone bond formation between the prenylated protein and resin was catalyzed with the
addition of m-phenylenediamine, consistent with literature reports.34 Protein immobilization by
hydrazone formation was followed by washing of the column with phosphate buffer and KCl to
remove nonspecifically bound protein, before removal the resin from the column for analysis and
subsequent release of the immobilized protein.
While tracking fluorescence during the procedure, a small amount of fluorescence was
detected on the hyrdrazide resin after immobilization. To confirm that these small fluorescence
readings were evidence of protein immobilization, negative controls were performed through
several different immobilization conditions in which WT FTase, endogenous FPP, or –GCVLS
tagged protein replaced the use of RL FTase, aryl FPP analogue, or –GCVDS tagged protein,
respectively. Under these conditions, no immobilization on hydrazide resin should be observed as
indicated by presence of the target protein in the flow-through and PB or KCl washes with no
fluorescence detection on the resin. UV-Vis and fluorescence data confirmed that all protein
loaded onto the hydrazide resin was present in the flow-through or wash steps in these controls,
with no protein being detected on the resin (Table 3.4).
There was evidence of target protein immobilization using this method, as evidenced by a
positive fluorescence reading at 555 nm when testing the resin for the presence of TagRFP.
However, the technique was found inefficient with only about 50% of the total target protein found
to be immobilized and released (Example #1, Table 3.5). Two hypotheses were tested as to why
the immobilization was not more efficient. A second pulldown (Example #2, Table 3.5) tested the
hypothesis that the amount of hydrazide resin used may not have a sufficient binding capacity to
capture a large amount of the target protein. This theory was tested by doubling the amount of
hydrazide resin used for immobilization, from 300 µL to 600 µL. A third pulldown (Example #3,
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Table 3.4 Control experiments for protein immobilization using hydrazide resin

Controls include (left to right): Use of WT FTase with TagRFP-GCVDS and aryl aldehyde FPP
(2), RL FTase with FPP and TagRFP-GCVDS, and RL FTase with aryl aldehyde FPP (2) and
TagRFP-GCVLS. Total protein amounts were calculated by first using Beer’s Law (ε=Abc) at 555
nm for TagRFP to determine molar concentration. The concentration was then converted to total
protein using the volume of the sample and the MW of TagRFP-GCVDS (28 kDa); n.d. = not
determined
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Table 3.5) tested the hypothesis that the reaction volume was too large for efficient prenylation.
The theory was tested by performing the reaction on a smaller scale with the same total protein
through the use of 10 - 1 mL reactions in low-adhesion tubes before combining them into the 10
mL total volume after overnight reaction. In all three trials under these differing conditions,
immobilization and release of the aldehyde-functionalized TagRFP-GCVDS protein was observed
via fluorescence (Table 3.5).
When comparing the three different pulldown conditions, pulldown #2 results were
comparable to those previously observed in pulldown #1 with a recovery of 0.04 mg protein. A
small improvement in pulldown #3 was observed with recovery of 0.07 mg from an initial 0.31
mg protein but much of the sample was still being lost after immobilization in the flow through.
After evidence of successful isolation and release in pulldown #1 as reflected UV-Vis and
fluorescence detection of TagRFP, it was decided to track UV-vis absorbance measurements at
time points throughout pulldowns #2 and #3 that would monitor the progress of immobilization
and release of the protein (Figure 3.10). A decrease in protein concentration in the supernatant was
observed during the first thirty minutes of the two hour immobilization as the protein was isolated
to the resin. Release of the protein was observed to occur more slowly over the course of 1-3 hours
in both of the pulldown/release reactions monitored.
As a complement and verification for the spectroscopic measurements of protein release
described above, the supernatant from the resin release reactions was analyzed by gel
electrophoresis followed by Coomassie staining to detect total protein and anti-His6 Western
blotting to specifically detect the target protein containing a His6 affinity tag. These analyses
provided evidence of release of the immobilized protein, but the detection of released target
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Table 3.5 Tracking of total protein throughout three pulldowns.

Total protein amounts were calculated by first using Beer’s Law (ε=Abc) at 555 nm for TagRFP
to determine molar concentration. The concentration was then converted to total protein using the
volume of the sample and the MW of TagRFP-GCVDS (28 kDa); n.d. = not determined, n.a. = not
applicable
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protein was inconsistent between trials (Figure 3.11). Although UV-Vis absorbance and
fluorescence readings provide evidence for successful release of protein in all three trials, , no
bands consistent with the target protein were present in the “release” lane of the Coomassie stained
gel or Western blot for pulldown #3. With these inconsistent results, the question arises as to
whether the issue of immobilization and release lies in the immobilization of the protein on the
resin or in the ability of RL FTase to prenylate a full length protein with enough efficiency to allow
subsequent labeling and isolation. Chapter 4 answers the latter question through development of a
new technique for detecting protein lipidation. This work aimed and was successful in showing
successful and complete prenylation of eGFP-GCVDS by RL FTase under multiple conditions.
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Figure 3.10 Monitoring of isolation and release of His6-TagRFP-GCVDS via UV-Vis
absorbance at 555 nm over time. A. Pulldown #2, B. Pulldown #3; 1) immobilization, 2)
release
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Figure 3.11 Coomasie staining and anti-His Western Blot analysis of hydrazide
immobilization of His6-TagRFP-GCVDS. A) Pulldown #1, B) Pulldown #2, C) Pulldown #3
(see Table 2) Legend: (C) His6-TagRFP control, (FT) flow-through after immobilization reaction,
(PB) PB wash of resin, (KCl) KCl wash of resin, (R) supernatant after release of protein from
resin. His6-TagRFP-GCVDS = 28 kDa
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3.7 Streptavidin beads and biotin-hydrazide as an alternative pulldown system
While the use of hydrazide beads to isolate functionalized prenylated protein shows
promising results, inconsistency between trials led us to another alternative method for use of
biorthogonal selectivity and subsequent pulldown of target proteins. This alternative utilizes
biotin-streptavidin interactions through use of a hydrazide-linked biotin and streptavidin beads
(Scheme 3.4). The interaction between biotin and streptavidin has one of the highest reported
affinities with a Kd of ~10-14 M.35 While this interaction is a popular tool for protein isolation,36-38
this high affinity leads to issues in retrieving proteins after binding to the streptavidin beads used
for isolation. Using hydrazone ligation chemistry, functionalized protein with FPP analogues can
be retrieved from streptavidin beads using hydroxylamine cleavage of the hydrazone bond. This
will leave the hydrazide-biotin still bound to the streptavidin but release the protein with the FPP
analogue “tag” intact. To release the immobilized protein, hydroxylamine is added to the resin to
reverse the hydrazone bond via oxime formation with m-PDA being used as a catalyst.
As done previously for pulldowns with hydrazide beads, fluorescent fusion proteins
TagRFP-GCVDS or eGFP-GCVDS were used to monitor and track pulldown and release of
functionalized protein. Readings of both UV-Vis absorbance (555 nm and 488 nm for TagRFP and
eGFP, respectively) and fluorescence (excitation/emission wavelength of 555/585 or 488/515 for
TagRFP and eGFP, respectively) were taken at each step during the procedure to track the
fluorescent

protein,

determine

potential

protein

loss,

and

observe

evidence

of

immobilization/release from the streptavidin beads (Scheme 3.5). Absorbance measurements of
protein immobilized to the streptavidin beads were found to be non-reproducible due to settling of
the beads and high background arising from light scattering, resulting in only fluorescence
measurement being used for monitoring of bead-bound proteins.
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Scheme 3.4 Hydrazide-biotin labeling of functionalized protein allows for isolation on
streptavidin beads Hydrazide bond is shown in red and streptavidin bead is shown in blue.
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Incubate with mixing for 2 hours at room
temperature, then analyze via SDS-PAGE
and Streptavidin blot

1:10 addition of 50 mM hydrazide-biotin
in DMSO to a final concentration of 5 mM

Scheme 3.5 Immobilization of target proteins using aryl aldehyde FPP (2) and hydrazidebiotin.
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Using bacterial lysates, prenylation with FPP analogue (2) was performed as previously
described above and as shown in the flow chart above. Biotinylation was performed using 1 mL
total volume prenylation reactions with 2.5 µM of fluorescent protein based on UV-Vis absorbance
of the lysate. For several trials of the biotin-streptavidin pulldown protocol, samples of TagRFPGCVDS were taken at each step in the biotinylation process for both fluorescence analysis as
before and detection via SDS-PAGE gels using Coomassie stain and streptavidin-HRP blotting
(Figures 3.12 and 3.13). In trial #1, TagRFP-GCVDS is present throughout the preparation and
biotinylation process evidenced by bands at 28 kDa, visualized by Coomassie stain. Exposure of
proteins to streptavidin-HRP after transfer from SDS-PAGE gels to a PVDF membrane and
blocking with 3% BSA in TBST produces a band at the correct size in the biotinylation lane only.
These two gels together provides evidence for retention of the target protein throughout
prenylation with FPP analogue (2), NAP-5 desalting column, and biotinylation which resulted in
the target protein biotinylated as evidence by lane 3 in the Streptavidin blot.
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Figure 3.12 Results of TagRFP-GCVDS immobilization using biotin and streptavidin - Trial
#1. SDS PAGE and Streptavidin blot analysis of TagRFP-GCVDS Lysate is bacterial lysate prior
to prenylation, L) Ladder, 1) after overnight prenylation, 2) after elution on NAP-5 column, 3)
after biotinylation. Red arrow denotes band believed to be biotinylated target protein. His 6TagRFP-GCVDS = 28 kDa. Streptavidin-HRP = 1:10,000 dilution
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Figure 3.13 Results of TagRFP-GCVDS immobilization using biotin and streptavidin - Trial
#2. SDS PAGE and Streptavidin blot analysis of TagRFP-GCVDS Lysate is bacterial lysate prior
to prenylation, L) Ladder, 1) bacterial lysate prior to prenylation, 2) after overnight prenylation, 3)
after concentration to 500 uL, 4) after elution on NAP-5 column, 5) after biotinylation. It is unclear
if either of the two bands in lane 5 are the target protein. His6-TagRFP-GCVDS = 28 kDa.
Streptavidin-HRP = 1:20,000 dilution
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In Trial #2, protein loss can be seen after elution from the NAP-5 column which coincides
with loss of total protein in the fluorescence data of Table 3.2. Fortunately, sufficient protein is
retained to visualize TagRFP-GCVDS before and after biotinylation. Unlike Trial #1, two bands
are present in lane 5 of the Streptavidin blot for trial #2, which was performed with half the amount
of Streptavidin-HRP as in Trial #1. The close proximity of the bands makes it difficult to determine
which band represents an interaction with biotin or that biotinylation occurred in this trial. The
appearance of two bands indicated that optimization of streptavidin blot conditions was needed
before further analysis of biotinylated products during the streptavidin bead isolation and release
of the target protein.
In the two trials above, 3% BSA in TBST was used to block PVDF membranes before
exposure to streptavidin-HRP as per the manufacturer’s recommendation. BSA is typically
preferred over non-fat milk in streptavidin blots as it has been found that using the traditional nonfat milk blocking procedure can result in non-specific binding of streptavidin to the membrane.
The two blots above were also incubated with streptavidin-HRP overnight at room temperature as
opposed to incubation at 4˚C. To optimize the results of streptavidin-HRP blotting, several changes
to these conditions were explored. Blocking solution was changed to 10% non-fat milk (NFM) in
TBST with rocking at room temperature for 3 hours. The 1:10,000 dilution of streptavidin-HRP
was repeated as in Trial #1 with incubation at 4˚C overnight. As shown in Figure 3.14, optimization
of these two conditions yields clean, single bands for both previously run trials at the expected size
of TagRFP-GCVDS after adjustment of both the blocking solution and streptavidin-HRP
incubation temperature.
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Figure 3.14 Optimization of streptavidin blot detection of TagRFP-CVDS following
functionalization with biotin hydrazide. Trials 1 and 2 above were analyzed under new
conditions to yield single bands at the appropriate size. His6-TagRFP-GCVDS = 28 kDa.
Streptavidin-HRP = 1:10,000 dilution
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3.8 Conclusions
Prenylation presents a promising avenue for chemoselective protein immobilization. The
use of a naturally occurring protein modification with the substrate specificity of a mutant enzyme
would allow for precise protein immobilization with minimal endogenous protein interference
during purification. While this technique has shown promising results, inconsistent success in
release of immobilized protein makes this work difficult to bring to fruition at a usable level. With
inconsistent results from both methods of protein isolation, the question is still raised as to whether
or not these full length proteins are undergoing efficient prenylation with RL FTase and
functionalized FPP. In Chapter 4 we describe a new technique for direct detection of full-length,
prenylated proteins from both purified and cell lysate samples. This work confirms complete
prenylation of our target proteins prior to immobilization and provides evidence that the issue of
immobilization is not at the level of prenylation.
While this work describes a new avenue for bioorthogonal labeling of proteins in the
presence of competitor proteins, further optimization with consistent results would be needed for
this work to be considered at a level which is useful for protein research. Avenues of optimization
include increasing the scale of total protein being used, altering the concentrations of m-PDA or
hydroxylamine used in both the pulldown and release steps, and controlling for loss of protein
during NAP-5 and concentration steps. If optimization is achieved, a target model protein should
be chosen for isolation. The target protein should be one in which the C-terminal sequence can be
varied to allow for the addition of the –GCVDS motif necessary for the chemoselective pulldown
approach.
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3.9 Materials and Methods
3.9.1 Purification of RL FTase using FPLC: Chemically competent BL21(DE3) E. coli were
thawed on ice for 15 minutes. An aliquot of each plasmid containing the RL FTase α and β subunit
genes (100 ng) was added to the cells (50 L). Bacteria were incubated on ice for 30 min before
heat shocking at 42⁰C for 10 seconds with subsequent incubation on ice for 5 min. An aliquot (50
L) of cells were then plated on warm LB-Amp plates were incubated overnight at 37°C. A colony
was chosen from the plate and inoculated into a 5 mL culture of LB media with ampicillin (final
concentration 100 µg/mL). Cultures were incubated and shaken at 225 rpm for 4 hours at 37°C.
Cultures were then added to 1L rich media (20 g tryptone, 10 g yeast extract, 5 g NaCl, 1% glucose,
and 100 µg/mL ampicillin) and grown at 37°C with shaking (225 rpm) until an OD600 of between
0.6-0.8 was reached as monitored using a NanoDrop 2000c spectrophotometer. Cultures were then
induced with 0.5 mM IPTG. Cultures were grown 14 hours at 25⁰C with shaking (225 rpm). Cells
were harvested by centrifugation and resuspended in 50 mL buffer (50 mM HEPES – pH 7.8, 10
mM ZnCl2, 2 mM TCEP). Cell resuspension was incubated at 37°C for 45 min in the presence of
0.625U/mL benzonase, 0.25 mg/mL lysozyme, and 17 µg/mL PMSF before incubation on ice.
Lysis of cell culture was done using a Misonix Sonicator (Langford lab, Syracuse University)
using 8 rounds of 30 seconds sonication with 30 seconds rest while on ice (pulse method). Lysates
were centrifuged at 4°C and supernatant was transferred to a clean flask. At 4°C, precipitation of
DNA was performed through addition dropwise of 1/10th volume of 10% (w/v) streptomycin
sulfate. Precipitation was incubated for 30 min with gentle stirring. Precipitated DNA was then
separated from the sample through centrifugation at 4°C before clarification of the final sample
though filtration with a 0.45 µm filter.
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The prepared sample was purified using a AKTAprime Plus FPLC, first on a 15 mL HiTrap
DEAE FF column (GE Healthcare) using 75 mL running buffer (50 mM HEPES – pH 7.8, 10 µM
ZnCl2, 2 mM TCEP) to equilibrate the column before addition of sample. A 30 mL wash was then
done with running buffer before elution. Elution buffer (50 mM HEPES – pH 7.8, 10 µM ZnCl2,
50 mM NaCl, and 2 mM TCEP) was used to elute the protein over the course of 300 mL elution
with fractions containing protein then concentrated using a PALL Macrosep 10 MWCO
concentrator to a volume of 2 mL following manufacturer’s protocol. Concentrated sample was
then desalted using a 10 mL HiTrap desalting column (GE Healthcare) with running buffer
following the AKTAprime Plus FPLC desalt application template. Desalted sample (15 mL) was
then loaded onto a 15 mL HiTrap Q sepharose column (GE Healthcare) with an equilibration with
75 mL running buffer before loading of the sample. The column was then washed with 30 mL
running buffer before elution using 500 mL elution buffer into 7 mL fractions. The resulting
product was then concentrated and desalted as described above before a final concentration was
done to a volume of 2 mL. This sample was divided into 20 L aliquots before being flash frozen
with liquid nitrogen and storage at -80°C. Enzyme concentration was measured using absorbance
at 280 nm using a NanoDrop 2000c spectrophotometer.

3.9.2 PCR mutagenesis of pJExpress-414_eGFP-GCVIA to eGFP-GCVDS: Forward and
reverse primers for the isoleucine/alanine mutation to arginine/serine consisted of two point
mutations and were synthesized by Integrated DNA Technologies. Primers were dissolved in 100
L of ultra pure water and their concentrations were determined by UV absorbance of 260 nm
using a NanoDrop 2000c spectrophotometer. The PCR reaction (50 L) contained 10x PFU Turbo
buffer (5 L), 10mM dNTPs (1 L), reverse primer(125 ng), forward primer (125 ng), and
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template plasmid (10 ng). The reaction was mixed and centrifuged before adding PFU Turbo DNA
polymerase (1 L, 2.5U/L). PCR mutagenesis was performed on a BioRad MyCycler under the
following thermal program: Initial denaturation (95˚C, 1 min.); eighteen cycles of denaturation
(95˚C, 50s), annealing (60˚C, 50s), and extension (68˚C, 12min); final extension (68˚C, 12min);
and a final hold (10˚C, ∞). The reaction was then digested with DpnI (1 L, 10U/L) for 1 hour
at 37⁰C. 18 PCR mutagenesis reactions were transformed into chemically competent E.coli for
plasmid isolation using the Z-competent transformation system (Zymo Research). Chemically
competent DH5α E. coli were thawed on ice for 15 minutes. An aliquot of the PCR reaction (5 L)
was added to DH5α cells (50 L) and incubated on ice for 30 min before plating cells on warm
LB-Amp plates. Cells were incubated overnight at 37°C. Three colonies were chosen from the LBAmp plate and inoculated into separate 5 mL culture of LB media with ampicillin (final
concentration 100 g/ml). Cultures were incubated overnight at 37°C with shaking (225 rpm).
After incubation, glycerol stocks were made for each culture by adding 500 L of cultured cells
into 500 L of 20% glycerol in water. These were stored at -80°C. The remaining plasmid DNA
was then purified using BIO Basic Inc. EZ-10 Spin Column Plasmid DNA Minipreps Kit following
the manufacturer’s protocol. Site mutation from the sequence IA to DS was verified using DNA
sequencing (Genscript, Inc).

3.9.3 PCR construction of TagRFP to include -GCVDS, -GCVLS, or -GSVDS C-terminal
motifs and insertion into expression vectors: One round of PCR was performed for the extension
of TagRFP in the TagRFP-N vector (Evrogen) with either –GCVDS, -GCVLS, or –GSVDS Cterminal motifs in the 3’ primers along with HindIII restriction sites for CDF-Duet-1 cloning. The
5’ primer included addition of the EcoRI restriction site for CDF-Duet-1 cloning For this PCR,
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forward and reverse primers were designed by Dr. James Hougland and synthesized by Integrated
DNA Technologies. Primers were dissolved in 100 L of ultra pure water and their concentrations
were measured using a NanoDrop 2000c spectrophotometer at a UV absorbance of 260 nm. The
PCR reaction (50 L) contained Standard OneTaq buffer (10 L), 10mM dNTPs (1 L), reverse
primer (125 ng), forward primer (125 ng), and template plasmid (10 ng). The reaction was mixed
and centrifuged before adding OneTaq DNA polymerase (0.25 L, 5U/L). PCR was performed
on BioRad MyCycler under the following conditions: Initial denaturation (94°C, 1 min.); thirty
cycles of denaturation (94°C, 30s), annealing (56°C, 1min.), and extension (68°C, 2min); final
extension (68°C, 5min); and a final hold (10°C, ∞). After PCR, products were purified using BIO
Basic Inc. EZ-10 Spin Column PCR Purification Kit following the manufacturer’s instructions. A
double digestion (20 L) was then performed. The reaction consisted of 10x NEB buffer 4 (2 L),
100x BSA (0.2 L), plasmid DNA or PCR product that will act as insert (3 g), and restriction
enzymes depending on the vector being cloned into: EcoRI ( 1 L, 20 U/L) and HindIII (1 L,
20U/L) for ligation into CDF-Duet-1. The reactions were mixed and centrifuged prior to adding
enzymes and the reactions were incubated for 2 hours at 37⁰C. Digested DNA was then purified
using 0.8% agarose gel (1x TAE buffer, 120 V). DNA was excised from the gel and purified using
BIO Basic Inc. EZ-10 Spin Column DNA Gel Extraction Kit following the manufacturer’s
instructions. Ligation reactions (40 L) contained: 2x quick ligase (20 L), vector DNA (200 ng),
insert DNA 20 (85.7 ng), and quick ligase (1 L). Controls contained the same reaction
components excluding the enzyme. The reaction was incubated at room temperature for 5 minutes
then placed on ice before transformation. Chemically competent DH5α E. coli cells were thawed
on ice for 15 minutes. An aliquot of the ligation reaction (5 L) was added to the cells (50 L) and
kept on ice for 30 min. before plating. Cells were plated on prewarmed LB-Strep plates for CDF155

Duet-1 vector ligations. Plates were then incubated overnight at 37⁰C. Three colonies were chosen
from each plate and inoculated into separate 5 mL cultures of LB media with streptomycin (final
concentration 100 g/mL). Cultures were incubated and shaken at 225 rpm overnight at 37°C.
After incubation, glycerol stocks were made for each culture by adding 500 L of cultured cells
into 500 L of 20% glycerol in water. These were stored at -80°C. The remaining plasmid DNA
was then purified using BIO Basic Inc. EZ-10 Spin Column Plasmid DNA Minipreps Kit following
the manufacturer’s protocol. Successful ligation was confirmed through an analytical digest (500
ng scale) using EcoRI and HindIII restriction enzymes (0.5 L each) and the appearance of bands
matching the size of the insert on 0.8% agarose gel (1x TAE buffer, 120V).

3.9.4 Expression of eGFP and TagRFP proteins in BL21(DE3) cells: Vectors described above
were transformed into competent E.coli for plasmid isolation using the Z-competent
transformation system (Zymo Research). Chemically competent BL21(DE3) 21 E. coli were
thawed on ice for 15 minutes. An aliquot of each plasmid (100 ng) was added to the cells (50 L).
These were incubated on ice for 30 min before heat shocking at 42⁰C for 10 seconds with
subsequent incubation on ice for 5 min. SOC media (950 L) was added to the cells and incubated
at 37⁰C for 1 hour with shaking (225 rpm). An aliquot (50 L) of cells were then plated on warm
LB-Strep plates (50 mg/mL streptomycin sulfate). Cells were incubated overnight at 37°C. A
colony was chosen from each plate and inoculated into separate 5 mL cultures of LB media with
streptomycin (final concentration 100 g/mL for both). Cultures were incubated and shaken at 225
rpm overnight at 37°C. An aliquot of each culture (100 L) was inoculated into 10 mL of fresh
LB media containing streptomycin (final concentration 100 g/mL) and incubated at 37⁰C with
shaking (225 rpm) until an OD600 of between 0.6-0.8 was reached as monitored using a NanoDrop
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2000c spectrophotometer. Cultures were then induced with 0.5 mM IPTG (10 L/mL of culture
using a 500 mM IPTG stock solution). Cultures were then grown 14 hours at 28⁰C with shaking
(225 rpm). Aliquots of 1 mL cultures were then harvested and stored at -80˚C. SDS-PAGE and
Coomasie staining confirmed the expression of target proteins in cells.

3.9.5 Titration of FB lysis reagent, ampicillin, and LB media into RL FTase reactions: Prior
to reactions, dns-GCVDS or dns–GCVLS peptide (20 M) was incubated in the presence of 1x
reaction buffer (50 mM NaHEPPSO – pH 7.8. 5 mM TCEP) and 5 mM MgCl2 (50 L total) for
20 minutes. Additionally 0, 2, 5, 10, or 20 L of either FB lysis reagent (1/10th diluted stock),
amipicillin, or LB media were titrated into these reactions. After incubation, reactions were
initiated with a reaction mixture (50 L containing 100 nM RL FTase, 40 µM FPP, 5 mM MgCl2,
and 1x reaction buffer and incubated at RT for 14 hours before adding an equal volume of 20%
acetic acid in isopropanol to stop the reaction. Reactions (100 L) were analyzed via HPLC
(Zorbax EclipseXDB-C18 column) using a linear gradient of 30:70 TFA in water
(0.05%):acetonitrile (HPLC grade) to 0:100 TFA in water(0.05%):acetonitrile with a flow rate of
1 mL/min over 30 min. The column was then equilibrated for 2 min back to the original 30:70
ratio. Peptides and products were detected by fluorescence with excitation/emission of 340/496
nm.
3.9.6 Monitoring of RL FTase reactions with aryl aldehyde FPP analogue via HPLC: Prior
to reactions, dns-GCVDS or dns–GCVLS peptide (6 M) was incubated in the presence of 1x
reaction buffer (50 mM NaHEPPSO – pH 7.8. 5 mM TCEP), 1/10th diluted FB lysis reagent (10
L) and 5 mM MgCl2 (50 L total) for 20 minutes in 0.65 mL low-adhesion eppendorf tubes. For
titration of the aryl aldehyde analogue, reactions were initiated with a reaction mix (50 L)
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containing 100 nM RL FTase or WT FTase, 5 mM MgCl2, 1x reaction buffer, and 10, 30, 70, or
100 M aryl aldehyde analogue. Reactions were incubated at RT for 14 hours before adding an
equal volume of 20% acetic acid in isopropanol. Reactions were analyzed via HPLC as outlined
in section 3.9.5. For timed reactions between RL FTase, aryl aldehyde analogue, and either dnsGCVLS or dns-GCVDS, reactions conditions were as described above with final concentrations
of 50 nM RL FTase, 10 M aryl aldehyde analogue, 5 M dns-GCVLS or dns-GCVDS. Time
points were taken at 10 and 30 min, and 1, 2, 3, and 5 hours.

3.9.7 Competing reactions between dns-GCVDS and dns-GCVLS with RL FTase and aryl
aldehyde analogue: Reactions conditions were as described in section 3.9.6 with a final
concentration of 10 M aryl aldehyde analogue, 50 nM RL FTase and 3 M each of dns-GCVDS
and dns-GCVLS. Reactions were run at RT and stopped using 20% acetic acid in isopropanol at
time points of 30 min, 1 2, 3, 4, 5, 8, and 16 hours. After all time points had been taken, analysis
using HPLC was done as described previously.

3.9.8 Reactions for Steady-state analysis: Reactions consisted of a peptide mix of 0.5-3.0 µM
dns-GCVDS or dns-GCVLS, reaction buffer (50 mM HEPPSO, pH 7.8 and 5 mM TCEP) and 10
mM MgCl2 incubated for 20 min at RT to reduce disulfide bonds. To this mix was added an
enzyme mix consisting of 100 nM RL FTase or 20 nM WT FTase, 10 μM FPP, and 10 mM MgCl2
in reaction buffer at 25 °C in a low-adhesion Eppendorf tube. Fluorescence at 340/520 nm was
measured as a function of time, over 2 hours, in a BioTek H1 Synergy plate reader from which the
initial linear velocity (slope) as well as the reaction end point were determined. The total change
in fluorescence (amplitude, amp) was divided by the initial concentration of peptide for each
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reaction to yield a conversion factor (conv), changing relative fluorescence units to concentration
of product. Velocity (µM product/sec) was determined through the equation V = slope/conv. The
steady-state kinetics were determined from a fit of the Michaelis−Menten equation to the initial
velocity divided by enzyme concentration (V/E) in the presence of saturating FPP.

3.9.9 Pulldown of TagRFP-GCVDS on hydrazide beads (10 mL scale): Several 1 mL aliquots
(3 – 1.5 mL samples) of Bl21(DE3) cells containing TagRFP-GCVDS was thawed on ice. These
aliquots were pelleted at 10,000xg for 2 min and all three pellets were resuspended in supernatant
together as a 1 mL total sample. To 900 L of this cell suspension, 100 L of Fast Break lysis
reagent was added and the mixture was moderately shaken for 15 min. The resulting lysate was
centrifuged at 4°C and 1000xg for 5 min. The UV-Vis absorbance of the supernatant was measured
on a NanoDrop 2000c spectrophotometer at 555 nm. An extinction coefficient (ε) of 100,000 was
used for TagRFP. Fluorescence of 200 µL of this sample (excitation/emission of 555/585) was
taken in a 96 well plate on a BioTek H1 Synergy plate reader. Prenylation was initiated in a 10
mL glass culture tube containing 200 nM RL FTase, 10 M aryl aldehyde analogue, 5 mM MgCl2,
reaction buffer (50 mM NaHEPPSO – pH 7.8. 5 mM TCEP), and sufficient lysate supernatant to
reach a final concentration of 1-2 M TagRFP-GCVDS. Supernatant containing the protein was
incubated with reaction buffer for 20 min prior to initiation of the reaction to reduce disulfide
bonds. The reaction was incubated for overnight at room temperature at a final volume of 10 mL.
The 10 mL sample was then concentrated to 500 µL, first using a 10K PALL 15 mL
Macrosep concentrator (to 2 mL), followed by a PALL 1 mL Nanosep concentrator. Removal of
excess FPP analogue (2) was done through use of a 0.5 mL illustra NAP-5 column (GE
Healthcare). NAP-5 columns were equilibrated with 50 mM Tris-HCl (10 mL, pH 7.5) before
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application of the 0.5 mL sample. Elution followed with 50 mM Tris-HCl (1.0 mL, pH 7.5) into a
low-adhesion eppendorf tube. Concentration of the protein was calculated using UV-Vis
absorbance of the eluent, fluorescence readings were also taken. The eluent was then added to the
hydrazide beads. An aliquot (600 L) of Ultralink hydrazide resin slurry (Thermo Scientific) was
added to a gravity column and allowed to settle for 15 min. Liquid present from the slurry was
then drained from the column and the resin was washed with 0.1M phosphate buffer (3 x 500 L,
pH 7). The bottom of the column was capped and more 0.1M phosphate buffer was added to the
resin (300 L) in addition to the 1 mL prepared sample. Immobilization was initiated with mphenylenediamine (100 mM) to a final volume of 2 mL. The column was gently rocked at 25°C
for 2 hours. The resin was then drained before being washed with 0.3M phosphate buffer, pH 7.3
(3 x 300 µL), followed by 1M KCl in 50 mM Tris-Cl, pH 7.5 (3 x 300 L). Fluorescence was read
on a BioTek Synergy H1 Microplate Reader using a 96-well transparent-bottom plate containing
a 200 µL sample of the hydrazide resin. Blank control readings consisted of unreacted hydrazide
beads washed with 1M KCl. UV-Vis absorbance and fluorescence of the flow through and
phosphate buffer and KCl washes were also read.

3.9.10 Release of immobilized protein from hydrazide resin using m-phenylenediamine: To
immobilized resin (300 µL) was added a final concentration of 100 mM m-PDA and 200 mM
hydroxylamine HCl. Phosphate buffer (0.3M, pH 7) was added to a final reaction volume of 1 mL
in a low adhesion Eppendorf tube. The tube was incubated for 6 hours at RT with gentle shaking.
The sample was spun down at 5000xg for 5 min and supernatant was analyzed by UV-Vis at 555
nm and by fluorescence of 200 µL of the sample (excitation/emission of 555/585) taken in a 96
well plate on a BioTek H1 Synergy plate reader.
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3.9.11 SDS PAGE and anti-His Western blot analysis of proteins: For SDS PAGE and
Coomasie blue staining: Each sample (15 L) was denatured by boiling at 95⁰C in 3x SDS sample
buffer for 3 min. before loading each sample onto a 12% SDS-PAGE gel. The gel was run at 150v
for 1 hour.
The gel was then visualized through Coomasie blue staining. The gel was rinsed in milli-Q water
and covered in ~75 mL of destain solution (stock: 2L water, 1.6L MeOH, 0.4L acetic acid). Gels
in this solution were then microwaved for 18 seconds. Destain solution was poured off and to the
gels ~75 mL of Coomasie blue stain (stock: 0.25g Coomasie blue dye, 500 mL MeoH, 75 mL
acetic acid) was added. The gel was microwaved for 30 seconds and then rocked in the stain for 5
min. Coomasie blue stain was poured off and ~75 mL destain solution was added. The gel was
rocked for 15 min before destain was poured off and fresh destain was added and rocked for
another 15 min. After this incubation, destain was poured off and milli-Q water was added and the
gel was rocked overnight. Gels were imaged on BioRad XRS+ gel imager.
For anti-His Western blot analysis: Samples were run on a 12% SDS-PAGE gel until
loading dye was removed, about 1 hour. Gels were transferred to PVDF membranes using the
TransBlot Turbo RTA Transfer kit, following manufacturer’s instructions. Protein was transferred
to the membrane using a BioRad TurboBlot with 3x 10 min transfers at 25 volts. Blocking was
immediately performed using 30 mL of 10% nonfat milk in TBST. Membranes were rocked in
blocking solution a minimum of 2 hours at room temperature. Blocking solution was then poured
off the membranes and 10 mL of 1:60 HRP conjugated anti-His monoclonal antibody His-probe
(H-3) (Santa Cruz Biotechnology, Inc.) in TBST was added. The membrane was rocked overnight
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prior to washing of membrane with 30 mL of TBST six times before incubation with SuperSignal
West Pico Chemiluminescent Substrate (Thermo Scientific) and imaging.

3.9.12 Biotinylation of TagRFP-GCVDS after functionalization with aryl aldehyde analogue:
A 1 mL aliquot of Bl21(DE3) cells containing TagRFP-GCVDS was thawed on ice. To 900 L of
these cells, 100 L of Fast Break lysis reagent was added and the mixture was moderately shaken
for 15 min. The resulting lysate was centrifuged at 4°C and 1000xg for 5 min. The UV-Vis
absorbance of the supernatant was measured on a NanoDrop 2000c spectrophotometer at 555 nm.
This absorbance was converted to concentration in µM using Beer’s law, A = εbc, where A is the
absorption, b is the path length of 1 cm, and c is the molar concentration. The extinction coefficient
(ε) of 100,000 was used for TagRFP. Fluorescence of 200 µL of sample (excitation/emission of
555/585) was taken in a 96 well plate on a BioTek H1 Synergy plate reader. Prenylation was
initiated in a 0.65 mL low-adhesion eppendorf tube containing 200 nM RL FTase, 10 M aryl
aldehyde analogue, 5 mM MgCl2, reaction buffer (50 mM NaHEPPSO – pH 7.8. 5 mM TCEP),
and enough lysate supernatant to reach a final concentration of 2.5 M TagRFP-GCVDS.
Supernatant containing the protein was incubated with 1x reaction buffer for 20 min prior to
initiation of the reaction to reduce disulfide bonds. The reaction was incubated for overnight at
room temperature at a final volume of 1 mL.
The reaction was then concentrated to a volume of 500 L before addition of the sample
to NAP-5 column. Removal of excess FPP analogue (2) was done through use of a 0.5 mL illustra
NAP-5 column (GE Healthcare). NAP-5 columns were equilibrated with PBS (10 mL, pH 7.5)
before application of the 0.5 mL sample. Elution followed with PBS (1.0 mL, pH 7.5) into a lowadhesion eppendorf tube. Concentration of the protein was calculated using UV-Vis absorbance
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of the eluent, fluorescence readings were also taken. 50 mM hydrazide-biotin in DMSO was then
added to the eluent in a 1:10 ratio, giving a final concentration of 5 mM hydrazide-biotin. The
sample was mixed for two hours at room temperature gently before being analyzed via SDS-PAGE
gel and Streptavidin blots.

3.9.13 Analysis via streptavidin HRP blot: Samples were run on a 12% SDS-PAGE gel until
loading dye was removed, about 1 hour. Gels were transferred to PVDF membranes using the
TransBlot Turbo RTA Transfer kit, following manufacturer’s instructions. Protein was transferred
to the membrane using a BioRad TurboBlot with 3x 10 min transfers at 25 volts. Blocking was
immediately performed using 30 mL of 3% BSA in TBST or 10% nonfat milk in TBST.
Membranes were rocked in blocking solution a minimum of 2 hours at room temperature. Blocking
solution was then poured off the membranes and a 1:10,000 dilution of Pierce High Sensitivity
Streptavidin HRP in TBST was added (10 mL). The membrane was rocked overnight.
Following incubation, membranes were washed 6x in TBST, 5 min of rocking for each.
Membranes were then treated with West Pico Chemi substrate kit following manufacturer’s
instructions before imaging on a BioRad Imager with 500 sec exposure.
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Chapter 4: Development of a quantitative method to analyze prenylation activity: ProteinLipidation Quantitation
A portion of this chapter has been previously published in reference 80. Reprinted with permission
(Appendix VIII) from Shala-Lawrence, A.; Blanden, M. J.; Krylova, S. M.; Gangopadhyay, S. A.;
Beloborodov, S. S.; Hougland, J. L.; Krylov, S. N., Simultaneous Analysis of a Non-Lipidated
Protein and Its Lipidated Counterpart: Enabling Quantitative Investigation of Protein Lipidation’s
Impact on Cellular Regulation. Analytical Chemistry 2017, 89 (24), 13502-13507. Copyright
2017, American Chemical Society
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4.1 Introduction
Capillary electrophoresis (CE) is a separation technique first introduced in the 1960s in
which target molecules are separated by travel through electrolytic solutions under the influence
of an electric field.1-5 As the name suggests, CE is performed in small capillaries allowing
separation of samples based on ionic mobility and non-covalent interactions. CE can also be used
to focus, or separate and concentrate, analytes of a mixture by means of pH and conductivity
gradients.6-7
While there are many ways in which to separate analytes in CE, the overall scheme is the
same (Figure 4.1). After the sample to be analyzed is introduced into the capillary tube, analytes
in the sample are moved by force of an electric field to a destination vial which is read by a detector.
Ions within the sample move through the capillary at different rates in the same direction as they
are affected by the electroosmotic flow caused by the electric field in the mobile phase. Upon
reaching the detector, samples can be analyzed via UV-Vis absorbance or fluorescence and may
also be coupled with mass spectroscopy.2, 5, 8-12 Separation and detection is rather quick, on the
order of 3-30 minutes.5
The most commonly studied analytes by CE are nucleic acids, peptides, and small
molecules. CE has a wide variety of uses including forensic DNA fingerprinting, pharmaceutical
analysis, and testing for genetic abnormalities.13-21 One example of the analytical power of CE is
in its use as a means of detection in infectious disease. This is done most commonly through
detection of nucleic acids and recognition of sequences from specific proteins produced by the
infectious agent.22 This is achieved through PCR-based techniques which amplify conserved or
mutated gene sequences belonging to the microorganism prior to detection of that sequence using
CE.
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Figure 4.1 A general diagram of a capillary electrophoresis system. After sample injection,
analytes flow from the anode to the cathode through an electric field before reaching a detector.
Readout can be fluorescence or UV-Vis, for example. Separation of charged and neutral
analytes are shown as boxes labeled +, -, and N for positive, negative and neutral, respectively.
Circles shown in pink represent the positively charged cations present in the buffer solution.
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In 2012, Sobral and coworkers developed a CE method called High Throughput Multiple
Locus Variable Number of Tandem Repeat Analysis (MLVA-CE).22 This method uses several loci
containing variable number tandem repeats (VNTR) in Staphylococcus aureus which are amplified
through PCR and genotyped using CE to provide a quick identification of S. aureus in food sources
that could cause food poisoning.23-24 MLVA-CE was able to successfully identify and separate all
16 S. aureus VNTR DNA sequences from multiple sources. This one example highlights the ability
to specialize CE for detection of a variety targets under a different means of separation.
Despite the diversity of this technique, there are several limitations. Separation in these
capillaries is extremely sensitive to changes in pH and ionic strength of the mobile phase,
sometimes causing inconsistent results. The size of the molecules is also a factor, with large
molecules exhibiting poor separation. The work herein aims to develop a new CE method entitled
Protein-Lipidation Quantitation (PLQ), which eliminates the limitation of analyzing large
biomolecules through the detection and quantification of the modification state of a full length,
lipidated protein compared to its unmodified counterpart. This method builds upon one variant of
CE termed Micellar Electrokinetic Capillary Electrophoresis (MEKC).25 To design this new
technique, the reality in the challenges of studying protein lipidation need to be understood and
met with solutions as described below.
Posttranslational modification of proteins, such as phosphorylation, glycosylation,
ubiquitination, nitrosylation, methylation, acetylation, and lipidation, play important roles in
cellular function and biological regulation.26-27 Among this wide range of protein modifications,
protein lipidation plays a unique and essential role in regulating protein localization and trafficking
within the cell by directly mediating protein-membrane interactions (see Chapter 1). There are
several distinct lipidation modifications, such as N-terminal myristoylation, palmitoylation,
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prenylation of cysteine sidechain thiols, and attachment of glycophosphoinositol (GPI) groups.2843

However, the significance of each of the diverse lipid modifications, as well as the mechanism

by which lipidation controls function and activity of the proteins, remain topics of intense study.
One central challenge in studying protein lipidation has been the difficulty in measuring
the distribution and relative populations of precursor and lipidated forms of proteins. The lack of
a quantitative method that could simultaneously measure the amounts of both protein forms has
complicated quantitative analysis of the regulation, functional impact, and biological requirement
for protein lipidation. To date, analytical methods used to study protein lipidation have focused
primarily on identifying lipidated proteins.44-46 In terms of protein prenylation, the earliest studies
utilized metabolic labeling with radioactive prenyl donors or biosynthetic precursors, separating
the prenylated product from the excess lipid donor by gel electrophoresis followed by detection by
autoradiography.34, 47-50 Subsequent studies have employed chemically modified FPP and GGPP
analogues containing groups allowing for protein detection by bioorthogonal chemical tagging or
affinity detection.51-60 Proteins labeled with these analogues can be detected using either gel
electrophoresis and/or mass spectrometry following affinity-based pulldown protein isolation.51,
61-62

Prenylation of specific proteins can be detected within the cell using fluorescent fusion

proteins and microscopic imaging to detect the lipidated product based on protein localization to
cellular membranes.56, 63-66 Each of the above methods has only limited quantitative capabilities
for measuring protein prenylation and none of them can efficiently quantitate the unmodified
substrate. Some prenylated proteins such as H-Ras exhibit a mobility shift on gel electrophoresis
following prenylation pathway modifications,67-68 although this behavior is considered highly
ambiguous amongst naturally occurring prenylated proteins.

In these cases, simultaneous

detection of both the precursor and modified forms of the prenylated protein can be achieved by
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separation with SDS-PAGE and detection by Western blot analysis.69-70 Known limitations of
Western blot analysis make this method only semi-quantitative.
A quantitative understanding of the role played by protein lipidation in cells requires a
method that measures both unmodified substrate (S) and modified product (P); an approach which
the aforementioned techniques fall short of. In designing a suitable method, we determined three
requirements that should be met by the approach. The first is its ability to detect both S and P with
a known relation between their signal/concentration ratios. This allows for direct quantitation. The
second is its ability to discriminate between signals for S and P clearly from each other. Third, for
biological application, it should be able to examine crude cell lysates as to avoid bias of S or P
from use of sample purification. The methods listed above find difficulty in satisfying the ability
to identify unmodified substrate and those that do, cannot effectively separate the two species.
In exploring analytical methods that satisfy all three requirements for efficiently separating
the prenylated and non-prenylated forms of a protein, we can draw inspiration from the proposed
role of protein lipidation modifications in increasing protein association with cellular membranes.
Micellar Electro-Kinetic Chromatography (MEKC) utilizes detergent or lipid micelles to provide
molecular separation during capillary electrophoresis (Figure 4.2).71-73 In MEKC, a detergent such
as SDS is used to form micelles in the running buffer with which the analyte can interact. Micelles
with or without interacting analyte travel quite slowly through the capillary tube as compared to
free analyte or buffer. This is due to an electrophoretic mobility caused by the drag associated with
the viscosity and charge of the micelle as it moves through the electric field within capillary. This
electrophoretic mobility is counter to the electroosmotic flow (EOF) of the capillary resulting in
micelle-associated analytes exhibiting a slower overall velocity towards the cathode.
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in the buffer solution.
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This technique has been used to separate peptides and small molecules based on
hydrophobicity-dependent partitioning into the detergent micelles,74-76 and has been used to
separate short farnesylated peptides from the non-lipidated precursor.77-78 An example from
Berezovski and coworkers in 2002 demonstrated separation of unmodified and farnesylated small
peptides labeled with 2’,7’-difluorofluorescein (dff) for fluorescence detection. The samples were
analyzed using CE in the presence and absence of SDS micelles, with addition of SDS as used in
MEKC providing the best resolution between substrate and modified product (Figure 4.3). This
technique was applied further in using the ability of MEKC to measure the rate of accumulating
product to determine kinetic parameters of the farnesylation of the pentapeptides.78
As with any analytical technique, MEKC has experimental limitations. It has generally
been considered not applicable for full-length protein separation due to the inability of a protein to
fit within the hydrophobic micelle interior without denaturation.79-80 This work was motivated by
our insight that the unique chemical characteristics of protein lipidation modifications may allow
us to leverage MEKC as a method to separate and identify lipidated proteins. To examine the
applicability of MEKC for analysis of protein lipidation, we used fluorescent reporter proteins
(eGFP and TagRFP) which have been designed to become substrates of protein farnesyltransferase
(FTase) and protein geranylgeranyltransferase type I (GGTase-I) through cloning at their Cterminus (See Chapter 3). The use of fluorescent proteins allows simultaneous detection of the
lipidated and non-lipidated forms of the reporter proteins. We found that MEKC utilizing SDS
micelles can rapidly and efficiently separate a farnesylated protein from the non-farnesylated
precursor. The efficiency of this separation is dependent on protein charge, with eGFP separating
more efficiently than the more negatively charged TagRFP.
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We foresee that PLQ will facilitate transformation of protein-lipidation studies towards
quantitative analysis of in vivo protein modifications and may prove extendable to the analysis of
a wide range of different protein lipidation modifications. PLQ has the advantage of both positively
and negatively charged proteins reaching the detector due to the presence of a strong
electroosmotic flow (EOF). It also allows for separation of two analytes with similar charge-tosize ratios through addition of a pseudo-stationary phase (micelles) to the running buffer.
Specifically, addition of suspended molecules to the buffer can introduce a shift in an analyte’s
electrophoretic mobility through preferential analyte binding. PLQ was inspired by an insight that
an ionic surfactant could serve as a pseudo-stationary phase for separation of P and S through
binding of the lipid moiety of P. While this approach as been achieved using small lipidated
peptides, our fine tuning of the stationary and mobile phases using differing concentrations of SDS
achieves enhancement of full-length protein separation.
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Figure 4.3 CE separation of a farnesylated peptide (peak 1) from the parent unmodified
peptide (peak 2). The reaction mixture contained 0.8 M dff-GCVIA, 20 M FPP and 46 nM
PFTase after 48 h incubation at 30˚C in the enzymatic buffer. Running buffers: (A) 25 mM
borax, pH 9.1; (B) 50 mM borax, 20 mM β-cyclodextrin, pH 9.5; (C) 50 mM TES, 50 mM
SDS, pH 7.3; (D) 25 mM borax, 25 mM SDS, pH 9.3. This figure has been reused with
permission from reference 78 (Appendix IX).
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4.2 PLQ separation of lipid modified fluorescent proteins from their unmodified
counterparts
To validate PLQ as a potential method for spearation, we chose purified enhanced green
fluorescent protein (eGFP) fused with a GCVDS peptide to permit modification by protein
farnesyltransferase (FTase) using a farnesyl diphosphate (FPP) lipid donor (see section 4.7 and
Chapter 3 for design and cloning of this protein). The use of a fluorescent protein grants the ability
to detect substrate and produce via a readout of fluorescence at the detector. The GCVDS motif
was chosen as part of an ongoing study into a bioorthogonal substrate-enzyme relationship in
which a mutant FTase lipidates a noncanonical prenylation motif (see Chapter 3).81
In order to achieve sufficient separation of substrate and product in PLQ, an appropriate
surfactant, along with its ideal concentration, must first be determined. This was achieved through
testing of different surfactants at varying concentrations for their ability to separate a mixture of
the purified, unmodified eGFP-GCVDS and its farnesylated product. Nonionic surfactants were
tested and did not introduce noticeable mobility shift. We began tests of anionic surfactants with
sodium dodecyl sulfate (SDS) because it has been previously used in CE as a pseudo-stationary
phase for small-molecule separation.82 The concentration of SDS was kept well below that
typically used for protein denaturation (∼70 mM SDS, with sample heating to 100 °C and addition
of reducing agents). To determine optimum SDS conditions, the mixture of farnesylated and nonfarnesylated eGFP were analyzed at SDS concentrations ranging from 0 to 25 mM at pH 9.2
(Figure 4.4). The maximum resolution was achieved with SDS concentration in a range of 15 to
25 mM, with the electropherograms being exhibiting reproducibility in this range. As expected,
the farnesylated product migrated slower in agreement with our model in which a negatively
charged surfactant should slow down migration of P during PLQ analysis (Figure 4.5).

179

Figure 4.4 Influence of changing SDS concentration on separation of the farnesylated
and non-farnesylated eGFP. All of the experiments were conducted in a buffer containing
25 mM borax at different concentrations of SDS (indicated at left) and pH of 9.2. For clarity
of presentation, 3-min time offsets and 5-unit signal offsets units are applied. This figure has
been reused with permission from reference 80 (Appendix VIII) with CE analysis performed
by Krylov and coworkers, York Univeristy.

180

The composition of the run buffer was then optimized with regards to SDS concentration, pH, and
ionic strength to achieve maximum resolution between peaks of S and P. This optimized buffer
(20 mM SDS, 25 mM sodium tetraborate, pH 9.2) facilitated baseline separation of farnesylated
and nonfarnesylated eGFP-GCVDS (Figure 4.6a). A test of the ability of PLQ to separate S and P
efficiently at a biological level required analysis of crude bacterial cell lysate containing both
eGFP-GCVDS

and

its

farnesylated

product.

We

observed

high-quality

separation

undistinguishable from that of purified S and P (Figure 4.6a). We found that farnesylation did not
affect relative fluorescence intensity of eGFP-GCVDS, and the presence of 20 mM SDS (optimal
concentration) did not change fluorescence from eGFP-GCVDS above normal experiment-toexperiment variation. This important observation defines PLQ as quantifiable with accurate
signal/concentration ratios for both S and P, not influenced by the surfactant or buffer. This allows
simple quantitation of S and P concentrations in the sample based on areas of the corresponding
peaks, with absolute quantitation possible through use of an internal standard.
To determine if PLQ-based separation was farnesylation specific or applicable to a wider
variety of lipid moieties, we next explored a different lipid donor by replacing FPP with
geranylgeranyl diphosphate (GGPP). The substrate of lipidation was eGFP fused with the GCVLL
peptide sequence with the enzyme geranylgeranyltransferase type I (GGTase-I) used to
geranylgeranylate eGFP-GCVLL. Separation was achieved for nongeranylgeranylated and
geranylgeranylated eGFP-GCVLL without reoptimization of the conditions used for farnesylation
(Figure 4.6b).
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Figure 4.5 Conceptual illustration of PLQ. (a) Nonlipidated fusion protein (S) and its
lipidated product (P) with an anionic (for example) surfactant bound to a lipid moiety of the
latter. (b) S and P in a capillary filled with the surfactant in the run buffer (not shown), an
electric field and EOF. Both S and P are propelled toward the cathode by EOF, however, the
charge added to P by the lipid-bound surfactant makes its resulting velocity (vP) different
(smaller in our example) than that of S (vS). (c) Schematic dependence of fluorescence signal
on time for the separated S and P. Areas of peaks are proportional to the respective
concentrations. This figure has been reused with permission from reference 80 (Appendix VIII).
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Figure 4.6 PLQ separation of various prenylation constructs. (a) S, eGFP-GCVDS; P;
farnesylated eGFP-GCVDS. Top trace, purified S and P in 50 mM NaHEPPSO pH 7.8 and 5
mM TCEP; bottom trace, S and P present in the crude bacterial cell lysate. The run buffer was
25 mM Borax, 20 mM SDS at pH 9.2. (b) S, eGFP-GCVLL; P, geranylgeranylated eGFPGCVLL. Purified S and P were in 50 mM NaHEPPSO pH 7.8 and 5 mM TCEP; run buffer was
25 mM Borax, 20 mM SDS at pH 9.2 (c) S, TagRFP-GCVDS; P, farnesylated TagRFPGCVDS. Purified S and P were in 50 mM Na-HEPPSO pH 7.8 and 5 mM TCEP; run buffer
was 25 mM sodium tetraborate, 20 mM SDS at pH 10.0. This figure has been reused with
permission from reference 80 (Appendix VIII) with CE analysis performed by Krylov and
coworkers, York Univeristy.
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To determine if PLQ is applicable to different full length proteins, eGFP was replaced with
red fluorescent protein (TagRFP) while maintaining the GCVDS farnesylation motif. With
differing isoelectric points of 5.8 and 7.1 for eGFP and TagRFP, respectively (determined using
ExPASy Bioinformatics Resource Portal), a reoptimization of pH was needed for maximum
resolution between the S and P forms of TagRFP-GCVDS and was achieved at pH 10.0 (Figure
4.6c). Interestingly, the need to optimize pH based on different protein suggests that while the lipid
moiety directly interacts with SDS micelles during separation as expected, there is some indirect
interaction of the fluorescent protein itself with the micelle. Through adjustment of the buffer pH
we can minimize this interaction and measure separation based solely on the presence or absence
of lipid modification.

184

4.3 PLQ separation of unmodified and farnesylated eGFP-HRas from mammalian cell lysate
To investigate the biologically relevant use of PLQ, the short C-terminal peptide appended
to eGFP in previous samples was replaced with full length human HRas, a well-studied protein
which undergoes farnesylation.83-85 In cells, eGFP-HRas is readily prenylated by endogenous
FTase, providing us with a product but potentially no unmodified substrate from which to separate
it from. In order to generate an unmodified form of eGFP-HRas with which to analyze separation
between S and P, the FTase inhibitor tipifarnib was used to block prenylation in one sample of
HEK293 cells.86 The cell lysate prepared from cells treated with tipifarnib produced two prominent
peaks less than 1 minute apart (Figure 4.7, lower curve). The cell lysate prepared from cells grown
without the FTase inhibitor presented a new peak corresponding to the farnesylated protein and
the decreased 2 peaks associated with the substrate (Figure 4.7, upper curve). Separation of S from
P for this larger size fusion protein (54 kDa) required reoptimization of conditions, with the
optimum separation achieved at a higher ionic strength of the SDS-containing run buffer: 50 mM
instead of 25 mM sodium tetraborate. Quantitative features of PLQ allowed us to determine the
level of lipidated substrate in the presence of inhibitor being below the limit of detection while in
the absence of inhibitor it grew to 58%, which demonstrates the ability of PLQ to accurately
determine the fraction of a given protein within a cell that undergoes lipid modification.
PLQ is sensitive to a wide range of protein concentrations making it widely applicable in
research. The commercial instrument used in this study supports a limit of detection below 10 pM
and a linear dynamic range of at least 3 orders of magnitude. Importantly, all quantitative
characteristics are retained in the analysis of crude cell lysates since the cell debris is fully
separated from the fluorescent analytes and does not affect detection. The quantitative
characteristics are also independent of the substrate protein nature because they are defined by the
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fluorescent properties of GFP or RFP which do not change significantly upon fusion to a substrate
protein and are not greatly affected by substrate lipidation. We confirmed that PLQ satisfied the
requirements necessary to produce a quantitative analysis of protein modification while also
showing that PLQ is robust to changes in lipid donor, fluorescent protein, and lipid acceptor with
minimal reoptimization. These findings emphasize the practicality of PLQ approach and suggest
that PLQ implementation with a fluorescent fusion protein and SDS-mediated CE as a stationaryphase-free column separation method is a robust approach for investigating protein lipidation in
biologically relevant contexts.
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Figure 4.7 PLQ analysis of endogenous farnesylation of eGFP-HRas fusion protein. The
lower curve corresponds to sampling cell lysate prepared from HEK293 cells grown in the
presence of a FTase inhibitor and shows peaks generated by the nonfarnesylated eGFP-HRas.
The upper trace corresponds to sampling cell lysate prepared from HEK293 cells grown without
inhibition of FTase and shows the peak of farnesylated eGFP-HRas at the right and peaks of
nonfarnesylated eGFP-HRas at the left. The run buffer was 50 mM sodium tetraborate, 20 mM
SDS at pH 9.2. Percentile shows concentrations of nonfarnesylated and farnesylated eGFPHRas calculated from the areas of corresponding peaks. This figure has been reused with
permission from reference 80 (Appendix VIII) with mammalian lysates prepared by
Soumyashree Gangopadhyay, Syracuse University, and CE analysis performed by Krylov and
coworkers, York Univeristy.
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4.4 PLQ analysis of the impact of p53 mutation on cellular prenylation activity
The most commonly mutated gene in cancer is p53, a tumor suppressor gene which codes
for a protein responsible for regulation of the cell growth cycle.87-90 The majority of p53 mutations
are found to be single amino acid missense mutations affecting the DNA binding domain of the
protein.91 It was recently reported that the presence of mutated in the MDA-231 breast cancer cell
line is associated with prenylation-dependent changes in cell morphology and growth.90
Prenylation is suggested in this study to be impacted by the mutated p53 in the breast cancer cells.
Our ability to separate nonprenylated and prenylated proteins using PLQ provides an ideal
approach to directly probe the impact of the presence of mutated p53 on cellular protein
prenylation and to test PLQ as a valuable tool in discerning prenylation’s role in disease states.
To examine the influence of a p53 mutation on prenylation activity, we used the MDA231shp53 cell line which has been engineered to express a doxycycline (Dox)-inducible short
hairpin RNA (shRNA) silencing of the endogenous mutant p53 gene.90 MDA231shp53 cells were
transfected with an RFP-tagged substrate for GGTase-I in the presence and absence of Dox (Figure
4.8a). Crude lysates from these cells were analyzed by PLQ using conditions optimized for
TagRFP-containing fusion protein substrates. In the presence of Dox (when mutated p53 was
silenced), the peak of the geranylgeranylated form of the TagRFP substrate was below the limit of
detection, confirming that less than 5% of the substrate was prenylated (Figure 4.8b). In contrast,
in the absence of Dox (when mutated p53 was expressed), the peak corresponding to the
geranylgeranylated product of TagRFP indicated that more than 95% of the substrate was
prenylated. Control experiments using HEK293 cells indicate that Dox treatment alone does not
influence protein geranylgeranylation in the absence of the mutated p53 gene (Figure 4.9). This
study demonstrates that silencing of mutant p53 expression exhibits a functional effect on cellular
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GGTase-I activity similar to that of direct inhibition of cellular FTase activity by FTase inhibitor
treatment with Tipifarnib. These findings support the proposed model wherein p53 mutations lead
to altered cellular prenylation activity and suggests that altered protein prenylation may play a
direct role in cellular changes involved in development of cancer cells.
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Figure 4.8 PLQ analysis of the impact of p53 mutation on cellular prenylation activity.
(a) Schematic representation of cellular model for testing the impact of mutant p53 expression
on protein prenylation. (b) PLQ analysis of cell lysates prepared from cells grown in the
absence (top trace) and presence (bottom trace) of Dox. This figure has been reused with
permission from reference 80 (Appendix VIII) with samples prepared by Soumyashree
Gangopadhyay, Syracuse University, and CE analysis performed by Krylov and coworkers,
York Univeristy.
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Figure 4.9 Control experiments with HEK293 cells in the absence of mutated p53 gene. The
upper trace shows signal of geranylgeranylated product of TagRFP-link(HRas)-CVLL expressed
in HEK293 cells in the absence of doxycycline. The bottom trace shows the same peak of
geranylgeranylated product expressed in HEK293 cells in the presence of doxycycline, which
indicates that doxycycline treatment alone does not influence protein geranylgeranylation in the
absence of the mutated p53 gene. This figure has been reused with permission from reference 80
(Appendix VIII) with samples prepared by Soumyashree Gangopadhyay, Syracuse University and
CE analysis performed by Krylov and coworkers, York University.
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4.5 Conclusions
Protein-Lipidation Quantitation is the first successful approach for simultaneous analysis
of substrate and product levels for full length proteins capable of undergoing lipidation. We have
been able to demonstrate its practical execution with multiple fluorescent fusion proteins as
substrates in an SDS-mediated CE as a stationary-phase-free column separation method. This
method is applicable not only to purified sample but also in crude cell lysates without any sample
purification, emphasizing its value in providing a snapshot of the extent of lipidation of target
proteins in a cell. PLQ provides a powerful complement to While fluorescence microscopy is
valuable for determining the ability for a protein to be lipidated, PLQ offers a complementary
picture of the extent of lipidation in a quantitative manner. Used together, the change in protein
cellular localization upon lipidation can be combined with an accurate assessment in the extent of
protein lipidation potentially at both the single-cell and population scales. The combined use of
PLQ and microscopy will uniquely enable researchers to identify and study proteins in which the
role of lipidation is not to enhance plasma localization, for example, Ydj1p heat shock protein
recently reported on by Hildebrant and co-workers.92 With this shunt pathway for prenylated
proteins, as described in Chapter 2, membrane-localized fluorescence analysis will not provide a
complete picture of the prenylated proteome. In the growing field of protein lipidation, the
quantitative capabilities of PLQ will allow researchers to formulate and address quantitative
questions that were once too difficult to answer. PLQ thus promises to become a powerful tool in
studies of roles of protein lipidation in cellular regulation and biological function. This work also
adds lipidation to a set of postrtranslational modifications of proteins (PEGylation, glycosylation,
carbonylation, phosphorylation) for which CE analyses have been developed.93-96
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4.6 Materials and Methods
4.6.1 Miscellaneous: Fused silica capillary (75 μm inner diameter, 360 μm outer diameter) was
purchased from Molex (Phoenix, AZ). All chemicals were obtained from SigmaAldrich (Oakville,
ON, Canada) unless otherwise stated. Disodium Tetrborate (borax) was purchased from EMD
(Toronto, ON, Canada). All solutions were made using deionized Mili-Q water filtered through
0.22 μm Millipore filter (Millipore, Nepean, ON, Canada).

4.6.2 Design of pJExpress414 plasmid containing His6-eGFP-GCVDS or His6-eGFPGCVLL: For the eGFP-GCVDS reporter protein, site directed mutagenesis of the plasmid
pJExpress_eGFP-GCVIA59 was used to prepare an eGFP reporter protein with a C-terminal GCVDS sequence. PCR reactions contained final concentrations of 1 Pfu Turbo buffer, 10 mM
dNTPs, reverse primer (125 ng), forward primer (125 ng), template plasmid (10 ng), and Pfu Turbo
DNA polymerase (1 µL, 2.5 U/µL). PCR mutagenesis was performed under the following thermal
program: Initial denaturation (95C, 1 min.); eighteen cycles of denaturation (95C, 50 s),
annealing (60C, 50 s), and extension (68C, 12 min); final extension (68C, 12 min); and a final
hold (10C, ∞). The reaction was then digested with DpnI (1 µL, 10 U/µL) for 1 h at 37C. PCR
mutagenesis reactions were transformed into chemically competent E.coli for plasmid isolation
using the Z-competent transformation system (Zymo Research). An aliquot of the PCR reaction (5
µL) was added to DH5α cells (50 µL) and incubated on ice for 30 min before plating cells on warm
LB-Amp plates. Cells were incubated overnight at 37°C. Colonies were chosen from the LB-Amp
plate and inoculated into separate 5 mL culture of LB media with ampicillin (final concentration
100 µg/mL). Cultures were incubated overnight at 37°C with shaking. The plasmid DNA was then
purified using BIO Basic Inc. EZ-10 Spin Column Plasmid DNA Minipreps Kit following the
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manufacturer’s protocol. Mutations were verified by commercial DNA sequencing (Genewiz).
The gene for the His6-eGFP-GCVLL reporter protein was prepared by above protocol using
appropriately designed mutagenic primers. Mutations were verified by commercial DNA
sequencing (Genewiz).

4.6.3 pCDF-Duet-1 plasmid containing the His6-TagRFP-GCVDS reporter protein: A gene
encoding the His6-TagRFP-GCDVS reporter protein was prepared by PCR using the TagRFP-N
vector97 (Evrogen) as template with the –GCVDS C-terminal sequence and HindIII restriction site
present in the 3’ primer. The PCR reaction (50 L) contained final concentrations of 1x Standard
OneTaq buffer, 10 mM dNTPs, reverse primer (125 ng), forward primer (125 ng), template
plasmid (10 ng), and OneTaq DNA polymerase (0.25 µL, 5 U/µL). PCR was performed S3 under
the following conditions: Initial denaturation (94°C, 1 min); thirty cycles of denaturation (94°C,
30 s), annealing (56°C, 1 min), and extension (68°C, 2 min); final extension (68°C, 5 min); and a
final hold (10°C, ∞). PCR products were purified using BIO Basic Inc. EZ-10 Spin Column PCR
Purification Kit following the manufacturer’s instructions. Following digestion by EcoRI and
HindIII, the His6-TagRFP-GCDVS insert was ligated into the pCDF-Duet-1 expression plasmid.
Insert ligation was verified by analytical restriction digest and DNA sequencing (Genewiz).

4.6.4 Expression and purification of RL FTase and GGTase-I: Wild-type (WT) rat GGTase-I
and W102R W106L rat FTase variants were expressed in BL21(DE3) Escherichia coli (E. coli)
employing previously described pET23a-based GGTase-I and variant FTase vectors, with
expression and purification using previously reported protocols with the following changes to
protein expression.98-100 Initial cultures were added to 1 L rich media (20 g tryptone, 10 g yeast
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extract, 5 g NaCl, 1% glucose, 0.5 mM IPTG and 100 µg/mL ampicillin) and grown at 28°C with
shaking for 18 hours. Upon purification, enzyme concentration was measured by active-site
titration using dansylated peptides, as described previously.101

4.6.5 Expression and purification of His6-eGFP-GCVxx and His6-TagRFP-GCVDS:
proteins: Chemically competent BL21 (DE3) E. coli were transformed with reporter protein
expression vectors (pJExpress414-eGFP-GCVDS, pJExpress414-GCVLL, or CDF-Duet1_TagRFP-GCVDS). Following transformation and antibiotic selection, a colony from the
transformation plate was inoculated into LB media (5 mL) containing either 100 µg/mL ampicillin
(for pJExpress414 vectors) or 100 µg/mL streptomycin (for CDF-Duet-1 vector). Cultures were
incubated and shaken at 225 rpm for 4 h at 37°C. Each culture was then transferred to 1 liter of
prewarmed auto-induction media (10 g tryptone, 5 g yeast extract, 20 mL 50 5052 media [25%
glycerol, 10% lactose, 2.5% glucose], 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM
Na2SO4, 2 mM MgSO4, 200 µL trace metals [50 µM FeCl2, 20 µM CaCl2, 10 µM MnCl2, 10 µM
ZnCl2], 100 µg/mL ampicillin or streptomycin.7 Expression cultures were incubated for 19 h at
37˚C with shaking. Cells were harvested by centrifugation and resuspended in 50 mL resuspension
buffer (20 mM NaH2PO4, 500 mM NaCl, and 10 mM imidazole). Bacterial cell suspensions were
lysed by sonication, clarified by centrifugation, and purified by affinity chromatography using a
Ni-NTA HisTrap column (GE S4 Healthcare). Fractions containing the fluorescent protein were
combined and concentrated using a centrifugal concentrator. Concentrated samples were buffer
exchanged to 50 mM Tris buffer (pH 7.5), divided into 20 µL aliquots, and flash frozen with liquid
nitrogen for storage at −80°C. Protein concentrations were determined using molar absorptivities
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of eGFP at 488 nm of 488 = 55,000 M−1cm−1 and of TagRFP at 555 nm of 555 = 100,000 M−1
cm−1 , respectively.59, 97

4.6.6 Farnesylation of purified His6-eGFP-GCVDS and His6-TagRFP-GCVDS proteins:
Farnesylation of purified fluorescent proteins was performed by incubation of the appropriate
substrate protein (His6-eGFP-GCVDS or His6-TagRFP-GCVDS, 2.5 µM) with 200 nM FTase, 10
µM of Farnesyl pyrophosphate (FPP), and 5 mM MgCl2 in reaction buffer (50 mM NaHEPPSO,
5 mM TCEP, pH 7.8) in a final volume of 0.5 mL. Substrate proteins were incubated in reaction
buffer for 20 min prior to reaction initiation by addition of FTase and FPP to reduce disulfide
bonds. Reactions were covered with foil and incubated overnight at room temperature.

4.6.7 Geranylgeranylation of purified His6-eGFP-GCVLL: Geranylgeranylation of purified
His6-eGFP-GCVLL fluorescent proteins was performed MgCl2 in reaction buffer (50 mM
NaHEPPSO, 5 mM TCEP, pH 7.8) in a final volume of 0.5 mL. The substrate protein was
incubated in reaction buffer for 20 min prior to reaction initiation by addition of GGTase-I and
Geranylgeranyl pyrophosphate (GGPP) to reduce disulfide bonds. Reactions were covered with
foil and incubated overnight at room temperature.

4.6.8 Farnesylation of His6-eGFP-GCVDS in bacterial lysates: A frozen 1 mL aliquot of BL21
(DE3) cells expressing His6-eGFP-GCVDS was thawed on ice. Bacterial cells in suspension (900
mL) were lysed by addition of 100 mL of Fast Break lysis reagent (Promega) followed by moderate
shaking for 15 min at room temperature. The resulting lysate was clarified by centrifugation (1,000
 g, 5 min). The concentration of the His6-eGFPGCVDS in the clarified lysate was determined by
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absorbance of eGFP at 488 nm of 488 = 55,000 M−1cm−1). Farnesylation of His6-eGFP-GCVDS
in crude lysate was performed by incubation of sufficient lysate supernatant to reach a final
concentration of 2.5 M protein with 200 nM RL FTase, 10 M FPP, 5 mM MgCl2, reaction buffer
(50 mM NaHEPPSO, 5 mM TCEP, pH 7.8) in a final volume of 0.5 mL. Supernatant containing
the protein was incubated with 1 reaction buffer for 20 min to reduce disulfide bonds prior to
initiation of the reaction. Reactions were incubated for overnight at room temperature.

4.6.9 Preparation of HEK293 cells expressing eGFP-HRas (There experiments were
performed Soumyashree Gangopadhyay, Syracuse University): The mammalian cell line
HEK293 (ATCC) was maintained in 75 mL vented tissue culture flasks (Celltreat), and were split
upon reaching 80% confluency. The cells were grown in complete DMEM (Dulbecco's Modified
Eagle's Medium supplemented with 10% fetal bovine serum (FBS) and 1% (v/v) penicillinstreptomycin (MediaTech)) in a humidified atmosphere with 5% CO2 at 37°C. For expression of
the eGFP-HRas reporter protein, 9 × 104 cells were placed in 2 mL of complete DMEM per well
of a tissue culture treated 6-well plate (Corning) (total of 5 wells). The cells were incubated 18-20
hours prior to transfection. The DNA-transfection reagent complex was prepared by incubating 4
µg of the reporter protein expression plasmid pEGFP-HRas (Casey laboratory, Duke University)
and 9 µL of the Turbofect transfection reagent (Thermo Scientific) in a total volume of 500 µL
supplement free DMEM for 15 minutes at room temperature.102 The cells were then transfected
with the prepared DNA-transfection reagent complex by drop wise addition into the wells of a 6well tissue culture plate. A parallel set of wells was treated with the FTase inhibitor tipifarnib at a
concentration of 500 nM. Following transfection for 24 h, live cells were imaged using a Zeiss
Axio Vert.A1 inverted fluorescence microscope with a 470/40 nm excitation filter, a 495 nm beam

197

splitter and a 525/50 nm emission filter to verify fluorescent protein expression and analyze
fluorescence localization behavior in presence and absence of tipifarnib. The cells were then
scraped and resuspended in phosphate buffered saline (PBS) followed by centrifugation to harvest
the cell pellet. The cell pellets were stored at −80°C.

4.6.10 Creation of pCAF mammalian expression plasmid containing the TagRFPlink(HRas)- CVLL reporter protein: A gene encoding the Tag RFP-link(HRas)-CVLL reporter
protein was prepared by PCR mutagenesis by mutating the terminal serine residue of the
previously reported TagRFPlink(HRas)-CVLS reporter protein to a leucine residue to obtain the
pCAF1-TagRFP-link(HRas)-CVLL vector.63 In the Tag RFP-link(HRas)-CVLL reporter protein,
the 15 amino acids of HRas upstream of the farnesylation site within Hras and a C-terminal GCVLL sequence are fused to TagRFP (-KLNPPDESGPGCMSCGCVLL). Primers were
dissolved in ultra-pure water and concentrations were measured by UV absorbance at 260 nm (1
OD = 33 µg/mL). The PCR mutagenesis reaction (50 µL) contained 10 x Pfu reaction buffer (5
µL), pCAF1-TagRFPlink(HRas)-CVLS template plasmid (10 ng), forward primer (125 ng),
reverse primer (125 ng), 10 mM dNTPs, and Pfu Turbo DNA polymerase (1 L, 2.5 U/L ). PCR
mutagenesis was performed using the following temperature program: Initial denaturation (95°C,
1 min); 18 cycles of denaturation (95°C, 50 sec); annealing (60°C, 50 sec) and extension (68°C,
12 min) followed by final extension (68°C, 12 min). Following PCR, reactions were treated with
DpnI (1 µL, 10 units/µL) and incubated at 37°C for 1 hour. Z-competent DH5α E. coli cells (Zymo
Research) were thawed on ice for 10 minutes and then transformed with 5 µL of the PCR reaction
following which the cells were plated on pre-warmed LB-Amp plates and incubated overnight at
37°C. Two colonies were picked from each plate and inoculated into LB media (5 mL) containing
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100 µg/mL ampicillin and incubated with shaking (225 rpm) overnight at 37°C. Following
overnight growth, a 10% glycerol stock was prepared stored at -80°C. Plasmid DNA was purified
from the remaining saturated culture using EZ-10 spin column DNA purification kit (BioBasic)
per the manufacturer’s protocol. The mutations were confirmed by DNA sequencing (Genscript).

4.6.11 Preparation of MDA-231shp53 cells expressing TagRFP-link(HRas)-CVLL in the
presence and absence of doxycycline (There experiments were performed Soumyashree
Gangopadhyay, Syracuse University): The mammalian cell line MDA-231shp53 (CUNYHunter College, New York) was maintained in 75 mL vented tissue culture flasks (Celltreat), and
were split upon reaching 80% confluency.90 The cells were grown in complete DMEM in a
humidified atmosphere with 5% CO2 at 37°C. For doxycycline treatment, doxycycline (6 µg/mL)
was added to the 75 mL culture flask and the cells were incubated as described above. The cells
were grown in the presence of doxycycline for at least 8 days to ensure suppression of mutant p53
expression. For expression of the reporter protein, 1 × 105 cells were placed in 2 mL of complete
DMEM per well (5 total wells) of a tissue culture treated 6-well plate (Corning). For the
doxycycline treated cells, 6 µg/mL doxycycline was added to each well prior to transfection. Both
doxycycline treated and untreated cells were incubated 18- 20 h prior to transfection. The DNAtransfection reagent complex was prepared by incubating 1 µg of the pCAF1-TagRFP-link(Hras)CVLL reporter protein plasmid and 2 µL of the XtremeGENE HP transfection reagent (Roche) in
a total volume of 100 µL supplement free DMEM for 30 min at room temperature. The cells were
then transfected with the prepared DNA-transfection reagent complex by drop wise addition into
the wells of a 6-well tissue culture plate. Upon 24 h transfection, live cells were imaged using a
Zeiss Axio Vert.A1 inverted fluorescence microscope with a 545/525 nm excitation filter, a 565
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nm beam splitter, and a 605/70 nm emission filter to verify fluorescent protein expression. The
cells were then scraped and resuspended in PBS, followed by centrifugation to harvest the cell
pellet. The cell pellets were stored at −80°C.

4.6.12 Control experiments with HEK293 cells expressing TagRFP-link(HRas)-CVLL
(There experiments were performed Soumyashree Gangopadhyay, Syracuse University):
The mammalian cell line HEK293 (ATCC) was maintained in 75 mL vented tissue culture flasks
(Celltreat), and were split upon reaching 80% confluency. The cells were grown in complete
DMEM penicillin-streptomycin (MediaTech)) an in a humidified atmosphere with 5% CO2 at
37°C. For expression of the reporter protein, 1 × 105 cells were placed in 2 mL of complete DMEM
per well of a tissue culture treated 6-well plate (Corning) (5 total wells). For the doxycycline
treated cells, 6 µg/mL doxycycline was added to each well prior to transfection. Both doxycycline
treated and untreated cells were incubated 18-20 h prior to transfection. The DNA-transfection
reagent complex was prepared by incubating 4 µg of the pCAF1-TagRFP-link(Hras)-CVLL
reporter protein plasmid and 9 µL of the Turbofect transfection reagent (Thermo Scientific) in a
total volume of 500 µL supplement free DMEM for 15 min at room temperature. The cells were
then transfected with the prepared DNA-transfection reagent complex by drop wise addition into
the wells of a 6-well tissue culture plate. Upon 24 h transfection, live cells were imaged using a
Zeiss Axio Vert.A1 inverted fluorescence microscope with a 545/525 nm excitation filter, a 565
nm beam splitter and a 605/70 nm emission filter to verify fluorescent protein expression. The
cells were then scraped and resuspended in PBS followed by centrifugation to harvest the cell
pellet. The cell pellets were stored at −80°C.
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4.6.13 Preparation and analysis of proteins by capillary electrophoresis (Capillary
electrophoresis experiments were performed in the Krylov laboratory, York University):
Prior to the CE experiments, HEK293 and MDA-231 shp53 cells were centrifuged for 2
min at ∼13000 × g (Eppendorf 5417R centrifuge with F45−30−11 rotor (Fisher scientific, PA,
USA)) at 4 °C and the supernatant was collected. The obtained supernatant as well as purified
proteins were diluted with the sample buffer consisting of 50 mM HEPES sodium salt
(NaHEPPSO), 10 mM MgCl2, 5 mM tris(2-carboxyethyl)- phosphine hydrochloride (TCEP), and
10 mg/mL bovine serum albumin (BSA) at pH 7.8. The BSA was added to reduce adsorption of
the proteins onto capillary surface.
CE experiments were carried out with MDQ-PACE instrument (Sciex, formerly
BeckmanCoulter, Caledon, ON, Canada) using laser-induced fluorescence (LIF) detection with
excitation at 488 nm and emission at 520 and 610 nm for the detection of eGFP and TagRFP
derivatives, respectively. Fused silica capillaries with total length of 84 cm were preconditioned
by sequential washing with 100 mM HCl, 100 mM NaOH, Milli-Q water and run buffer each for
2 min at 30 psi (206.84 kPa). In a beginning of each experiment capillaries were rinsed with each
of the following solutions: 100 mM HCl, 100 mM NaOH Milli-Q water for 2 min at 30 psi (206.84
kPa) and with run buffer for 2 min at 40 psi (275.79 kPa). The samples were injected into the
capillary by 1 psi (6.89 kPa) pressure pulse of 28 s. Electrophoretic separation was carried out with
a positive electrode at the injection end of the capillary, with electric field strength of 297 V/cm.
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Chapter 5: Conclusions and Future Work

5.1 Summary
Prenylation is an important post-translational lipidation involved in cell signaling and
growth through changes in protein structure, localization, and function.1-8 For over 3 decades, the
four amino acid, C-terminal “CaaX” box motif has been thought of as the required recognition motif
for prenylation through study of yeast mating factors and lamins.1, 3, 6, 8-15 Study of what makes a
protein a target for prenylation by FTase and GGTase-I has focused mainly on amino acid
selectivity within these four amino acids. Through biochemical, crystallographic, and
computational work, general rules for this selectivity and the proposed contacts within the enzyme’s
binding site have greatly increased our understanding of prenylation but have restricted
investigation to the CaaX box motif.5, 11, 16-29
Recently, yeast genetic screening involving the Hsp40 co-chaperone Ydj1p revealed that
yeast FTase could efficiently prenylate C(x)3X sequences.30 This finding led us to use fluorescentbased biochemical and cell-based studies at both the short peptide and full-length protein level to
determine that mammalian FTase can in fact recognize and prenylate a five amino acid recognition
motif. A search of the human genome using Prosite results in 1008 (as of June 2018) proteins ending
in a C(x)3X sequence with the potential to undergo prenylation, nearly doubling the number of
proteins that can be explored not only in humans, but also species such as yeast.. With previous
studies and current computational prediction models restricted to four amino acids, innovative
approaches to determining the role of this novel selectivity will need to be addressed for such as
large scale of potential proteins.
This finding increases our understanding of the impact prenylation has within cells and
raises many new questions concerning the role of these C(x)3X proteins. With FTase and GGTase216

I showing a stark difference in their acceptance of these longer sequences, a question is raised as to
why these “sister” enzymes present such a dissimilarity in their flexibility for substrates. Alongside
the question of how FTase recognizes these sequences, is the consideration of the biological role of
C(x)3X proteins. The potential for a shunt pathway in humans, as seen with yeast, would define a
new cytosolic role for prenylation in mammalian cells.31
The new method protein-lipidation quantitation (PLQ) may prove useful in studying
lipidation at a quantitative level for these new C(x)3X sequences in cells.32 The ability of PLQ to
quantify both unmodified substrate and product rapidly in small quantities gives an opportunity to
examine C(x)3X motifs in relation to endogenous FTase in a biological setting. PLQ sample
preparation is minimal due to its ability to examine crude cell lysate and would allow for quicker
sample analysis than other traditional methods. While a powerful tool, there is limitation in the
cloning of these human proteins to eGFP or TagRFP to allow for detection by PLQ - how best to
address this restraint remains unclear.
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5.2 Future Directions
5.2.1 Investigation of FTase vs GGTase-I in C(x)3X substrate selectivity
Perhaps the most surprising finding after determining the ability of FTase to prenylate a
C(x)3X sequence is the inability of GGTase-I to accept any of the sequences tested.30 These two
enzymes recognize the same classic CaaX motif with variations in the amino acids they accept and
the type of isoprenoid group to be attached, a chain of 15 carbons for FPP vs 20 carbons for
GGPP.3, 33-34 FTase or GGTase-I present both distinctions and similarities in amino acid preference
in the “X” position of the prenylation motif with FTase accepting X = M, Q, S, T, and A and
GGTase-I most efficiently prenylating sequences of X = I or L.1 The difference in activities for
these two enzymes lies in their active site with the active site of FTase consisting of amino acids
W102, W106, and Y361 as compared to T49, F53, and L320 for GGTase-I (See Chapter 1). These
closely related enzymes have the ability to cross-talk in cells, with one enzyme taking up the role
of prenylating certain sequences when the other is inhibited.35 An example of this is seen with the
protein KRas, which has shown to be geranylgeranylated in the presence of FTase inhibitors.
Despite the evidence in their similarities and its larger active site, not one C(x)3X sequence tested
was found to be accepted by GGTase-I.
To begin understanding this difference between the enzymes, one of the next goals in this
research is to determine the crystal structure of FTase interacting with C(x)3X motifs. The ability
to prenylate these large sequences suggests a flexibility within the FTase active site not currently
predicted through computational studies or found in GGTase-I. Understanding the contact points
and spacing of amino acids within the FTase binding site will provide insight into why GGTase-I
in much stricter in its substrate selectivity. To obtain these crystal structures, a high-yielding
“single-band” purification of FTase is necessary and work has begun on optimizing that process.
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5.2.2 Identification of endogenous C(x)3X proteins and the potential of a human shunt
pathway
Considering activity of both Cxxx and C(x)3X sequences in yeast and humans, this newly
discovered activity of non-canonical sequences nearly doubles the number of proteins that can be
potentially prenylated within cells even when removing sequences containing other cysteines
within the motif. Through our Prosite search it was found that 1008 human proteins (accessed June
2018) follow a C-terminal C(x)3X sequence with 816 of those sequences containing no other
cysteine other than that required for prenylation. (See Appendix II) This is comparable to the 1205
potential Cxxx proteins in the human genome. The same can be said for yeast in which 120 proteins
contain a canonical Cxxx motif. It was found that 117 proteins containing C-terminal C(x)3X
sequences are also possible targets of prenylation with 88 of those containing no other cysteine
within the sequence. (See Appendix III) Many of these yeast proteins remain uncharacterized.
These numbers underscore the importance of exploring and characterizing more C(x)3X proteins,
especially in the human genome, to determine their prenylation state within the cell.
The original C(x)3X sequences identified for analysis from yeast used a screening that
discriminates for proteins that are prenylated but not proteolyzed. This raises the question as to
whether all C(x)3X sequences that serve as prenyltransferase substrates are unable or resistant to
undergo subsequent processing. This possibility makes analysis of C(x)3X sequences through
fluorescence microscopy difficult as membrane localization can no longer be used as a proxy for
prenylation. Regardless of the challenges this creates, implications of this newly discovered
C(x)3X sequence reactivity opens a door to the potential of alternate uses of a farnesyl group
beyond serving as a membrane anchor in prenylation, with the possible existence and role of a
“shunt pathway” in mammalian cells.31
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An ultimate goal in examining these human C(x)3X proteins is to find one which undergoes
endogenous prenylation. Due to the number of potential proteins to test, this objective presents a
“needle in a haystack” obstacle. While the current use of HPLC to identify potential proteins is
overall quick, production of the peptides required to test all 1008 sequences is costly and time
consuming. In addition to this initial hurdle, the next steps of cloning, transfection, imaging, and
metabolic labeling of the proteins whose sequences produce a product peak on HPLC is even more
of a financial and time-intensive obstacle than the initial screening.
A reasonable way to tackle the number of potential sequences is to use an approach similar
to how we originally chose our six human proteins for an initial screening (see Chapter 2).30 While
it does not solve the concern of how many sequences there are to be tested, it may provide the best
option for finding a protein sooner. The first option is to reduce the potential complexity of proteins
being examined by choosing proteins which are produced from genes that do not produce C(x)3X
C-termini upon splicing. Protein splice variants are produced during regulation of gene expression
and allow for a single gene to produce several functional proteins. For example, the protein
Serine/threonine-protein kinase Chk2 ends in “CAAVL” and contains six splice variants
(Appendix II).36 Choosing this protein for study may prove problematic at the cellular level where
gene regulation will affect which and how many variants of this one protein we are examining.
Another way to take the first step in eliminating and/or finding potential C(x)3X human
proteins which undergo prenylation is through a “sub-family” approach. Upon examination of the
protein list generated from Prosite, some C-terminal sequences are conserved across a related
family of proteins. For example, there are nine distinct cAMP-responsive element modulator
proteins all ending in the sequence “CHKVE”(Appendix II).37 This conservation may be important
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to the proteins’ function and can be used as a guided approach to selecting the first series of C(x)3X
sequences to be studied.
For yeast and other species, the smaller proteome makes for an easier target to finding
target proteins. Future work could include pathogenic organisms that employ either endogenous
or host-mediated farnesylation, such as Plasmodium falciparum, Candida albicans, and Legionella
pneumophila which have two, ten, and fourteen proteins ending in C(x)3X, respectively (Appendix
IV).23, 38-43

5.2.3 Expansion of PLQ to include other classes of lipidation
As was discussed earlier in section 5.1, PLQ could prove useful in determining the ability
of C(x)3X proteins to undergo prenylation in cells without using fluorescence membrane
localization as the only readout. Besides this directly related work, there is much that can be
explored further with PLQ including the examination of how other lipid modifications fare with
this new method.
Palmitoylation, myristoylation, and GPI anchors are also important in protein trafficking
for cell signaling. The strength of PLQ as a new research method will lie in its ability to be used
for multiple lipidation states. Proteins which undergo prenylation are also commonly
palmitoylated upstream of the C-terminus While the role of this palmitoylation has been discerned
as significant for membrane localization, the extent of palmitoylation needed for efficient
localization and its details are still investigated.11, 44-47 PLQ could be useful for these types of
investigations after determining the protocol modifications, if any, necessary to separate these
other types of lipidation.
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Appendix I: Supplemental Data for Chapter 2

Table S1 Fluorescence screening data for dns-GC(x)3X peptides.

Table S2 Summary of fragments and assignments from ESI-MS analysis of dns-GCMIIM
and dns-GCAVGP.

229

Appendix I: Supplemental Data for Chapter 2

Figure S2 HPLC analysis of dns-GC(x)3X peptide farnesylation by FTase. Farnesylation
reactions were performed in the presence (+, red trace) and absence (-, blue trace) of 10 µM FPP.
All reactions contained 3 µM peptide substrate and 100 nM FTase as described in Experimental
Procedures. The peak observed at short retention time is due to the reaction buffer, with an identical
retention time and intensity in the +FPP and -FPP samples. a) dns-GCWGEV; b) dns-GCSSLQ;
c) dns-GCSRLQ; d) dns-GCIPVQ; e) dns-GCGGDD; f) dns-GCAYVL; g) dns-GCFFYI; h) dnsGCFNSL; i) dns-GCLPIV; j) dns-GCQGFL; k) dns-GCSIQG; l) dns-GCVSFG; m) dnsGCWAGG; n) dns-GCWGGA; o) dns-GCLLHP; p) dns-GCSQGP; q) dns-GCQTGP; r) dnsGCSVKM; s) dns-GCFSKM; t) dns-GCDREV
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Appendix II: Table of Human C(x)3X Sequences

C-terminus

Protein Name

Size
(aa)

Number of
splice variants

Cxxxx
CREHT

5-hydroxytryptamine receptor 1E

365

0

CLWNT

5-hydroxytryptamine receptor 3D

454

3

CLWNT

5-hydroxytryptamine receptor 3E

456

4

CGFNL

Putative ankyrin repeat domain-containing protein 30B-like

251

0

CDAEV

DNA dC->dU-editing enzyme APOBEC-3H

200

0

CDSVD

Alpha/beta hydrolase domain-containing protein 4

342

0

CDTVD

1-acylglycerol-3-phosphate O-acyltransferase ABHD5

349

0

CKRNN

Acetyl-coenzyme A transporter 1

549

0

CSTAN

Neuronal acetylcholine receptor subunit alpha-7

102

0

CLTIQ

Acetyl-coenzyme A synthetase, cytoplasmic

701

1

CSRYW

Adrenocorticotropic hormone receptor

297

0

CQEEP

Adenylate cyclase type 10

372

0

CILLL

Alcohol dehydrogenase 6

375

0

1612

0

CFPWG

Afadin

CNGTI

Adhesion G-protein coupled receptor F1

218

0

CFEVE

Type-1 angiotensin II receptor

359

0

CTFLP

Aryl hydrocarbon receptor repressor

701

2

CRFVT

Aldehyde dehydrogenase family 8 member A1

160

0

CMEDK

ALK and LTK ligand 2

91

0

CGGND

Annexin A11

505

1

CGGDD

Annexin A2

339

1

CGGDD

Annexin A3

323

0

CGGDD

Annexin A4

319

1

CGEDD

Annexin A5

320

0

CGGED

Annexin A6

673

1

CSIEA

Bis(5'-nucleosyl)-tetraphosphatase [asymmetrical]

147

0

CPKLS

Apolipoprotein D (Apo-D)

189

0

CKNGN

Rho guanine nucleotide exchange factor 28

1651

0

CSPRA

Rho guanine nucleotide exchange factor 10-like protein

1067

0

CVHDS

cAMP-regulated phosphoprotein 21

108

0

CSLLL

Arylsulfatase B

413

0

CTLVL

Acid sphingomyelinase-like phosphodiesterase 3b

455

0

CLAPR

Protein asteroid homolog 1

520

0

CLVVR

Putative Polycomb group protein ASXL1

1541

1 (see below)

CVLSR

Putative Polycomb group protein ASXL1

479

SPLICE OF ABOVE

CLVVR

Putative Polycomb group protein ASXL2

1435

1

CLVVR

Putative Polycomb group protein ASXL3

2248

0

CTVNI

Phospholipid-transporting ATPase ID

387

0
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C-terminus

Protein Name

Size
(aa)

Number of
splice variants

CKLAS

Probable phospholipid-transporting ATPase IIB

1147

1

CTRKI

A disintegrin and metalloproteinase with thrombospondin motifs 18

1221

0

CPGRQ

A disintegrin and metalloproteinase with thrombospondin motifs 4

846

0

CGGDD

Putative annexin A2-like protein

339

0

CLYKN

5-azacytidine-induced protein 2

392

1 (see below)

CSLFA

5-azacytidine-induced protein 2

243

SPLICE OF ABOVE

CMTSQ

Beta-1,4 N-acetylgalactosaminyltransferase 1

533

1

CTTDE

Transcription regulator protein BACH1

736

0

CDAFL

Barrier-to-autointegration factor

89

0

CKKDH

B-cell scaffold protein with ankyrin repeats

785

3

CPRPL

Breast carcinoma-amplified sequence 4

CISVF

B-cell CLL/lymphoma 9-like protein

CTEKP

203

0

1395

0

Class E basic helix-loop-helix protein 22

381

0

CHEKP

Class E basic helix-loop-helix protein 23

225

0

CSRNP

BTB/POZ domain-containing protein 1

385

0

CYLVK

Coiled-coil domain-containing protein 144A

691

0

CYLVK

Coiled-coil domain-containing protein 144A

1154

0

CQYLD

Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1

309

0

CRRVI

Monofunctional C1-tetrahydrofolate synthase, mitochondrial

275

0

CLVAR

Putative inactive cytochrome P450 2G1

146

0

CSLQQ

Uncharacterized protein C1orf109

113

0

CITTL

Voltage-dependent L-type calcium channel subunit alpha-1D

2161

2

CVHAL

Voltage-dependent L-type calcium channel subunit alpha-1F

1977

5

CPRLV

Cadherin-18

574

0

CLLVY

Cadherin-23

530

0

CAGDN

Calbindin

261

1

CPKLK

Calpain-13

423

0

CFSVL

Calpain-2 catalytic subunit

700

1

CVWII

F-actin-capping protein subunit alpha-3

299

0

CMSLL

Carboxypeptidase O

374

0

CLHWP

Putative uncharacterized protein PQLC2L

118

0

CENDG

Coiled-coil domain-containing protein 178

867

2

CVHWD

Coiled-coil domain-containing protein 191

514

0

CMTWN

C-C motif chemokine 4-like

47

0

CMTWN

C-C motif chemokine 4-like

52

0

CSPDD

Coiled-coil domain-containing protein 85B

202

0

CRIQR

Coiled-coil domain-containing protein 34

373

0

CRTSV

Endosialin

757

1

CTSEI

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1

300

0

CREPG

Cyclin-dependent kinase 10

272

0
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CGAHL

Cyclin-dependent kinase 10

154

0

CSSDA

UPF0461 protein C5orf24

155

0

CRDKR

Centrosomal protein of 126 kDa

1117

0

CNNQY

Centromere protein I

756

0

CSMDD

Ceramide synthase 6

384

1

Cilia- and flagella-associated protein 46

247

0

Uncharacterized protein C7orf69

122

0

CKKAI

Putative uncharacterized protein C8orf49

230

0

CTEPE

Chromodomain-helicase-DNA-binding protein 7

1138

0

CAAVL

Serine/threonine-protein kinase Chk2

543

6

CEAGP

Chordin

86

0

CTSGH

Uncharacterized protein encoded by LINC01561

128

0

CRRAY

Uncharacterized protein C11orf53

236

0

CEFPF

C-type lectin domain family 11 member A

323

0

CFRDE

C-type lectin domain family 4 member M

399

3

CDSDL

Claudin-23

292

0

CHWKS

Clavesin-1

167

0

CHSIA

Uncharacterized protein C15orf41

281

1

CVEIT
CWFHK

CMRRT

Collagen alpha-1(IV) chain

1669

0

CMKNL

Collagen alpha-2(IV) chain

1712

0

CVKYS

Collagen alpha-4(IV) chain

1690

0

CMKRT

Collagen alpha-5(IV) chain

1685

1

CMKSL

Collagen alpha-6(IV) chain

1691

1

CRYFT

Acetylcholinesterase collagenic tail peptide

455

4

CPSAS

Uncharacterized protein C16orf95

158

0

CFIPV

Cytochrome P450 2C8

490

1

CFIPV

Cytochrome P450 2C9

490

0

CFIPV

Cytochrome P450 2C18

490

1

CFIPV

Cytochrome P450 2C19

490

0

CAVPR

Cytochrome P450 2D6

497

1

CAVPR

Putative cytochrome P450 2D7

515

0

CLRPR

Cytochrome P450 2F1

491

0

CAERR

Vitamin D 25-hydroxylase

501

0

CGTSS

Uncharacterized protein C17orf53

647

1

CTTGF

Complement component receptor 1-like protein

181

0

CTTGF

Complement component receptor 1-like protein

444

0

CHKSD

Cyclic AMP-responsive element-binding protein 1

327

1

CHKVE

cAMP-responsive element modulator

285

0

CHKVE

cAMP-responsive element modulator

102

0

CHKVE

cAMP-responsive element modulator

112

0
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CHKVE

cAMP-responsive element modulator

248

0

CHKVE

cAMP-responsive element modulator

299

0

CHKVE

cAMP-responsive element modulator

236

0

CHKVE

cAMP-responsive element modulator

348

0

CHKVE

cAMP-responsive element modulator

120

0

CHKVE

cAMP-responsive element modulator

108

0

CLSGL

Corticotropin-releasing factor-binding protein

322

0

CIDVR

COP9 signalosome complex subunit 9

252

0

CYNNY

Versican core protein

3370

0

CPRLA

Putative uncharacterized protein encoded by LINC00313

77

0

CVLHE

Cell cycle regulator of non-homologous end joining

69

0

CRRKK

Beta-defensin 103

67

0

CRQRI

Beta-defensin 105

78

0

CSPKA

DAN domain family member 5

189

0

CRIWR

Cynein assembly factor with WDR repeat domains 1

415

0

CFPFS

DDB1- and CUL4-associated factor 4-like protein 1

396

0

CFSYG

DDB1- and CUL4-associated factor 4-like protein 2

395

0

CYSYS

DDB1- and CUL4-associated factor 4

495

3

CWLLR

Glutamate decarboxylase 1

224

0

CTRVD

Neutrophil defensin 4

97

0

CLPEK

DEP domain-containing protein 4

294

0

CTVDV

Microprocessor complex subunit DGCR8

773

1

CTRPA

Homeobox protein DLX-5

191

0

CQDGY

Dentin matrix acidic phosphoprotein 1

513

1

CLSLL

Dipeptidase 1

411

0

CHRHL

Dipeptidase 2

258

0

CAVKS

DNA polymerase alpha catalytic subunit

1462

0

CFSLP

Dipeptidyl peptidase 4

766

0

CKEFS

Down syndrome cell adhesion molecule

1571

0

CSSSK

Protein ripply3

190

1

CSRLI

Desmoglein-3

999

0

CLEQQ

Probable E3 ubiquitin-protein ligase DTX2

622

1

CQLDD

Dynein heavy chain 12, axonemal

3092

2

CALDY

Dynein heavy chain 1, axonemal

4330

1

CQLDN

Dynein heavy chain 3, axonemal

4116

0

CQLSE

Dynein heavy chain 6, axonemal

4158

1 (see below)

CGLSS

Dynein heavy chain 6, axonemal

592

SPLICE OF ABOVE

CQLNS

Dynein heavy chain 7, axonemal

4024

1

CEKDD

Dihydrofolate reductase 2, mitochondrial

187

0

CMAAG

Emopamil-binding protein-like

97

0
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CTEEE

EGF-like repeat and discoidin I-like domain-containing protein 3

480

1

CKTLM

EF-hand domain-containing family member B

833

1

CKKDS

Epidermal growth factor-like protein 7

273

0

CTYGS

Epidermal growth factor receptor

628

0

CFVPQ

Elafin, Elastase-specific inhibitor

117

0

CVTVM

ETS domain-containing protein Elk-4

405

0

CVLTL

ELMO domain-containing protein 3

185

0

CTQQL

Endogenous retrovirus group K member 25 Env polyprotein

661

0

CVYLH

Ephrin type-A receptor 7

449

0

CLTSG

Ephrin type-B receptor 4

414

0

CPKAF

Receptor tyrosine-protein kinase erbB-3

331

0

CPLPL

Exocyst complex component 1-like

172

0

CFKFI

Exostosin-like 3

919

0

CKRRG

Eyes absent homolog 4

452

0

CFWWI

Protein FAM196B

535

0

CVPSS

Protein FAM32A

107

0

CQAQD

Protein FAM57B

274

1

CQTLI

Protein FAM92A

271

0

CPGKF

Fatty-acid amide hydrolase 2

532

0

CPAGS

Fanconi anemia core complex-associated protein 20

170

0

CSRLF

F-box only protein 3

471

0

CRSGE

F-box/LRR-repeat protein 5

691

1

CPPRS

F-box/WD repeat-containing protein 5

377

0

CSLNG

Forkhead-associated domain-containing protein 1

1453

0

CAKKL

Four and a half LIM domains protein 1

280

0

CAKKL

Four and a half LIM domains protein 1

309

0

CAKKL

Four and a half LIM domains protein 1

CKALA

Protein flightless-1 homolog

CLMLW

Fibronectin type III domain-containing protein 5

296

0

1269

2

153

0

2179

2

CSRKL

FRAS1-related extracellular matrix protein 1

CIWEF

Fascin-3

498

0

CLVIE

F-box/LRR-repeat protein 16

479

1

CHSDT

Frizzled-6

706

1

CLWDG

Glucose-6-phosphatase 2

102

0

74

0

CLAFL

Putative uncharacterized protein GAFA-1

CGSRK

220

1

CLWSH

Glutamine amidotransferase-like class 1 domain-containing protein
1
N-acetylgalactosamine-6-sulfatase

522

0

CEPHF

Glycerophosphodiester phosphodiesterase 1

331

0

CGSSN

Gem-associated protein 2

44

0
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CLHKE

GTP cyclohydrolase 1 feedback regulatory protein

CYIFD

Size
(aa)

Number of
splice variants

84

1

Gamma-glutamyl hydrolase

318

0

152

0

47

0

CTYFF

Glycosyltransferase 1 domain-containing protein 1

CQTGP

Putative glycosylation-dependent cell adhesion molecule 1

CESAF

Probable G-protein coupled receptor 150

434

0

CENNA

Probable G-protein coupled receptor 171

319

0

CVTLA

G-protein coupled receptor 35

309

1

CPKGK

G-rich sequence factor 1

480

1

CDYGL

Glutathione S-transferase omega-1

241

2

CPEPT

Solute carrier family 2, facilitated glucose transporter member 5

244

0

CHLYE

Hepatitis A virus cellular receptor 2

142

0

CSDDT

Pseudouridine-5'-phosphatase

208

0

CSEGK

Hepatocyte growth factor

210

0

CKEMV

Homeodomain-only protein

94

0

CKEMV

Homeodomain-only protein

112

0

CYFYQ

Hornerin

2850

0

CDMQK

Hippocalcin-like protein 4

191

0

CYAEN

Hyaluronan and proteoglycan link protein 2

340

0

CYRQH

Hyaluronan and proteoglycan link protein 3

360

0

CVVHA

Hermansky-Pudlak syndrome 3 protein

890

0

CPKGD

Homeobox protein Hox-D9

352

0

CMLGQ

Glucokinase

465

2

CKAKM

Interleukin-12 receptor subunit beta-1

662

0

CSHHL

Interleukin-15 receptor subunit alpha

267

4

CVEIP

Interleukin-22 receptor subunit alpha-2

263

1

CRSVS

Insulin growth factor-like family member 1

110

0

CQHIP

Interleukin-19

207

0

CPTSI

Interleukin-31 receptor subunit alpha

662

0

CPTSI

Interleukin-31 receptor subunit alpha

681

0

CLAKK

Importin subunit alpha-8

516

0

CMYRA

Integrator complex subunit 14

86

0

CTGGQ

Interferon regulatory factor 7

164

0

CVQGI

Iron-sulfur cluster assembly 2 homolog, mitochondrial

60

0

CATST

Intestine-specific homeobox

245

0

CLKQH

Izumo sperm-egg fusion protein 4

232

1

CSKDR

Dyslexia-associated protein KIAA0319

1072

3

CTMKS

UPF0258 protein KIAA1024

916

0

CGNGP

Kynurenine--oxoglutarate transaminase 1

250

0

CGKDS

Potassium channel subfamily K member 17

332

0

CQKRQ

Lysine-specific demethylase 4C

1056

0
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CREQK

Killer cell immunoglobulin-like receptor 3DS1

382

0

CSRHN

Kinesin-like protein KIF19

998

0

CLGSN

Kinesin-like protein KIF6

814

2

CWQRR

Kinesin-like protein KIFC2

838

0

CSPAN

Thymidine kinase, cytosolic

234

0

CFGLS

Kinesin light chain 4

315

0

CVSDS

Kelch domain-containing protein 8A

350

0

CVYNV

Kelch-like protein 23

558

0

CLTKM

Kelch-like protein 40

621

0

CPVRQ

Kinase non-catalytic C-lobe domain-containing protein 1

1141

0

CHFYH

Kinetochore scaffold 1

2342

1

CVSLL

Keratin-associated protein 10-4

401

0

CKKER

KRAB domain-containing protein 4

171

1

CRTKY

Keratin, type II cuticular Hb4

600

0

CLSVD

Ribosomal protein S6 kinase beta-2

154

0

CTVLF

Putative uncharacterized protein KTN1-AS1

53

0

1575

0

CASWQ

Laminin subunit gamma-3

CHSVH

Putative L-type amino acid transporter 1-like protein IMAA

180

0

CVAFD

Galectin-1

135

0

CPPPE

Late cornified envelope-like proline-rich protein 1

98

0

CDLTV

Leptin receptor

1165

0

CLGHY

Legumain

433

1

CEAVL

Lipase member M

423

1

CGGRH

Hormone-sensitive lipase

1076

1

CGLSR

Leucine-rich repeat protein 1

146

0

CTDSS

Low-density lipoprotein receptor-related protein 5

1615

0

CTDSS

Low-density lipoprotein receptor-related protein 6

1613

0

CIYFV

Leucine-rich repeat-containing protein 9

1111

0

CTAKE

Latent-transforming growth factor beta-binding protein 2

1821

0

CAEEN

Leucine zipper protein 1

1076

0

CDNFK

DNA helicase MCM9

391

0

CAFLS

MDS1 and EVI1 complex locus protein

169

0

CLSAA

Mediator of RNA polymerase II transcription subunit 15

788

1

CLSAA

Mediator of RNA polymerase II transcription subunit 15

677

0

CLARR

MICAL-like protein 2

680

0

CIMNW

Misshapen-like kinase 1

1332

4

CTKHY

Mitochondrial Rho GTPase 1

247

0

CAESV

Mitochondrial Rho GTPase 2

213

0

CVNRT

MMS19 nucleotide excision repair protein homolog

318

0

2-acylglycerol O-acyltransferase 3

341

0

CLTFI
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CWLRD

Mitochondrial-processing peptidase subunit beta

489

0

CFALE

Mitochondrial carrier homolog 1

389

2

CLSDA

Myotubularin-related protein 5

1868

2

CISDA

Myotubularin-related protein 13

1849

0

CQMSL

Mucin-17

4361

0

CGTTA

Musculin (Activated B-cell factor 1)

206

0

CPLGA

Matrix remodeling-associated protein 8

450

0

CTPAL

Myomegalin

2346

1

CSWGK

Myozenin-3

87

0

CHHGY

NEDD4-binding protein 2-like 1

243

0

429

0

95

0

CFLSS

N-alpha-acetyltransferase 16, NatA auxiliary subunit

CLYLA

Putative uncharacterized protein encoded by LINC00301

CALQA

Nuclear cap-binding protein subunit 1

790

0

CLSEP

Neurochondrin

729

2

CGSQG

Nck-associated protein 5-like

1330

1

CPVSV

Sodium/potassium/calcium exchanger 1

1099

2

CPVSI

Sodium/potassium/calcium exchanger 2

661

1

CREDD

Sodium/potassium/calcium exchanger 4

622

3

CSIFI

Nuclear receptor coactivator 7

102

0

CLVFE

NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4

120

0

CYRIF

Serine/threonine-protein kinase Nek4

781

0

CTASS

Serine/threonine-protein kinase Nek7

302

0

CRPSL

Serine/threonine-protein kinase Nek9

979

0

CLQNN

Protein kinase C-binding protein NELL1

810

1

CLQEL

Protein kinase C-binding protein NELL2

816

3

CSFPL

Neuferricin

264

1

CSPWH

Neurofascin

CIEQK

Nidogen-1

CLNDR

619

0

1247

1

Substance-P receptor

311

0

CKHKL

NKG2-A/NKG2-B type II integral membrane protein

233

1

CKHKL

NKG2-C type II integral membrane protein

231

0

CTVEM

NLR family CARD domain-containing protein 3

1065

2

CHPRR

Glutamate receptor ionotropic, NMDA 2A

1281

0

CRKMK

Polynucleotide 5'-hydroxyl-kinase NOL9

702

0

CFQLP

Nuclear pore-associated protein 1

1156

0

CRAAA

Neuropeptides B/W receptor type 1 (G-protein coupled receptor 7)

328

0

CSEER

Nephronectin

565

4

CRQIN

Neuronal pentraxin-1

432

0

CVVHS

Neurexin-3

1392

0

CSKLN

NUAK family SNF1-like kinase 1

661

0
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CSKLT

NUAK family SNF1-like kinase 2

CLLFS

Size
(aa)

Number of
splice variants

628

0

Nuclear mitotic apparatus protein 1

1776

0

CILVR

Nuclear mitotic apparatus protein 1

1763

0

CPLET

NXPE family member 3

559

0

CPLSS

Olfactory receptor 10H3

316

0

CPPSS

Olfactory receptor 10H4

316

0

CDRSI

Olfactory receptor 2AT4

320

0

CQWKI

Olfactory receptor 51A2

313

0

CQRKI

Olfactory receptor 51A4

313

0

CFWKD

Olfactory receptor 51G1

321

0

CGNIP

Olfactory receptor 52R1

315

0

CLAVK

Olfactory receptor 5AL1

328

0

CRRGS

Putative uncharacterized protein OBSCN-AS1

158

1 (see below)

CGTQA

Putative uncharacterized protein OBSCN-AS1

113

SPLICE OF ABOVE

CVLEH

Odorant-binding protein 2a

170

1

CVPEH

Odorant-binding protein 2b

170

0

CPVLS

Obscurin-like protein 1

1543

0

CGEKG

Mu-type opioid receptor

128

0

CSGKM

Olfactory receptor 2L3

312

0

CSVKM

Olfactory receptor 2L8

312

0

CSKLN

Olfactory receptor 4A8

315

0

CKIAV

Olfactory receptor 5M10

315

0

CNIFV

Olfactory receptor 8K3

312

0

CPDIY

Oxysterol-binding protein-related protein 2

480

1

CPDIF

Oxysterol-binding protein 1

807

0

CPNIF

Oxysterol-binding protein 2

916

5

CTWAK

Protein OSCP1

223

0

CGGTA

Protein odd-skipped-related 2

276

0

CIAGL

3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial

459

1

CLFRK

Proline-rich protein 23D1

279

0

CLFRK

Proline-rich protein 23D2

279

0

CDEHP

Pannexin-3

392

0

CLKRQ

Monocyte to macrophage differentiation factor 2

193

0

CLKTL

Partitioning defective 6 homolog beta

115

0

CNEDL

Prostate and testis expressed protein 1

126

1

CNFKL

Prostate and testis expressed protein 3

98

0

CVVFS

PAX3- and PAX7-binding protein 1

815

0

CTFQG

Proprotein convertase subtilisin/kexin type 5

913

0

CLLAG

Proprotein convertase subtilisin/kexin type 6

969

1

CSWPL

Programmed cell death protein 1

288

0
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CDREV

Prostamide/prostaglandin F synthase

198

3

CSALG

PHD finger protein 12

704

0

CKKSK

PHD finger protein 7

381

1

CVSVS

Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma

700

0

CSFIW

GPI ethanolamine phosphate transferase

463

0

CSFIW

GPI ethanolamine phosphate transferase 2

341

0

CTHSP

phospholipase A2 inhibitor & Ly6/PLAUR domain-containing protein

204

2

CQYNS

Pituitary homeobox 1

314

0

CWIIK

Pleckstrin homology domain-containing family S member 1

465

0

CIRLK

Prokineticin receptor 1 (PK-R1) (G-protein coupled receptor 73)

393

0

CIRLK

Prokineticin receptor 2 (G-protein coupled receptor 73-like 1)

384

0

Phospholipase D4

506

0

CVWQG
CYSEA

Plexin-D1

1925

0

CDFFL

Polyamine-modulated factor 1-binding protein 1

1022

0

CGQLE

Peptidyl-prolyl cis-trans isomerase A

165

1

CGEYV

Peptidyl-prolyl cis-trans isomerase E

301

0

CGQLS

Peptidyl-prolyl cis-trans isomerase F, mitochondrial

207

0

CVAHS

Protein phosphatase 1 regulatory subunit 32

425

0

CYRSV

Pre-mRNA-processing factor 40 homolog B

195

0

CFMPN

Melanoma antigen preferentially expressed in tumors

509

0

CRKDE

Probable histone-lysine N-methyltransferase PRDM7

407

0

CREDE

Histone-lysine N-methyltransferase PRDM9

894

0

CQIDE

Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2

984

0

CLAQK

Prokineticin-2

129

1

CASLS

Proline-rich protein 5-like

368

2

CMTEQ

Prostaglandin-H2 D-isomerase

190

0

CNRTG

Receptor-type tyrosine-protein phosphatase eta

539

0

CDIDI

Securin

202

0

CLISS

Regulator of G-protein signaling 7-binding protein

257

0

CLLHP

Ras association domain-containing protein 5

336

0

CESLV

Ras association domain-containing protein 10

507

0

CPSQA

Putative uncharacterized protein encoded by RBM12B-AS1

102

0

CFIPP

RNA-binding protein 34

225

0

CGPQR

ATP-dependent DNA helicase Q5

991

1

CEELG

ATP-dependent DNA helicase Q5

410

SPLICE OF ABOVE

CKFKN

Lithostathine-1-alpha

166

0

CKFKN

Lithostathine-1-beta

166

0

CKFTD

Regenerating islet-derived protein 3-alpha

175

0

CKFKD

Regenerating islet-derived protein 3-gamma

175

1

CKYRP

Regenerating islet-derived protein 4

158

0
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CRGAE

N-acylglucosamine 2-epimerase

427

0

CRVQP

Resistin

108

1

CLLRG

All-trans-retinol 13,14-reductase

481

0

CSDDA

RNA exonuclease 4

422

1

CQVLH

Replication factor C subunit 4

303

0

CLKKN

Rab11 family-interacting protein 1

142

0

CRNNI

Regulator of G-protein signaling 1

169

0

CRIQQ

Blood group Rh(D) polypeptide

493

0

CGERS

egulating synaptic membrane exocytosis protein 4

269

1

CVLVA

60S ribosomal protein L27a

148

0

CAHKS

60S ribosomal protein L28

CVGSS

Zinc finger protein Rlf

CPTLK

169

0

1914

0

RING finger protein 214

703

1

CEQAV

E3 ubiquitin-protein ligase RNF43

783

2

CHPLW

RING finger and transmembrane domain-containing protein 2

321

0

CGSKL

Probable ribonuclease 11

199

0

CKIPY

60 kDa SS-A/Ro ribonucleoprotein

534

0

CGVES

Reactive oxygen species modulator 1

59

0

CLFLS

Regulation of nuclear pre-mRNA domain-containing protein 2

152

0

CLLMR

Ras-related GTP-binding protein B

374

0

CFTSE

Receptor-transporting protein 4

246

0

CVYYW

Protein RUBCNL-like

635

0

CLGAQ

Mitochondrial RNA pseudouridine synthase RPUSD4

377

1

CPDRP

Protein S100-A2

98

0

CQPPE

Multidrug and toxin extrusion protein 1

586

0

CNVTS

Orphan Na- and Cl-dependent neurotransmitter transporter NTT5

736

0

CLGPK

SUMO-activating enzyme subunit 1

346

1 (see below)

CPLPS

SUMO-activating enzyme subunit 1

299

SPLICE OF ABOVE

CARRN

Scaffold attachment factor B2

115

0

CQLLN

Protein transport protein Sec24D

1032

1

CFPNS

Semaphorin-5B

1151

2

CRLGV

Semaphorin-6B

677

0

CPVPV

tRNA-splicing endonuclease subunit Sen54

177

0

CKLTV

Sentrin-specific protease 3

574

0

CRLMD

Sentrin-specific protease 5

755

1

CPTAE

Neuronal-specific septin-3

358

0

CSTGN

Sperm-associated antigen 11B

103

1

CGNTH

Beta-sarcoglycan

318

1

CLKAP

SH2 domain-containing protein 1A

128

1

CGPVP

Protein shisa-like-2A

190

0
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CDGAT

Alpha-2,8-sialyltransferase 8B

375

0

CSPSV

Small integral membrane protein 28

152

0

CPVGN

NAD-dependent protein deacetylase sirtuin-7

183

0

CLHKK

SLIT and NTRK-like protein 2

733

0

CRRLT

Schlafen family member 12

578

0

CNSEL

Secreted Ly-6/uPAR-related protein 1

103

0

CSSMS

Mothers against decapentaplegic homolog 2

467

1

CSSVS

Mothers against decapentaplegic homolog 3

425

3

CFFLR

Schlafen family member 12-like

588

1

CSQGP

Sushi, nidogen and EGF-like domain-containing protein 1

1324

0

CFSKM

Sorting nexin-4

450

1

CRYVF

Sterol O-acyltransferase 1

550

2

CVMSV

Sorcin

198

1

CRVHG

Spermatogenesis-associated protein 2-like protein

152

0

CQEAV

Serpin A9

201

0

CPLDV

Spermatogenesis-associated protein 7

599

2

CLMEN

Snurportin-1

360

0

CLLHH

Spermatogenesis-associated protein 3

192

0

CHIPN

Serine palmitoyltransferase 3

175

0

CGQAD

Steroid receptor-associated and regulated protein

169

0

CYGGL

Succinate-semialdehyde dehydrogenase, mitochondrial

535

1

CVDYL

Suppressor of tumorigenicity 7 protein-like

555

0

CVDYL

Suppressor of tumorigenicity 7 protein-like

538

0

CLDQE

StAR-related lipid transfer protein 13

687

0

CRYPD

Metalloreductase STEAP2

454

0

CRYAF

Serine/threonine-protein kinase 4

462

0

CKQPG

Surfeit locus protein 2

256

0

CASYL

Nesprin-2

285

0

CVVHI

TP53-target gene 3 protein

102

0

CVQTS

Thymosin beta-15A

45

0

CVQTS

Thymosin beta-15B

45

0

CRVPG

TANK-binding kinase 1-binding protein 1

222

0

CVLDL

F-box-like/WD repeat-containing protein TBL1Y

522

0

CSLMQ

Transcription elongation factor A protein 3

154

0

CKAYS

Tectonic-2

697

1

CLGSP

Transcription elongation factor, mitochondrial

171

0

CPSQQ

Testis-expressed protein 45

505

0

CVQRE

Acetyl-CoA acetyltransferase, cytosolic

397

1

CHVRR

Acetyl-CoA acetyltransferase, mitochondrial

162

0

CWPDP

Threonine synthase-like 2

384

0
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CMLLN

Transketolase-like protein 1

596

2

CSDPI

Transmembrane protein 108

487

0

CKTVI

Transmembrane protein 220

160

1

CLKGD

Transmembrane protein 241

123

0

CIEEI

Transmembrane protein 17

198

0

CRSGV

Tropomodulin-1

359

1

CLGPP

Tumor necrosis factor receptor superfamily member 25

253

0

CPQNR

DNA topoisomerase 3-alpha

1001

2

CLKLA

Trafficking protein particle complex subunit 12

735

0

CVKDR

Trafficking protein particle complex subunit 13

309

0

CHPDT

Tryptophan 5-hydroxylase 1

466

0

CAPFP

Putative protein TPRXL

258

0

CAERM

Triggering receptor expressed on myeloid cells 1

225

0

CPPSS

E3 ubiquitin-protein ligase TRIM22

498

1

CPPSS

Tripartite motif-containing protein 34

488

0

CHGSK

Tripartite motif-containing protein 77

450

0

CSPSS

Tripartite motif-containing protein 5

493

0

CEEGG

Transient receptor potential cation channel subfamily M member 1

300

0

CLPGT

Taste receptor type 1 member 1

480

0

CAGLG

Tuberin

239

0

CYRDF

Testis-specific gene 10 protein

698

0

70

0

860

1

1053

0

CMGWW

Translocator protein 2

CLKKL

Tetratricopeptide repeat protein 13

CKLAF

Putative tetratricopeptide repeat protein 41

CRPTS

Tubby-related protein 3

170

0

CAFMK

T cell receptor alpha variable 38-1

116

0

CAYRS

T cell receptor alpha variable 38-2/delta variable 8

116

0

CAMRE

T cell receptor alpha variable 14/delta variable 4

116

0

CALSE

T cell receptor alpha variable 19

116

0

CAVRD

T cell receptor alpha variable 3

114

0

CLVGD

T cell receptor alpha variable 4

109

0

CIVRV

T cell receptor alpha variable 26-1

109

0

CILRD

T cell receptor alpha variable 26-2

109

0

CASSL

T cell receptor beta variable 13

124

0

CASSQ

T cell receptor beta variable 14

115

0

CASSQ

T cell receptor beta variable 16

115

0

CASSP

T cell receptor beta variable 18

115

0

CASSI

T cell receptor beta variable 19

14

0

CASSE

T cell receptor beta variable 2

115

0

CASSQ

T cell receptor beta variable 3-1

114

0
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CASSQ

T cell receptor beta variable 4-1

114

0

CASSQ

T cell receptor beta variable 4-2

114

0

CASSQ

T cell receptor beta variable 4-3

114

0

CASSL

T cell receptor beta variable 5-1

114

0

CASSL

T cell receptor beta variable 5-4

114

0

CASSL

T cell receptor beta variable 5-5

114

0

CASSL

T cell receptor beta variable 5-6

114

0

CASSL

T cell receptor beta variable 5-8

114

0

CASSE

T cell receptor beta variable 6-1

114

0

CASSY

T cell receptor beta variable 6-2

114

0

CASSY

T cell receptor beta variable 6-3

114

0

CASSD

T cell receptor beta variable 6-4

114

0

CASSY

T cell receptor beta variable 6-5

114

0

CASSY

T cell receptor beta variable 6-6

114

0

CASSY

T cell receptor beta variable 6-8

113

0

CASSY

T cell receptor beta variable 6-9

114

0

CASSL

T cell receptor beta variable 7-2

115

0

CASSL

T cell receptor beta variable 7-4

115

0

CASSL

T cell receptor beta variable 7-6

115

0

CASSL

T cell receptor beta variable 7-7

115

0

CASSL

T cell receptor beta variable 7-8

115

0

CASSL

T cell receptor beta variable 7-9

115

0

CASSV

T cell receptor beta variable 9

114

0

CASSE

T cell receptor beta variable 10-1

114

0

CASSE

T cell receptor beta variable 10-2

114

0

CAISE

T cell receptor beta variable 10-3

114

0

CASSL

T cell receptor beta variable 11-1

115

0

CASSL

T cell receptor beta variable 11-2

115

0

CASSL

T cell receptor beta variable 11-3

115

0

CASSL

T cell receptor beta variable 12-4

115

0

CASGL

T cell receptor beta variable 12-5

115

0

CSKVN

Thioredoxin domain-containing protein 16

825

0

CGRPS

TYMS opposite strand protein

123

0

CPSVG

tRNA wybutosine-synthesizing protein 2 homolog

448

0

CLRIF

NEDD8-conjugating enzyme UBE2F

120

0

CTEDK

(E3-independent) E2 ubiquitin-conjugating enzyme

1292

0

CMHTN

Ubiquitin carboxyl-terminal hydrolase 15

981

2

CKSEE

Ubiquitin carboxyl-terminal hydrolase 30

517

0

CSSAV

Basic helix-loop-helix domain-containing protein USF3

2245

0

CGTDD

Transcription cofactor vestigial-like protein 4

41

0

250
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C-terminus

Protein Name

CSNTF

Protein virilizer homolog

CDIQK

Size
(aa)

Number of
splice variants

1147

0

Visinin-like protein 1

191

0

CGMPE

Synaptic vesicular amine transporter

209

0

CSLSW

Pantetheinase

513

0

CIIMT

Vascular non-inflammatory molecule 2

195

0

CREMK

Visual system homeobox 1

280

0

CHVRG

WD repeat-containing protein 26

216

0

CMSIL

WAP four-disulfide core domain protein 10A

79

0

CMSIL

Protein WFDC10B

73

1

CKKYH

WAP four-disulfide core domain protein 6

131

0

CYNTG

Whirlin

345

0

CYRIA

WW domain-containing oxidoreductase

311

0

CSQAS

Xaa-Pro aminopeptidase 3

507

2

CSRPT

Transmembrane protein LOC653160

218

0

CPVIT

Putative uncharacterized protein FLJ45035

140

0

CVAAL

YjeF N-terminal domain-containing protein 3

299

1

CSDNV

Putative uncharacterized protein FLJ43343

128

0

CNFLT

Putative uncharacterized protein FLJ46792

126

0

CADSF

Putative uncharacterized protein FLJ45275, mitochondrial

168

0

CTAAG

Putative uncharacterized protein FLJ42384

140

0

CSLWR

Putative uncharacterized protein FLJ40606

135

0

CSVFL

Putative uncharacterized protein FLJ39060

123

0

CGKAF

Putative zinc finger protein 355P

428

0

CGEAK

Zinc finger and BTB domain-containing protein 40

1239

0

CRRVQ

Zinc finger CCHC domain-containing protein 24

241

0

CHMAL

Palmitoyltransferase ZDHHC17

216

0

CRRKR

Zinc finger MYND domain-containing protein 11

602

2

CPTDL

RING finger and CHY zinc finger domain-containing protein 1

75

0

CEHFS

Zinc finger protein 407

1660

0

CIDTP

Zinc finger protein 433

673

1

CAGEK

Zinc finger protein 492

531

0

CQATM

Zinc finger protein 680

123

0

CFTNK

Putative protein ZNF720

178

0

CAKAF

Zinc finger protein 729

1252

0

CGWAR

Zinc finger protein 839

811

2

CVIIP

Zinc finger protein 24

193

0

CGKDF

Putative zinc finger protein 56

161

0

CAGEK

Zinc finger protein 98

572

0

CGRHS

Tight junction protein ZO-2

993

0

CQMPF

Protein zyg-11 homolog A

759

1
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Appendix II: Table of Human C(x)3X Sequences

C-terminus
CWPRS

Protein Name
Zinc finger ZZ-type and EF-hand domain-containing protein 1

Size
(aa)

Number of
splice variants

811

0

CCxxx
CCLGM

AP-3 complex subunit mu-2

273

0

CCSRK

Biliverdin reductase A

296

0

CCVLV

Calpain-8

703

0

CCSVK

COBW domain-containing protein 1

113

0

CCNWA

Acidic mammalian chitinase

476

2

CCTWN

Chitotriosidase-1

466

2

CCCIF

Chondroitin sulfate glucuronyltransferase

666

0

CCSEN

utative uncharacterized protein encoded by LINC00469

141

0

CCSGC

Cysteine-rich C-terminal protein 1

99

0

CCVIS

Cysteine-rich tail protein 1

144

0

CCCPR

Cysteine and tyrosine-rich protein 1

64

0

CCLQQ

Beta-defensin 110

67

0

CCKKP

Beta-defensin 4A

64

0

CCGHS

Protein FAM107A

135

0

CCVIL

F-box/LRR-repeat protein 2

423

1

CCPFP

L-fucose kinase

1084

1

CCIIL

F-box/LRR-repeat protein 20

436

1

CCTKF

Neuronal membrane glycoprotein M6-b

265

2

CCVVQ

Type I inositol 1,4,5-trisphosphate 5-phosphatase

412

0

CCSYA

Immunoglobulin lambda variable 2-23

113

0

CCCKK

Mucolipin-3

553

1

CCVSD

Metastasis-associated protein MTA3

594

0

CCACV

Protein myomaker

221

0

CCWPS

Sialidase-4

484

2

CCSEA

Neuropilin-2

931

2

CCVVM

Paralemmin-2

379

1

CCAVM

Paralemmin-3

673

0

CCSIM

Paralemmin-1

387

1

CCVVN

Nuclear pore membrane glycoprotein 210

967

0

CCLLM

Protein phosphatase 1 regulatory subunit 16A

528

0

CCRIS

Protein phosphatase 1 regulatory inhibitor subunit 16B

567

1

CCSSG

Ras-related protein Rab-21

225

0

CCISL

Ras-related protein Rab-25

213

0

CCNFN

Ras-related protein Rab-30

203

0

CCSFM

Ras-related protein Rab-37

223

3

CCQNI

Ras-related protein Rab-11A

216

0
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C-terminus

Protein Name

Size
(aa)

Number of
splice variants

CCQNL

Ras-related protein Rab-11B

218

0

CCHLT

Resistin-like beta

111

0

CCKVL

Rho-related GTP-binding protein RhoB

196

0

CCSII

Rho-related GTP-binding protein RhoJ

214

1

CCLIT

Rho-related GTP-binding protein RhoQ

205

0

CCVAH

Zinc finger protein SNAI2

268

0

CCPGP

Zinc finger protein SNAI3

292

0

CCHVI

SNF-related serine/threonine-protein kinase

765

0

CCSSK

Syntaxin-19

294

0

CCIHF

Putative tripartite motif-containing protein 49B

452

0

CCIHF

Putative tripartite motif-containing protein 49C

452

0

CCVHL

Tripartite motif-containing protein 49D

452

0

CCIHF

Tripartite motif-containing protein 49

452

0

CCSHF

Tripartite motif-containing protein 51

452

1

CCVIL

Ubiquitin-like protein 3

117

0

CCYQN

Vascular non-inflammatory molecule 3

207

0

CCAIM

Synaptobrevin homolog YKT6

198

1

CCYVA

Zinc finger protein 64 homolog, isoforms 3 and 4

415

0

220

2

CxCxx
CGCLG

Artemin

CACFL

Barrier-to-autointegration factor-like protein

90

1

CSCLR

BSD domain-containing protein 1

474

0

CSCLR

BSD domain-containing protein 1

353

0

CSCLR

BSD domain-containing protein 1

99

0

CKCWS

Cytidine and dCMP deaminase domain-containing protein 1

99

0

CVCDD

Uncharacterized protein C20orf24 (Rab5-interacting protein)

87

0

CSCGG

Ephrin type-B receptor 2

1055

0

CLCNT

Fc receptor-like protein 3

742

0

CTCIF

Interleukin-17B

180

0

CQCKI

Keratin-associated protein 5-10

202

0

CQCKI

Keratin-associated protein 5-11

156

0

CQCKI

Keratin-associated protein 5-1

278

0

CQCKI

Keratin-associated protein 5-2

177

0

CQCKI

Keratin-associated protein 5-3

238

0

CQCKI

Keratin-associated protein 5-4

288

0

CQCKI

Keratin-associated protein 5-5

237

0

CQCKI

Keratin-associated protein 5-6

129

0

CQCKI

Keratin-associated protein 5-7

165

0
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C-terminus

Protein Name

Size
(aa)

Number of
splice variants

CQCKI

Keratin-associated protein 5-8

187

0

CHCVH

Putative L-type amino acid transporter 1-like protein MLAS

180

0

CSCCA

Metallothionein 1H-like protein 1

CTDEE

Mitogen-activated protein kinase kinase kinase 4

CSPVG

Membrane-spanning 4-domains subfamily A member 6A

CKIEF

61

0

1608

1

141

0

Microtubule-associated protein 1A

2803

1

CKIEL

Microtubule-associated protein 1B

2468

0

CKVEF

Microtubule-associated protein 1S

1059

1

CLFHA

Methionine adenosyltransferase 2 subunit beta

259

0

CEFPI

Mannose-binding protein C

248

0

CFTLP

Metallo-beta-lactamase domain-containing protein 2

199

0

CRTSD

Muscleblind-like protein 1

342

0

CLCRL

Malectin

292

0

CSCCA

Metallothionein-1A

61

0

CRCCA

Metallothionein-1B

61

0

CSCCA

Metallothionein-1E

61

0

CSCCD

Metallothionein-1F

61

0

CSCCA

Metallothionein-1G

62

1

CSCCA

Metallothionein-1H

61

0

CSCCA

Metallothionein-1L

61

0

CSCCA

Metallothionein-1M

61

0

CSCCA

Metallothionein-1X

61

0

CSCCA

Metallothionein-2

61

0

CSCCQ

Metallothionein-3

68

0

CSCCP

Metallothionein-4

62

0

CKCSC

Noggin

232

0

CNCCR

Neuropeptide FF receptor 2 (G-protein coupled receptor 74)

132

0

CGCGG

Persephin

156

0

CGCCS

Rho GTPase-activating protein 19

517

0

CPCQL

Protein shisa-5

118

0

CPCLK

Syntaxin-11

287

0

CRCGP

SURP and G-patch domain-containing protein 1

222

0

CPCPC

Transmembrane protein 138

177

0

CVCKL

Transmembrane protein 39A

146

0

CDCVD

Twisted gastrulation protein homolog 1

75

0

CHCSS

Putative uncharacterized protein LOC151760

199

0

274

1

CxxCx
CFSCN

Putative ATP-binding cassette sub-family C member 13
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Protein Name

Size
(aa)

Number of
splice variants

CVGCS

Bromodomain-containing protein 4

794

0

CGRCP

Coiled-coil domain-containing protein 43

154

0

CWPCW

Protein C19orf12

107

0

CAKCI

Putative uncharacterized protein encoded by ERC2-IT1

136

0

CLYCV

Gamma-tubulin complex component 3

824

0

CVLCR

Probable G-protein coupled receptor 141

305

0

CTGCL

Guanylate cyclase activator 2B

112

0

CQNCH

RanBP-type and C3HC4-type zinc finger-containing protein 1

510

1

CLLCN

LON peptidase N-terminal domain and RING finger protein 3

610

0

CKDCL

Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A

741

0

CQGCL

Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B

792

2

CEQCC

Membrane-spanning 4-domains subfamily A member 5

200

0

CSICC

PACRG-like protein

248

2

CALCA

Slit homolog 1 protein

1534

0

CLACS

Slit homolog 3 protein

1523

2

CGPCR

Transcription factor 7

383

0

CGPCR

Transcription factor 7

268

0

CFGCT

Putative tripartite motif-containing protein 64B

449

0

CFGCT

Tripartite motif-containing protein 64C

450

0

CFGCT

Tripartite motif-containing protein 64

449

0

CLACV

Tubulin polyglutamylase TTLL13P

459

0

CYYCH

Zinc finger MYM-type protein 2

462

0

CxxxC
CNVLC

ADAMTS-like protein 1

683

0

CRSRC

Calpain-10

544

0

CRSRC

Calpain-10

513

0

CSVGC

Coiled-coil domain-containing protein 47

480

0

CYDIC

Uncharacterized protein C12orf74

190

0

CKNFC

CCR4-NOT transcription complex subunit 4

767

0

CEPSC

Cartilage acidic protein 1

661

0

CRDRC

Zinc finger protein DPF3

195

0

CPHPC

Peptidyl-prolyl cis-trans isomerase FKBP1B

80

0

CRRTC

605

0

CRRTC

Immunoglobulin-like and fibronectin type III domain-containing
protein 1
Keratin-associated protein 11-1

163

0

CRSTC

Keratin-associated protein 13-2

175

0

CYSSC

Keratin-associated protein 21-1

79

0

CEPTC

Keratin-associated protein 1-3

177

0

CEPTC

Keratin-associated protein 1-4

121

0
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CEPTC

Keratin-associated protein 1-5

174

0

CEPRC

Keratin-associated protein 3-1

98

0

CGSSC

Keratin-associated protein 4-1

146

0

CAMNC

Protein lin-54 homolog

749

3

CQRDC

Arachidonate 5-lipoxygenase

533

0

CLDKC

Volume-regulated anion channel subunit LRRC8B

803

0

CTFFC

RNA-binding protein MEX3B

158

0

Male-specific lethal 3 homolog

416

0

CDFFC

NACHT, LRR and PYD domains-containing protein 7

980

2

CLFLC

Olfactory receptor 2AJ1

328

0

CRLRC

39S ribosomal protein L4, mitochondrial

263

0

CQISC

Sodium-dependent noradrenaline transporter

628

0

CETGC

Structural maintenance of chromosomes flexible hinge domaincontaining protein 1
Taste receptor type 2 member 50

762

0

299

0

CQAWC

CQIRC

256
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C-terminus

Protein Name

Size (aa)

Cxxxx
CHYEF

Aberrant microtubules protein 1

123

CIFTY

Actin-like protein ARP8

881

CKKSR

Protein ASG7

209

CKKSR

Protein ASG7

209

CISEE

Metal homeostasis factor ATX2

313

CKPTY

Barrierpepsin

587

CKKMT

Putative uncharacterized protein BUD26

CASTD

Pre-mRNA-splicing factor BUD31

157

95

CVVFT

Calnexin homolog

502

CRRHM

Anaphase-promoting complex subunit CDC23

626

CHMQE

Anaphase-promoting complex subunit CDC27

758

CKQKR

S-phase entry cyclin-6

380

CHFTQ

GTP-binding protein CIN4

191

CLEDH

Cobalt uptake protein COT1

439

CRKRE

Probable S-adenosylmethionine-dependent methyltransferase CRG1

291

CAKPF

Exosome complex component CSL4

292

CPITA

Protein ECM13

257

CALVA

Putative glucokinase-2

500

CHLPV

Probable folylpolyglutamate synthase

430

CLYEL

Galactokinase

528

CLYEQ

Protein GAL3

520

CKAAE

E3 ubiquitin-protein ligase HEL1

551

CALVA

Glucokinase-1

500

CVLDA

Dihydroxy-acid dehydratase, mitochondrial

585

CDGKV

J protein JJJ2

584

CDGKV

J protein JJJ2

583

CGTPK

Protein LDB17

491

CLSFM

Protein LIN1

340

CDTGH

M1-1 protoxin

316

CKDNS

Mitochondrial intermembrane space cysteine motif-containing protein MIX23

196

CKNTV

E3 ubiquitin-protein ligase linker protein MMS1

CGLIL

MIOREX complex component 8

CLHMP

1407
314

N-alpha-acetyltransferase 40

285

CTYKI

Nucleoporin NUP145

1317

CFYKE

Nucleoporin NUP170

1502

CQAFM

Nucleoporin NUP85

744

Ornithine aminotransferase

424

CIDLL

257
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CADIF

Oxysterol-binding protein homolog 1

1188

CGDIF

Oxysterol-binding protein homolog 2

1283

CRSLW

Peroxisomal coenzyme A diphosphatase 1, peroxisomal

340

CSSKD

Peroxisomal membrane protein PEX25

394

CRIIV

Peroxisomal membrane protein PEX34

144

CKKKL

Transcriptional regulatory protein PHO23

330

CGQQN

Orotidine 5'-phosphate decarboxylase

267

CFERD

25S rRNA

490

CLREQ

DNA repair and recombination protein RDH54

924

CLREQ

DNA repair and recombination protein RDH54

924

CLREQ

DNA repair and recombination protein RDH54

924

CLREQ

DNA repair and recombination protein RDH54

924

CLREQ

DNA repair and recombination protein RDH54

958

CPITQ

DNA-directed RNA polymerases I and III subunit RPAC1

335

CNEYI

Chromatin structure-remodeling complex subunit RSC7

435

CIFGK

37S ribosomal protein SWS2, mitochondrial

143

CRFGG

Protein SWT21

357

CRFGG

Protein SWT21

357

CRFGG

Protein SWT21

357

CRFGG

Protein SWT21

357

CRFGG

Protein SWT21

357

CRFGG

Protein SWT21

357

CLPDE

Uncharacterized oxidoreductase TDA5

326

CLSLS

Vacuolar basic amino acid transporter 4

768

CEAIL

Vacuolar protein sorting-associated protein 13

CWRGT

Putative uncharacterized protein YBL006W-A

49

CAGGM

Uncharacterized protein YBR056W-A

66

CLLNM

Putative uncharacterized protein YBR226C

CAIYP

Uncharacterized protein YCR108C

63

CKDFI

Uncharacterized protein YDR124W

324

CFEDG

Uncharacterized protein YDR209C

137

CSTAT

Putative uncharacterized protein YDR445C

135

CFNGE

Putative uncharacterized protein YDR521W

111

CNVYI

Uncharacterized protein YER078W-A

CGRTQ

Putative uncharacterized membrane protein YFL021C-A

3144

136

54
284

CTIFS

Uncharacterized protein YGR146C-A

53

CGNYF

Uncharacterized protein YGR122W

402

CTSDD

Uncharacterized protein YGL015C

130

CLYSI

Uncharacterized protein YGL193C

103

CKNIT

Uncharacterized protein YHR125W

101

CTDAP

Uncharacterized oxidoreductase YJR096W

282

258
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CLMFS

Putative uncharacterized protein YJL169W

CRDLA

Uncharacterized protein YLR163W-A

CLKAR

Uncharacterized protein YLR255C

CSGTS

Putative uncharacterized protein YLR399W-A

CEFIL

Uncharacterized protein YMR134W

237

CYYIL

Putative uncharacterized membrane protein YML031C-A

111

CIPFK

Uncharacterized protein YOR376W-A

CIRGA

Uncharacterized membrane protein YOR376W

122

CVLII

Putative uncharacterized protein YPL238C

129

Protein ZPS1

249

CLGNL

122
37
117
34

51

CCxxx
CCFFN

Transcriptional regulatory protein EDS1

919

CCFFN

Transcriptional regulatory protein EDS1

919

CCFFN

Transcriptional regulatory protein EDS1

919

CCFFN

Transcriptional regulatory protein EDS1

919

CCFFN

Transcriptional regulatory protein EDS1

919

CCFFN

Transcriptional regulatory protein EDS1

919

CCTLM

Guanine nucleotide-binding protein subunit gamma

110

CCSGK

Copper metallothionein 1-1

61

CCSGK

Copper metallothionein 1-2

61

CCIIC

Ras-like protein 1

309

CCIIS

Ras-like protein 2

322

CCIIL

GTP-binding protein RHO2

192

CCTVM

Flavoprotein-like protein YCP4

247

CCDVF

Cysteine-rich and transmembrane domain-containing protein YDR034W-B

51

CCISK

Putative uncharacterized protein YHR180C-B

34

CCIIM

Synaptobrevin homolog YKT6

200

CxCxx
CFCCC

Casein kinase I homolog 3

524

CQCNK

SEH-associated protein 4

1038

CHCTT

Uncharacterized protein YJL077W-A

CVCTQ

Putative uncharacterized membrane protein YPR170C

28
111

CxxCx
CWWCR

Aquaporin-like protein 2

149

CWWCR

Aquaporin-like protein 2

149

CWWCR

Aquaporin-like protein 2

149

CWWCR

Aquaporin-like protein 2

149

CWWCR

Aquaporin-like protein 2

149

CHLCV

Uncharacterized protein YMR122C

124

CVFCV

Uncharacterized protein YPR064W

139

259
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CxxxC
CFRRC

Putative uncharacterized protein YNL097W-A

CRRNC

Uncharacterized protein YPL277C

51
487

260

Appendix IV: Table of C(x)3X Sequences in Select Pathogenic Organisms

C-terminus

Protein Name

Size
(aa)

Plasmodium falciparum
CFFIM

25 kDa ookinete surface antigen

217

CQIEG

Putative phosphatidylethanolamine-binding protein

190

Candida albicans
CYVLV

Candidapepsin-9

544

CNMIH

Hypha-specific G1 cyclin-related protein 1

785

CLGQN

Adenylate kinase

249

CQGQI

Mediator of RNA polymerase II transcription subunit 8

239

CNDHQ

Mitogen-activated protein kinase MKC1

509

CTRIE

Protein OS-9 homolog

258

CTATD

Pre-mRNA-splicing factor SLU7

350

CCVIV

Ras-like protein 1

290

CCVIV

Ras-like protein 1

288

CCVIV

Ras-like protein 1

290

Legionella pneumophila
CLSSL

ATP-dependent dethiobiotin synthetase BioD

212

CLSSL

ATP-dependent dethiobiotin synthetase BioD

212

CLSSL

ATP-dependent dethiobiotin synthetase BioD

212

CLSSL

ATP-dependent dethiobiotin synthetase BioD

212

CDSHR

30S ribosomal protein S18

75

CDSHR

30S ribosomal protein S18

75

CDSHR

30S ribosomal protein S18

75

CDSHR

30S ribosomal protein S18

75

CGVIK

Superoxide dismutase [Cu-Zn]

162

CGVIK

Superoxide dismutase [Cu-Zn]

162

CIRKG

Thiopurine S-methyltransferase

221

CIRKG

Thiopurine S-methyltransferase

221

CIRKG

Thiopurine S-methyltransferase

221

CPQCQ

Ferric uptake regulation protein

136
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3.1 All Works and all rights therein, including copyright rights, remain the sole and exclusive
property of the Rightsholder. The license created by the exchange of an Order Confirmation
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only those rights expressly set forth in the Order Confirmation and in these terms and conditions,
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and non-transferable and (iii) is subject to any and all limitations and restrictions (such as, but
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of the Work(s) and shall render inaccessible (such as by deleting or by removing or severing
links or other locators) any further copies of the Work (except for copies printed on paper in
accordance with this license and still in User's stock at the end of such period).
3.4 In the event that the material for which a republication license is sought includes third party
materials (such as photographs, illustrations, graphs, inserts and similar materials) which are
identified in such material as having been used by permission, User is responsible for
identifying, and seeking separate licenses (under this Service or otherwise) for, any of such third
party materials; without a separate license, such third party materials may not be used.
3.5 Use of proper copyright notice for a Work is required as a condition of any license granted
under the Service. Unless otherwise provided in the Order Confirmation, a proper copyright
notice will read substantially as follows: “Republished with permission of [Rightsholder’s
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conveyed through Copyright Clearance Center, Inc. ” Such notice must be provided in a
reasonably legible font size and must be placed either immediately adjacent to the Work as used
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where substantially all other credits or notices for the new work containing the republished Work
are located. Failure to include the required notice results in loss to the Rightsholder and CCC,
and the User shall be liable to pay liquidated damages for each such failure equal to twice the use
fee specified in the Order Confirmation, in addition to the use fee itself and any other fees and
charges specified.
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unlicensable) use that is not terminated immediately for any reason (including, for example,
because materials containing the Work cannot reasonably be recalled) will be subject to all
remedies available at law or in equity, but in no event to a payment of less than three times the
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8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
Service or to these terms and conditions, and CCC reserves the right to send notice to the User
by electronic mail or otherwise for the purposes of notifying User of such changes or additions;
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User may not assign or transfer to any other person (whether a natural person or an organization
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8.5 The licensing transaction described in the Order Confirmation document shall be governed
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266

Appendix VI: Reprint permission for reference 65, chapter 1

ELSEVIER LICENSE
TERMS AND CONDITIONS
Jun 12, 2018

This Agreement between Melanie J Blanden ("You") and Elsevier ("Elsevier") consists of your
license details and the terms and conditions provided by Elsevier and Copyright Clearance
Center.
License Number
4366670904617
License date
Jun 12, 2018
Licensed Content Publisher
Elsevier
Licensed Content Publication
Elsevier Books
Licensed Content Title
The Enzymes
Licensed Content Author
Michael A. Hast,Lorena S. Beese
Licensed Content Date
Jan 1, 2011
Licensed Content Pages
23
Start Page
235
End Page
257
Type of Use
reuse in a thesis/dissertation
Intended publisher of new work
other
Portion
figures/tables/illustrations
Number of figures/tables/illustrations
1
Format
both print and electronic
Are you the author of this Elsevier chapter?
No
Will you be translating?
No
Original figure numbers
Figure 1
Title of your thesis/dissertation
Thesis
Publisher of new work
Syracuse University
Author of new work
James L. Hougland
Expected completion date
Aug 2018
Estimated size (number of pages)
1

267

Appendix VI: Reprint permission for reference 65, chapter 1

Requestor Location
Melanie J Blanden
5591 Thompson Rd
Syracuse, NY 13214
United States
Attn:
Publisher Tax ID
98-0397604
Total
0.00 USD
Terms and Conditions

INTRODUCTION
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection
with completing this licensing transaction, you agree that the following terms and conditions
apply to this transaction (along with the Billing and Payment terms and conditions established by
Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account
and that are available at any time at http://myaccount.copyright.com).
GENERAL TERMS
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the
terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared
in our publication with credit or acknowledgement to another source, permission must also be
sought from that source. If such permission is not obtained then that material may not be
included in your publication/copies. Suitable acknowledgement to the source must be made,
either as a footnote or in a reference list at the end of your publication, as follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The Lancet,
Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from
Elsevier."
4. Reproduction of this material is confined to the purpose and/or media for which permission is
hereby given.
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd.
(Please contact Elsevier at permissions@elsevier.com). No modifications can be made to any
Lancet figures/tables and they must be reproduced in full.
6. If the permission fee for the requested use of our material is waived in this instance, please be
advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination
of (i) the license details provided by you and accepted in the course of this licensing transaction,
(ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed immediately
upon issuance of the license at the end of the licensing process for the transaction, provided that
you have disclosed complete and accurate details of your proposed use, no license is finally
effective unless and until full payment is received from you (either by publisher or by CCC) as
268

Appendix VI: Reprint permission for reference 65, chapter 1

provided in CCC's Billing and Payment terms and conditions. If full payment is not received on
a timely basis, then any license preliminarily granted shall be deemed automatically revoked and
shall be void as if never granted. Further, in the event that you breach any of these terms and
conditions or any of CCC's Billing and Payment terms and conditions, the license is
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12. No Amendment Except in Writing: This license may not be amended except in a writing
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you, which
terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and
conditions. These terms and conditions, together with CCC's Billing and Payment terms and
conditions (which are incorporated herein), comprise the entire agreement between you and
publisher (and CCC) concerning this licensing transaction. In the event of any conflict between
your obligations established by these terms and conditions and those established by CCC's
Billing and Payment terms and conditions, these terms and conditions shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in
this License at their sole discretion, for any reason or no reason, with a full refund payable to
you. Notice of such denial will be made using the contact information provided by you. Failure
to receive such notice will not alter or invalidate the denial. In no event will Elsevier or
Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred
by you as a result of a denial of your permission request, other than a refund of the amount(s)
paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.
LIMITED LICENSE
The following terms and conditions apply only to specific license types:
15. Translation: This permission is granted for non-exclusive world English rights only unless
your license was granted for translation rights. If you licensed translation rights you may only
translate this content into the languages you requested. A professional translator must perform all
translations and reproduce the content word for word preserving the integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply as
follows: Licensing material from an Elsevier journal: All content posted to the web site must
maintain the copyright information line on the bottom of each image; A hyper-text must be
included to the Homepage of the journal from which you are licensing
at http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books
at http://www.elsevier.com; Central Storage: This license does not include permission for a
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scanned version of the material to be stored in a central repository such as that provided by
Heron/XanEdu.
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier
homepage at http://www.elsevier.com . All content posted to the web site must maintain the
copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following clauses
are applicable: The web site must be password-protected and made available only to bona fide
students registered on a relevant course. This permission is granted for 1 year only. You may
obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been peerreviewed, nor has it had any other value added to it by a publisher (such as formatting, copyright,
technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the final versions of
articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to find, access, cite and use the best available version.
Please note that Cell Press, The Lancet and some society-owned have different preprint policies.
Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an article
that has been accepted for publication and which typically includes author-incorporated changes
suggested during submission, peer review and editor-author communications.
Authors can share their accepted author manuscript:
•

•

immediately
o via their non-commercial person homepage or blog
o by updating a preprint in arXiv or RePEc with the accepted manuscript
o via their research institute or institutional repository for internal institutional uses
or as part of an invitation-only research collaboration work-group
o directly by providing copies to their students or to research collaborators for their
personal use
o for private scholarly sharing as part of an invitation-only work group on
commercial sites with which Elsevier has an agreement
After the embargo period
o via non-commercial hosting platforms such as their institutional repository
o via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:
•

link to the formal publication via its DOI
270

Appendix VI: Reprint permission for reference 65, chapter 1

•
•

bear a CC-BY-NC-ND license - this is easy to do
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in alignment with our hosting policy not be added to or enhanced in any way to appear
more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the definitive final record
of published research that appears or will appear in the journal and embodies all value-adding
publishing activities including peer review co-ordination, copy-editing, formatting, (if relevant)
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articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
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links will help your users to find, access, cite, and use the best available version.
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posted publicly by the awarding institution with DOI links back to the formal publications on
ScienceDirect.
If you are affiliated with a library that subscribes to ScienceDirect you have additional private
sharing rights for others' research accessed under that agreement. This includes use for classroom
teaching and internal training at the institution (including use in course packs and courseware
programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author-selected end-user license
and should contain a CrossMark logo, the end user license, and a DOI link to the formal
publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.
18. For book authors the following clauses are applicable in addition to the above: Authors are
permitted to place a brief summary of their work online only. You are not allowed to download
and post the published electronic version of your chapter, nor may you scan the printed edition to
create an electronic version. Posting to a repository: Authors are permitted to post a summary
of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be published
commercially, please reapply for permission. These requirements include permission for the
Library and Archives of Canada to supply single copies, on demand, of the complete thesis and
include permission for Proquest/UMI to supply single copies, on demand, of the complete thesis.
Should your thesis be published commercially, please reapply for permission. Theses and
dissertations which contain embedded PJAs as part of the formal submission can be posted
publicly by the awarding institution with DOI links back to the formal publications on
ScienceDirect.
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly 2000
established subscription journals that support open access publishing. Permitted third party reuse of these open access articles is defined by the author's choice of Creative Commons user
license. See our open access license policy for more information.
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Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the article
nor should the article be modified in such a way as to damage the author's honour or reputation.
If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user license
and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, figures) has appeared in our publication with
credit or acknowledgement to another source it is the responsibility of the user to ensure their
reuse complies with the terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works
from the Article, to alter and revise the Article and to make commercial use of the Article
(including reuse and/or resale of the Article by commercial entities), provided the user gives
appropriate credit (with a link to the formal publication through the relevant DOI), provides a
link to the license, indicates if changes were made and the licensor is not represented as
endorsing the use made of the work. The full details of the license are available
at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, abstracts
and new works from the Article, to alter and revise the Article, provided this is not done for
commercial purposes, and that the user gives appropriate credit (with a link to the formal
publication through the relevant DOI), provides a link to the license, indicates if changes were
made and the licensor is not represented as endorsing the use made of the work. Further, any new
works must be made available on the same conditions. The full details of the license are
available at http://creativecommons.org/licenses/by-nc-sa/4.0.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of the
Article if it is changed or edited in any way, and provided the user gives appropriate credit (with
a link to the formal publication through the relevant DOI), provides a link to the license, and that
the licensor is not represented as endorsing the use made of the work. The full details of the
license are available at http://creativecommons.org/licenses/by-nc-nd/4.0. Any commercial reuse
of Open Access articles published with a CC BY NC SA or CC BY NC ND license requires
permission from Elsevier and will be subject to a fee.
Commercial reuse includes:
•
•
•
•

Associating advertising with the full text of the Article
Charging fees for document delivery or access
Article aggregation
Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.
20. Other Conditions:
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With minor editing privileges

no

For distribution to

Worldwide
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In the following language(s)

Original language of publication

With incidental promotional use no
The lifetime unit quantity of
new product

Up to 499

Title

Thesis

Instructor name

James L. Hougland

Institution name

Syracuse University

Expected presentation date

Aug 2018

Billing Type

Invoice

Billing Address

Melanie J Blanden
5591 Thompson Rd
Syracuse, NY 13214
United States
Attn: Melanie J Blanden

Total (may include CCC user
fee)

0.00 USD

Terms and Conditions

TERMS AND CONDITIONS
The following terms are individual to this publisher:
None
Other Terms and Conditions:
STANDARD TERMS AND CONDITIONS
1. Description of Service; Defined Terms. This Republication License enables the User to
obtain licenses for republication of one or more copyrighted works as described in detail on
the relevant Order Confirmation (the “Work(s)”). Copyright Clearance Center, Inc.
(“CCC”) grants licenses through the Service on behalf of the rightsholder identified on the
Order Confirmation (the “Rightsholder”). “Republication”, as used herein, generally means
the inclusion of a Work, in whole or in part, in a new work or works, also as described on
the Order Confirmation. “User”, as used herein, means the person or entity making such
republication.
2. The terms set forth in the relevant Order Confirmation, and any terms set by the
Rightsholder with respect to a particular Work, govern the terms of use of Works in
connection with the Service. By using the Service, the person transacting for a republication
license on behalf of the User represents and warrants that he/she/it (a) has been duly
authorized by the User to accept, and hereby does accept, all such terms and conditions on
behalf of User, and (b) shall inform User of all such terms and conditions. In the event such
person is a “freelancer” or other third party independent of User and CCC, such party shall
be deemed jointly a “User” for purposes of these terms and conditions. In any event, User
shall be deemed to have accepted and agreed to all such terms and conditions if User
republishes the Work in any fashion.
3. Scope of License; Limitations and Obligations.
3.1 All Works and all rights therein, including copyright rights, remain the sole and
exclusive property of the Rightsholder. The license created by the exchange of an Order
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Confirmation (and/or any invoice) and payment by User of the full amount set forth on that
document includes only those rights expressly set forth in the Order Confirmation and in
these terms and conditions, and conveys no other rights in the Work(s) to User. All rights
not expressly granted are hereby reserved.
3.2 General Payment Terms: You may pay by credit card or through an account with us
payable at the end of the month. If you and we agree that you may establish a standing
account with CCC, then the following terms apply: Remit Payment to: Copyright Clearance
Center, 29118 Network Place, Chicago, IL 60673-1291. Payments Due: Invoices are
payable upon their delivery to you (or upon our notice to you that they are available to you
for downloading). After 30 days, outstanding amounts will be subject to a service charge of
1-1/2% per month or, if less, the maximum rate allowed by applicable law. Unless
otherwise specifically set forth in the Order Confirmation or in a separate written agreement
signed by CCC, invoices are due and payable on “net 30” terms. While User may exercise
the rights licensed immediately upon issuance of the Order Confirmation, the license is
automatically revoked and is null and void, as if it had never been issued, if complete
payment for the license is not received on a timely basis either from User directly or
through a payment agent, such as a credit card company.
3.3 Unless otherwise provided in the Order Confirmation, any grant of rights to User (i) is
“one-time” (including the editions and product family specified in the license), (ii) is nonexclusive and non-transferable and (iii) is subject to any and all limitations and restrictions
(such as, but not limited to, limitations on duration of use or circulation) included in the
Order Confirmation or invoice and/or in these terms and conditions. Upon completion of
the licensed use, User shall either secure a new permission for further use of the Work(s) or
immediately cease any new use of the Work(s) and shall render inaccessible (such as by
deleting or by removing or severing links or other locators) any further copies of the Work
(except for copies printed on paper in accordance with this license and still in User's stock
at the end of such period).
3.4 In the event that the material for which a republication license is sought includes third
party materials (such as photographs, illustrations, graphs, inserts and similar materials)
which are identified in such material as having been used by permission, User is
responsible for identifying, and seeking separate licenses (under this Service or otherwise)
for, any of such third party materials; without a separate license, such third party materials
may not be used.
3.5 Use of proper copyright notice for a Work is required as a condition of any license
granted under the Service. Unless otherwise provided in the Order Confirmation, a proper
copyright notice will read substantially as follows: “Republished with permission of
[Rightsholder’s name], from [Work's title, author, volume, edition number and year of
copyright]; permission conveyed through Copyright Clearance Center, Inc. ” Such notice
must be provided in a reasonably legible font size and must be placed either immediately
adjacent to the Work as used (for example, as part of a by-line or footnote but not as a
separate electronic link) or in the place where substantially all other credits or notices for
the new work containing the republished Work are located. Failure to include the required
notice results in loss to the Rightsholder and CCC, and the User shall be liable to pay
liquidated damages for each such failure equal to twice the use fee specified in the Order
Confirmation, in addition to the use fee itself and any other fees and charges specified.
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3.6 User may only make alterations to the Work if and as expressly set forth in the Order
Confirmation. No Work may be used in any way that is defamatory, violates the rights of
third parties (including such third parties' rights of copyright, privacy, publicity, or other
tangible or intangible property), or is otherwise illegal, sexually explicit or obscene. In
addition, User may not conjoin a Work with any other material that may result in damage to
the reputation of the Rightsholder. User agrees to inform CCC if it becomes aware of any
infringement of any rights in a Work and to cooperate with any reasonable request of CCC
or the Rightsholder in connection therewith.
4. Indemnity. User hereby indemnifies and agrees to defend the Rightsholder and CCC, and
their respective employees and directors, against all claims, liability, damages, costs and
expenses, including legal fees and expenses, arising out of any use of a Work beyond the
scope of the rights granted herein, or any use of a Work which has been altered in any
unauthorized way by User, including claims of defamation or infringement of rights of
copyright, publicity, privacy or other tangible or intangible property.
5. Limitation of Liability. UNDER NO CIRCUMSTANCES WILL CCC OR THE
RIGHTSHOLDER BE LIABLE FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL
OR INCIDENTAL DAMAGES (INCLUDING WITHOUT LIMITATION DAMAGES
FOR LOSS OF BUSINESS PROFITS OR INFORMATION, OR FOR BUSINESS
INTERRUPTION) ARISING OUT OF THE USE OR INABILITY TO USE A WORK,
EVEN IF ONE OF THEM HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. In any event, the total liability of the Rightsholder and CCC (including their
respective employees and directors) shall not exceed the total amount actually paid by User
for this license. User assumes full liability for the actions and omissions of its principals,
employees, agents, affiliates, successors and assigns.
6. Limited Warranties. THE WORK(S) AND RIGHT(S) ARE PROVIDED “AS IS”. CCC
HAS THE RIGHT TO GRANT TO USER THE RIGHTS GRANTED IN THE ORDER
CONFIRMATION DOCUMENT. CCC AND THE RIGHTSHOLDER DISCLAIM ALL
OTHER WARRANTIES RELATING TO THE WORK(S) AND RIGHT(S), EITHER
EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. ADDITIONAL RIGHTS MAY BE REQUIRED TO USE ILLUSTRATIONS,
GRAPHS, PHOTOGRAPHS, ABSTRACTS, INSERTS OR OTHER PORTIONS OF THE
WORK (AS OPPOSED TO THE ENTIRE WORK) IN A MANNER CONTEMPLATED
BY USER; USER UNDERSTANDS AND AGREES THAT NEITHER CCC NOR THE
RIGHTSHOLDER MAY HAVE SUCH ADDITIONAL RIGHTS TO GRANT.
7. Effect of Breach. Any failure by User to pay any amount when due, or any use by User
of a Work beyond the scope of the license set forth in the Order Confirmation and/or these
terms and conditions, shall be a material breach of the license created by the Order
Confirmation and these terms and conditions. Any breach not cured within 30 days of
written notice thereof shall result in immediate termination of such license without further
notice. Any unauthorized (but licensable) use of a Work that is terminated immediately
upon notice thereof may be liquidated by payment of the Rightsholder's ordinary license
price therefor; any unauthorized (and unlicensable) use that is not terminated immediately
for any reason (including, for example, because materials containing the Work cannot
reasonably be recalled) will be subject to all remedies available at law or in equity, but in
no event to a payment of less than three times the Rightsholder's ordinary license price for
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the most closely analogous licensable use plus Rightsholder's and/or CCC's costs and
expenses incurred in collecting such payment.
8. Miscellaneous.
8.1 User acknowledges that CCC may, from time to time, make changes or additions to the
Service or to these terms and conditions, and CCC reserves the right to send notice to the
User by electronic mail or otherwise for the purposes of notifying User of such changes or
additions; provided that any such changes or additions shall not apply to permissions
already secured and paid for.
8.2 Use of User-related information collected through the Service is governed by CCC’s
privacy policy, available online
here:http://www.copyright.com/content/cc3/en/tools/footer/privacypolicy.html.
8.3 The licensing transaction described in the Order Confirmation is personal to User.
Therefore, User may not assign or transfer to any other person (whether a natural person or
an organization of any kind) the license created by the Order Confirmation and these terms
and conditions or any rights granted hereunder; provided, however, that User may assign
such license in its entirety on written notice to CCC in the event of a transfer of all or
substantially all of User’s rights in the new material which includes the Work(s) licensed
under this Service.
8.4 No amendment or waiver of any terms is binding unless set forth in writing and signed
by the parties. The Rightsholder and CCC hereby object to any terms contained in any
writing prepared by the User or its principals, employees, agents or affiliates and purporting
to govern or otherwise relate to the licensing transaction described in the Order
Confirmation, which terms are in any way inconsistent with any terms set forth in the Order
Confirmation and/or in these terms and conditions or CCC's standard operating procedures,
whether such writing is prepared prior to, simultaneously with or subsequent to the Order
Confirmation, and whether such writing appears on a copy of the Order Confirmation or in
a separate instrument.
8.5 The licensing transaction described in the Order Confirmation document shall be
governed by and construed under the law of the State of New York, USA, without regard to
the principles thereof of conflicts of law. Any case, controversy, suit, action, or proceeding
arising out of, in connection with, or related to such licensing transaction shall be brought,
at CCC's sole discretion, in any federal or state court located in the County of New York,
State of New York, USA, or in any federal or state court whose geographical jurisdiction
covers the location of the Rightsholder set forth in the Order Confirmation. The parties
expressly submit to the personal jurisdiction and venue of each such federal or state court.If
you have any comments or questions about the Service or Copyright Clearance Center,
please contact us at 978-750-8400 or send an e-mail to info@copyright.com.
v 1.1
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Jun 12, 2018

This Agreement between Melanie J Blanden ("You") and John Wiley and Sons ("John Wiley and
Sons") consists of your license details and the terms and conditions provided by John Wiley and
Sons and Copyright Clearance Center.
License Number
4366781489474
License date
Jun 12, 2018
Licensed Content Publisher
John Wiley and Sons
Licensed Content Publication
Electrophoresis
Licensed Content Title
Measuring the activity of farnesyltransferase by capillary electrophoresis with laser‐induced
fluorescence detection
Licensed Content Author
Maxim Berezovski, Wei‐Ping Li, C. Dale Poulter, et al
Licensed Content Date
Oct 8, 2002
Licensed Content Volume
23
Licensed Content Issue
19
Licensed Content Pages
6
Type of use
Dissertation/Thesis
Requestor type
University/Academic
Format
Print and electronic
Portion
Figure/table
Number of figures/tables
1
Original Wiley figure/table number(s)
Figure 3
Will you be translating?
No
Title of your thesis / dissertation
Thesis
Expected completion date
Aug 2018
Expected size (number of pages)
1
Requestor Location
Melanie J Blanden
5591 Thompson Rd
Syracuse, NY 13214

280

Appendix IX: Reprint permission for reference 78, chapter 4
United States
Attn:
Publisher Tax ID
EU826007151
Total
0.00 USD
Terms and Conditions

TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or one
of its group companies (each a"Wiley Company") or handled on behalf of a society with which a
Wiley Company has exclusive publishing rights in relation to a particular work (collectively
"WILEY"). By clicking "accept" in connection with completing this licensing transaction, you
agree that the following terms and conditions apply to this transaction (along with the billing and
payment terms and conditions established by the Copyright Clearance Center Inc., ("CCC's
Billing and Payment terms and conditions"), at the time that you opened your RightsLink
account (these are available at any time at http://myaccount.copyright.com).
Terms and Conditions
•

The materials you have requested permission to reproduce or reuse (the "Wiley
Materials") are protected by copyright.

•

You are hereby granted a personal, non-exclusive, non-sub licensable (on a stand-alone
basis), non-transferable, worldwide, limited license to reproduce the Wiley Materials for
the purpose specified in the licensing process. This license, and any CONTENT (PDF
or image file) purchased as part of your order, is for a one-time use only and limited
to any maximum distribution number specified in the license. The first instance of
republication or reuse granted by this license must be completed within two years of the
date of the grant of this license (although copies prepared before the end date may be
distributed thereafter). The Wiley Materials shall not be used in any other manner or for
any other purpose, beyond what is granted in the license. Permission is granted subject to
an appropriate acknowledgement given to the author, title of the material/book/journal
and the publisher. You shall also duplicate the copyright notice that appears in the Wiley
publication in your use of the Wiley Material. Permission is also granted on the
understanding that nowhere in the text is a previously published source acknowledged for
all or part of this Wiley Material. Any third party content is expressly excluded from this
permission.

•

With respect to the Wiley Materials, all rights are reserved. Except as expressly granted
by the terms of the license, no part of the Wiley Materials may be copied, modified,
adapted (except for minor reformatting required by the new Publication), translated,
reproduced, transferred or distributed, in any form or by any means, and no derivative
works may be made based on the Wiley Materials without the prior permission of the
respective copyright owner.For STM Signatory Publishers clearing permission under
the terms of the STM Permissions Guidelines only, the terms of the license are
extended to include subsequent editions and for editions in other languages,
provided such editions are for the work as a whole in situ and does not involve the
separate exploitation of the permitted figures or extracts,You may not alter, remove
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or suppress in any manner any copyright, trademark or other notices displayed by the
Wiley Materials. You may not license, rent, sell, loan, lease, pledge, offer as security,
transfer or assign the Wiley Materials on a stand-alone basis, or any of the rights granted
to you hereunder to any other person.
•

The Wiley Materials and all of the intellectual property rights therein shall at all times
remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or their
respective licensors, and your interest therein is only that of having possession of and the
right to reproduce the Wiley Materials pursuant to Section 2 herein during the
continuance of this Agreement. You agree that you own no right, title or interest in or to
the Wiley Materials or any of the intellectual property rights therein. You shall have no
rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding
("Marks") of WILEY or its licensors is granted hereunder, and you agree that you shall
not assert any such right, license or interest with respect thereto

•

NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, EXPRESS,
IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS OR THE
ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS,
INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF
MERCHANTABILITY, ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A
PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-INFRINGEMENT
AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED BY WILEY AND ITS
LICENSORS AND WAIVED BY YOU.

•

WILEY shall have the right to terminate this Agreement immediately upon breach of this
Agreement by you.

•

You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach of
this Agreement by you.

•

IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY
OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL,
CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR PUNITIVE
DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH
THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS
REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF
CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT
OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON
LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS
OF THIRD PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION
SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE
OF ANY LIMITED REMEDY PROVIDED HEREIN.
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•

Should any provision of this Agreement be held by a court of competent jurisdiction to be
illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as
nearly as possible the same economic effect as the original provision, and the legality,
validity and enforceability of the remaining provisions of this Agreement shall not be
affected or impaired thereby.

•

The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition of
this Agreement. No breach under this agreement shall be deemed waived or excused by
either party unless such waiver or consent is in writing signed by the party granting such
waiver or consent. The waiver by or consent of a party to a breach of any provision of
this Agreement shall not operate or be construed as a waiver of or consent to any other or
subsequent breach by such other party.

•

This Agreement may not be assigned (including by operation of law or otherwise) by you
without WILEY's prior written consent.

•

Any fee required for this permission shall be non-refundable after thirty (30) days from
receipt by the CCC.

•

These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes all
prior agreements and representations of the parties, oral or written. This Agreement may
not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives, and
authorized assigns.

•

In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.

•

WILEY expressly reserves all rights not specifically granted in the combination of (i) the
license details provided by you and accepted in the course of this licensing transaction,
(ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.

•

This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type
was misrepresented during the licensing process.

•

This Agreement shall be governed by and construed in accordance with the laws of the
State of New York, USA, without regards to such state's conflict of law rules. Any legal
action, suit or proceeding arising out of or relating to these Terms and Conditions or the
breach thereof shall be instituted in a court of competent jurisdiction in New York
County in the State of New York in the United States of America and each party hereby
consents and submits to the personal jurisdiction of such court, waives any objection to
venue in such court and consents to service of process by registered or certified mail,
return receipt requested, at the last known address of such party.
283

Appendix IX: Reprint permission for reference 78, chapter 4

WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish open
access articles under the terms of the Creative Commons Attribution (CC BY) License only, the
subscription journals and a few of the Open Access Journals offer a choice of Creative Commons
Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY license
permits commercial and nonCreative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is
not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is properly
cited, is not used for commercial purposes and no modifications or adaptations are made. (see
below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes requires
further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online
Library http://olabout.wiley.com/WileyCDA/Section/id-410895.html

Other Terms and Conditions:

v1.10 Last updated September 2015

Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1978-646-2777.
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Melanie J. Blanden
5591 Thompson Rd., Syracuse NY 13214
Email: mjdecker@syr.edu
Education
2011-present

2011-2013
2007-2011

Syracuse University, Ph.D. Candidate, Chemistry Department, College of Arts of
Sciences, Syracuse, NY
Thesis Title: Redefining the scope of Prenylation: Discovery of “forbidden”
substrate recognition and development of methods ultilizing prenylated
proteins, Supervised by Dr. James Hougland
M.Phil. Chemistry, Syracuse University, Syracuse, NY
B.Sc. Forensic Science, Bay Path University, Longmeadow, MA

Research Experience
2011-Present Graduate Assistant (Chemistry) Syracuse University
Supervisor: Dr. James Hougland
Summary – Discovery and characterization of lipidation for non-canonical protein
sequences in vitro and in mammalian cells. Investigated protein isolation techniques
using bioorthogonal chemistry of engineered enzymes in bacterial and mammalian cells.
Developed new method for studying protein modifications from cells.
Summer 2010

Intern (Bioinformatics and Integrative Genomics)
Harvard- MIT Health Sciences and Technology (Cambridge, MA)
Supervisors: Dr. Susanne Churchill and Dr. Robert Plenge
Summary – Evaluated Rheumatoid Arthritis biomarkers in human patient samples.
Techniques used include isolation of white blood cells from patient blood samples,
qPCR, DNA isolation from white blood cells, and statistically evaluating antibody
levels and single nucleotide polymorphisms as risk factors for developing rheumatoid
arthritis.

Teaching Experience
2018-Present Assistant Professor of Chemistry (tenure track) Utica College
Summary – Responsibilities include teaching four lectures or laboratories each semester
in both biochemistry and general chemistry sequences. Courses taught include
Biochemistry I/II lecture, Biochemistry lab, General Chemistry I lecture, and General
Chemistry I/II lab. Research with undergraduate students in biochemistry.

2017-2018

One Year Assistant Professor of Chemistry Utica College
Summary – Responsibilities include teaching four lectures or laboratories each semester
in both biochemistry and general chemistry sequences. Courses taught include
Biochemistry I/II lecture, Biochemistry lab, General Chemistry I lecture, and General
Chemistry I/II lab.
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Summer 2016 Instructor (Organic Chemistry Lab I) Syracuse University
Summary – Taught lecture, designed lab protocols, report templates, quizzes, and
exams. Held studentled discussions sections for review of lecture material. Supervised
teaching assistants in running lab experiments and grading reports
Summer 2014 Research Experience for Undergrate Students (REU) Research Mentor Syracuse
University
Supervisor: Dr. James Hougland
Summary –Advised summer student on experimental design, biochemical lab
techniques, and scientific communication skills. Techniques included mammalian tissue
culture, protein purification via FPLC, in vitro reactions from cell lysate, fluorescent plate
reader methods, bacterial cloning, and protein gel analysis. This research culminated in a
poster and oral presentation to the Syracuse University community.
2013-present

Teaching Assistant (Chemistry) Syracuse University
Classes – General Chemistry I, Organic Chemistry I, Organic Chemistry Lab I/II,
Prep & Analysis of Proteins and Nucleic Acids (Lab)
Summary: Lecture course responsibilities included teaching of multiple weekly
recitation classes, office hours, proctoring and grading of exams, and one-on-one
mentorship. Laboratory course responsibilities included preparation and ordering of
materials, maintenance of equipment, testing the validity of experiments prior to class,
assisting and guiding students during laboratory, office hours, holding lecture-style study
sessions, and grading of lab reports, quizzes, and exams.

2013-2014

Undergraduate Student Research Mentor Syracuse University
Supervisor: Dr. James Hougland
Summary – Training and guidance of a sophomore undergradate student in biochemistry
lab
techniques, experiments, and scientific
writing/presentations. Techniques mentored include protein purification via FPLC,
bacterial cloning, DNA and protein gel analysis, PCR, HPLC analysis and basic lab
maintenance and solution making

2009-2011

Undergraduate Teaching Assistant (Organic Chemistry I/II Lecture and Lab)
Bay Path University
Supervisor: Dr. Hsiang-Ching Kung
Summary – Taught weekly lecture recitations and supervised laboratory sections.
Prepared laboratory
materials and graded lab quizzes. Formatted, typed, and graded
lecture exams.

2008-2010

Student Tutor The Bashevkin Center for Academic Excellence - Bay Path University
Classes: General Chemistry I/II, Organic Chemistry I/II, Statistics, Calculus I
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Summary – Nominated by course instructor. Individual tutoring sessions with
undergraduate students several days per week. Duties include review of lecture material,
exam preparation, guidance in study methods, and homework help.
Awards and Honors:
Best Graduate Student Poster Presentation – 1st place, FASEB Science Research Conference 2017
William D. Johnson Award for Outstanding Graduate Teaching Assistant 2017
ACS Division of Biological Chemistry Travel Award 2016
Syracuse University Graduate Student Organization Travel Award 2015/2016
GAANN Fellowship 2011-2012
Syracuse University STEM Fellowship 2012 – 2014

Publications:
Zhang, Yi, Blanden, Melanie J., Sudheer, Ch., Gangopadhyay, Soumyashree A., Rashidian, Mohammad,
Hougland, James L., and Distefano, Mark D. Simultaneous Site-Specific Dual Protein Labeling Using
Protein Prenyltransferases Bioconjugate Chem., 2015, 26 (12), 2542–2553
Shala-Lawrence, Agnesa*, Blanden, Melanie J.*, Krylova, Svetlana M., Gangopadhyay, Soumyashree A.,
Beloborodov, Stanislav S., Hougland, James L., and Krylov, Sergey N. Simultaneous Analysis of a NonLipidated Protein and Its Lipidated Counterpart: Enabling Quantitative Investigation of Protein
Lipidation’s Impact on Cellular Regulation Anal Chem., 2017, 89 (24), 13502-13507
Blanden, Melanie J., Suazo, Kiall F., Hildebrandt, Emily R., Hardgrove, Daniel S., Patel, M., Saunders,
William P., Distefano, Mark D., Schmidt, Walter K., and Hougland, James L. Efficient farnesylation of
“forbidden” C-terminal C(x)3X sequences expands the scope of the prenylated proteome J. Biol. Chem.,
2018, 293 (8), 2770-2785
Oral Presentations:
Blanden, Melanie J., Suazo, Kiall F., Hildebrandt, Emily R., Hardgrove, Daniel S., Patel, M., Saunders,
William P., Distefano, Mark D., Schmidt, Walter K., and Hougland, James L. Efficient farnesylation of
“forbidden” C-terminal C(x)3X sequences expands the scope of the prenylated proteome FASEB Science
Research Conference: Protein Lipidation: Enzymology, Signaling and Therapeutics, Saxtons River, VT,
July 2017 (Elevator Pitch Presentation)
Blanden, Melanie J., Schmidt, Walter K., Hougland, James L. Redefining the potential prenylome:
Prenylation of non-canonical C-terminal sequences in peptides and proteins 252nd American Chemical
Society National Meeting & Exposition, Biological Division: Young Investigators. Philadelphia, PA 2016
Blanden, Melanie J., Schmidt, Walter K., Hougland, James L. Redefining the potential prenylome:
Prenylation of non-canonical C-terminal sequences in peptides and proteins Northeast Regional Meeting
of the American Chemical Society, Biological Division: Biochemistry, Binghamton, NY, 2016
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Poster Presentations:
Blanden, Melanie J., Suazo, Kiall F., Hildebrandt, Emily R., Hardgrove, Daniel S., Patel, M., Saunders,
William P., Distefano, Mark D., Schmidt, Walter K., and Hougland, James L. Efficient farnesylation of
“forbidden” C-terminal C(x)3X sequences expands the scope of the prenylated proteome FASEB Science
Research Conference: Protein Lipidation: Enzymology, Signaling and Therapeutics, Saxtons River, VT,
July 2017
Blanden, Melanie J., Shala-Lawrence, Agnesa, Krylova, Svetlana M., Gangopadhyay, Soumyashree A.,
Beloborodov, Stanislav S., Hougland, James L., and Krylov, Sergey N. Simultaneous Analysis of a NonLipidated Protein and Its Lipidated Counterpart: Enabling Quantitative Investigation of Protein
Lipidation's Impact on Cellular Regulation FASEB Science Research Conference: Protein Lipidation:
Enzymology, Signaling and Therapeutics, Saxtons River, VT, July 2017
Blanden, Melanie J., Shala, A., Zhang, Y., Krylov, S., Distefano, M., and Hougland, James L.
Chemoenzymatic protein labeling and isolation from eukaryotic cell lysates using prenyltransferases with
reengineered substrate selectivity 251st American Chemical Society National Meeting & Exposition,
Biological Division: Current Topics in Biochemistry. San Diego, CA 2016
Blanden, Melanie J. and Hougland, James, L. Investigation into the Degradation Pathway of Prenylated
Proteins Syracuse University Life Sciences Research Showcase, Syracuse, NY, 2013.
Blanden, Melanie J. and Hougland, James, L. Investigation into the Degradation Pathway of Prenylated
Proteins Northeast Regional Meeting of the American Chemical Society, Rochester, NY, 2012.

Leadership & Service:
2014-present

Nursery Childcare Volunteer Imperfect Church (Camillus, NY)
Care of children ages 0-3 years during church services.
Supervisor of Welcome Team Imperfect Church (Camillus, NY)
Welcoming first-time attendees to our church and providing them with information
about our values and Sunday service. Introduce the visitors to other church
members, leaders, and pastor, as well as answer questions the guest may have.
Organizing a guest information packet and receiving their demographic
information for future outreach. Scheduling volunteers to work at the desk.

2012-present

Board of Directors (Vice-President), Volunteer, Foster, Coordinator
CNY Cat Coalition (Syracuse, NY)
a) Adoption Center volunteer: Care, cleaning and enrichment for adoptable cats at
local PetSmart adoption centers. Liaison to the public for adoption information,
meet-and-greets of pet with potential adopters.
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b) Adoption Center Coordinator: Responsible for organization and direction of
fosters for cage assignments of adoptable pets, handled issues with the public
concerning the adoption center, organization of the adoption materials, supplies,
and volunteer schedule of the adoption center.
c) Board of Directors: Monthly meetings to discuss concerns and issues within the
organization. Design of new volunteer positions, donation events, and writing of
grants for animal rescue nonprofits
2009-2011

Resident Assistant – Bay Path College
Responsibilities included maintenance of dormitory, creating and holding social
and community service events, mentoring students, and mediation of concerns and
issues between students
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